Department of Medicine
Divisions of Diabetes and Infectious Diseases
University of Helsinki
Helsinki, Finland

data, citation and similar papers at core.ac.uk
brought to you b
provided by Helsingin yliopiston digita

PATHOGENESIS AND TREATMENT OF LIPODYSTROPHY IN HIV-INFECTED PATIENTS RECEIVING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY

Jussi Sutinen

ACADEMIC DISSERTATION

To be presented with the permission of the Medical Faculty of the University of Helsinki for public examination in Auditorium 2, Biomedicum, Haartmaninkatu 8,
on December 19th, 2003, at 1 p.m.

Helsinki 2003

Supervisor Professor Hannele Yki-Järvinen, MD, FRCP
Department of Medicine
Division of Diabetes
University of Helsinki
Helsinki, Finland

Reviewers Docent Petri Kovanen, MD
Wihuri Research Institute
Helsinki, Finland

Docent Esa Rintala, MD
Department of Infectious Diseases
Satakunta Central Hospital
Pori, Finland

Opponent Professor Peter Arner, MD
Department of Medicine
Huddinge University Hospital
Karolinska Institutet
Stockholm, Sweden.

ISBN 952-91-6730-X (paperback)
ISBN 952-10-1568-3 (pdf)
http://ethesis.helsinki.fi
Yliopistopaino
Helsinki 2003

ABSTRACT

Background and aims. Highly active antiretroviral therapy (HAART) has improved the prognosis of HIV-infected patients, but is also associated with adverse events, such as lipodystrophy and insulin resistance caused by unknown mechanisms. Glitazones appear promising drugs to treat HAART-associated lipodystrophy (HAL), since they both improve insulin sensitivity and increase the amount of subcutaneous adipose tissue (SAT) in patients with type 2 diabetes. Present studies were undertaken to gain insight into the pathogenesis of HAL, and to evaluate whether rosiglitazone could increase the amount of SAT in these patients.

Subjects and methods. Three groups were included in the study: HIV-infected, HAART-treated patients with (HAART+LD+, n=25-30) and without lipodystrophy (HAART+LD-, n=9–13), and HIV negative subjects (HIV-, n= 15–35). Effects of rosiglitazone (8 mg/d for 24 weeks) were studied in a randomized, double-blind, placebo-controlled trial in the HAART+LD+ group. Body composition was measured using magnetic resonance imaging, liver fat by proton spectroscopy, and gene expression in SAT by real-time PCR.

Results. Liver fat content was increased in the HAART+LD+ compared to the HAART+LD- and the HIV-group, and correlated with fasting serum insulin concentrations. Serum adiponectin and its expression in SAT were decreased in the HAART+LD+ compared to the HAART+LD- group, and correlated inversely with features of insulin resistance. The expression of peroxisome proliferator-activated receptor (PPAR) γ and δ, sterol regulatory element-binding protein 1c, PPARγ coactivator-1 (PGC-1), lipoprotein lipase, acyl CoA synthase and glucose transport protein 4 were decreased, whereas the expression of CD45 and interleukin 6 were increased in the HAART+LD+ compared to the HAART+LD- group. Rosiglitazone treatment did not increase the amount of SAT. Rosiglitazone decreased serum insulin concentration and liver fat content, but worsened dyslipidemia. Rosiglitazone increased the expression of adiponectin, PPARγ and PGC-1, and decreased the expression of IL-6. PAI-1 concentration in plasma and its expression in SAT were increased in the HAART+LD+ compared to the HAART+LD- and the HIV- group. Rosiglitazone did not change the expression of PAI-1 in SAT, but caused a decrease in plasma PAI-1 concentration, which correlated with the decrease in the liver fat content.

Conclusions. Increased liver fat content may contribute to insulin resistance and to plasma PAI-1 concentrations in patients with HAL. Multiple alterations in gene expression in SAT imply decreased adipocyte maturation, increased inflammation and decreased adiponectin production, which all may contribute to insulin resistance. The present data do not support use of rosiglitazone in patients with HAL, although it decreased liver fat content and fasting serum insulin concentrations. The insulin-sensitizing effects of rosiglitazone may have been mediated by the increased expression of adiponectin.

CONTENTS

LIST OF ORIGINAL PUBLICATIONS 8
ABBREVIATIONS 9
1. INTRODUCTION **11**
2. REVIEW OF THE LITERATURE **13**
2.1. INSULIN RESISTANCE AND ADIPOSE TISSUE METABOLISM........ 13
2.1.1.Physiologic actions of insulin 13
Glucose metabolism 13
Lipid metabolism 15
Fibrinolysis and other effects 16
2.1.2. Insulin resistance 16
Causes of insulin resistance 16
2.1.3. Adipose tissue 17
Differentiation and function of adipocytes 18
Adipose tissue as a regulator of whole body insulin resistance 22
Metabolic characteristics of different adipose tissue depots 26
2.1.4. Fat in insulin sensitive tissues other than adipose tissue 31
The liver 32
Skeletal muscle 32
Mechanisms of insulin resistance with fat accumulation in the liver and skeletal muscle 33
2.1.5. Mouse models of lipodystrophy 33
2.1.6. Non-HIV human lipodystrophies 34
2.2. HIV INFECTION AND ANTIRETROVIRAL THERAPY 35
2.2.1.History of the HIV epidemic 35
2.2.2.Pathogenesis 35
CD4+ T lymphocytes 35
Viral life cycle 36
2.2.3.Clinical course 36
2.2.4.Treatment 37
History of antiretroviral therapy 37
Antiretroviral agents 38
Initiation of therapy 40
2.3. HAART-ASSOCIATED LIPODYSTROPHY 41
2.3.1.Metabolic alterations of HIV infection before HAART 41
Body composition 41
Features of insulin resistance 41
2.3.2.Clinical and metabolic characteristics of HAL 41
2.3.3.Definition of HAL 41
2.3.4.Pathogenesis and etiology of HAL 42
Lipodystrophic human adipose tissue 42
Insulin resistance in patients with HAL 43
Etiology of HAL 43
Protease inhibitors 44
Nucleoside reverse transcriptase inhibitors 48
Non-nucleoside reverse transcriptase inhibitors 48
Host-associated factors 49
2.3.5.Prevalence of HAL 49
Lipodystrophy 49
Abnormalities in glucose metabolism 49
Lipid abnormalities 50
Impaired fibrinolysis 50

2.3.6. Significance of HAL 50
2.3.7. Treatment of HAL 51
Switching antiretroviral agents 51
Modifications of life style 52
Lipid-lowering agents 55
Metformin 55
Thiazolidinediones 55
Growth hormone 56
Other interventions 56
3. AIMS OF THE STUDY 57
4. SUBJECTS AND STUDY DESIGNS 58
5. METHODS 62
5.1. Body composition 62
5.2. Liver fat 62
5.3. Gene expression in SAT 64
5.4. Laboratory analyses 65
5.5. Statistical methods 67
6. RESULTS 69
6.1. Hepatic fat in HAL (Study I) 69
6.2. Adiponectin in HAL (Study II) 71
6.3. Gene expression in SAT in HAL (Study III) 72
6.4. Treatment of HAL with rosiglitazone (Study IV and V) 74
6.5. PAI-1 in HAL (Study VI) 78
7. DISCUSSION 83
7.1 SUBJECTS AND METHODS 83
7.1.1. Subjects 83
7.1.2. Liver fat 84
7.1.3. Body composition 84
7.1.4. Gene expression 85
7.2. GENE EXPRESSION IN SAT AND ADIPOCYTOKINE PRODUCTION 85
7.2.1. Transcription factors and co-activator 86
7.2.2. Genes of lipogenesis and fatty acid metabolism 87
7.2.3. Markers of inflammation 87
7.2.4. Adiponectin 88
7.2.5. Leptin 90
7.2.6. PAI-1 91
7.3. LIVER FAT 92
7.3.1. Liver fat and PAI-1 94
7.4. TREATMENT OF HAL WITH ROSIGLITAZONE 94
7.4.1. Clinical effects 94
7.4.2. Effects on gene expression in SAT 96
7.4.3. Effects on PAI-1 98
7.5. FUTURE PROSPECTS 99
8. SUMMARY 101
9. CONCLUSIONS 102
10. ACKNOWLEDGEMENTS 103
11. REFERENCES 105
ORIGINAL PUBLICATIONS

LIST OF ORIGINAL PUBLICATIONS

This thesis is based on the following publications, which are referred to in the text by their Roman numerals.

I. Sutinen J, Häkkinen AM, Westerbacka J, Seppälä-Lindroos A, Vehkavaara S, Halavaara J, Järvinen A, Ristola M, Yki-Järvinen H. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. *AIDS* 2002;16:2183-93.

II. Sutinen J, Korsheninnikova E, Funahashi T, Matsuzawa Y, Nyman T, Yki-Järvinen H. Circulating concentration of adiponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapy-associated lipodystrophy. *J Clin Endocrinol Metab* 2003;88:1907-1910.

III. Kannisto K, Sutinen J, Korsheninnikova E, Fisher RM, Ehrenborg E, Gertow K, Virkamäki A, Nyman T, Vidal H, Hamsten A, Yki-Järvinen H. Expression of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma co-activator 1, IL-6 and CD45 in subcutaneous adipose tissue in lipodystrophy associated with highly active antiretroviral therapy. *AIDS* 2003;17:1753-62.

IV. Sutinen J, Häkkinen AM, Westerbacka J, Seppälä-Lindroos A, Vehkavaara S, Halavaara J, Järvinen A, Ristola M, Yki-Järvinen H. Rosiglitazone in the treatment of HAART-associated lipodystrophy – a randomized double-blind placebo-controlled study. *Antivir Ther* 2003;8:199-207.

V. Sutinen J, Kannisto K, Korsheninnikova E, Fisher RM, Ehrenborg E, Nyman T, Virkamäki A, Funahashi T, Matsuzawa Y, Vidal H, Hamsten A, Yki-Järvinen H. Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy - associated lipodystrophy. Submitted.

VI. Yki-Järvinen H, Sutinen J, Silveira A, Korsheninnikova E, Fisher RM, Kannisto K, Ehrenborg E, Eriksson P, Hamsten A. Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy. *Arterioscler Thromb Vasc Biol* 2003;23:688-694.

The publications II and III have also been included in the doctoral thesis by Elena Korsheninnikova entitled ”Molecular mechanisms of insulin resistance in human skeletal muscle and lipodystrophic adipose tissue” (University of Helsinki, 2003).

The original publications are reproduced with permission of the copyright holders.

ABBREVIATIONS

11β-HSD	11β-hydroxysteroid dehydrogenase
ACC	acetyl coenzyme A carboxylase
ACS	acyl coenzyme A synthase
AIDS	acquired immunodeficiency syndrome
ALBP	adipocyte lipid binding protein
ALT	alanine aminotransferase
AMPK	adenosine monophosphate-activated protein kinase
ASP	acylation stimulating protein
BIA	bioelectrical impedance analysis
BMI	body mass index
cAMP	cyclic adenosine monophosphate
C/EBP	CCAAT/enhancer-binding protein
CETP	cholesteryl ester transfer protein
cIAP	cellular inhibitor of apoptosis protein
CoA	coenzyme A
CRP	C-reactive protein
CT	computed tomography
DEXA	dual-energy x-ray absorptiometry
DNA	deoxyribonucleic acid
FABP	fatty acid binding protein
FABPpm	plasma membrane-associated fatty acid binding protein
FAS	fatty acid synthase
FAT	fatty acid translocase
FATP	fatty acid transport protein
FFA	free fatty acids
GLUT	glucose transport protein
HAART	highly active antiretroviral therapy
HAART+LD+ group	HAART-treated patients with lipodystrophy
HAART+LD- group	HAART-treated patients without lipodystrophy
HAL	HAART-associated lipodystrophy
HDL	high density lipoprotein
HIV	human immunodeficiency virus
HIV- group	HIV-negative subjects
HSL	hormone sensitive lipase

IL	interleukin
IMCL	intramyocellular lipid
IRS	insulin receptor substrate
KLBP	keratinocyte lipid binding protein
LDL	low density lipoprotein
LPL	lipoprotein lipase
MAP kinase	mitogen-activated protein kinase
MRI	magnetic resonance imaging
mRNA	messanger RNA
mtDNA	mitochondrial DNA
NAFLD	nonalcoholic fatty liver disease
NASH	nonalcoholic steatohepatitis
ND	not done
NNRTI	non-nucleoside reverse transcriptase inhibitor
NRTI	nucleoside reverse transcriptase inhibitor
NS	non significant
OGTT	oral glucose tolerance test
PAI-1	plasminogen activator inhibitor-1
PBMC	peripheral blood mononuclear cell
PEPCK	phosphoenolpyruvate carboxykinase
PGC-1	PPARγ coactivator –1
PI	protease inhibitor
PI 3-kinase	phosphatidylinositol 3-kinase
PPAR	peroxisome proliferator-activated receptor
SAT	subcutaneous adipose tissue
SEM	standard error of mean
SREBP	sterol regulatory element-binding protein
TG	triglycerides
TNF	tumor necrosis factor
UCP	uncoupling protein
VAT	visceral adipose tissue
VLDL	very low density lipoprotein
WHR	waist to hip ratio

1. INTRODUCTION

The prognosis of human immunodeficiency virus (HIV) -infected people has dramatically improved after the introduction of highly active antiretroviral therapy (HAART) in 1996 (1). However, eradication of the virus is not possible with current regimens (2), and therefore patients need to use HAART permanently. HAART is also associated with adverse events, such as lipodystrophy, i.e. loss of subcutaneous fat (lipoatrophy) and accumulation of intra-abdominal fat, and insulin resistance (3). During the last few years, HAART-associated lipodystrophy (HAL) has become the most common form of human lipodystrophy. Severe lipodystrophy, especially facial lipoatrophy can be stigmatizing and reduce adherence to otherwise effective HAART (4,5). Long term consequences of the adverse events still remain unknown, but preliminary data suggest that HAART is associated with increased cardiovascular morbidity (6).

The pathogenesis of HAL remains unknown. It is not known whether lipoatrophy results from decreased differentiation of adipocytes, increased loss of adipocytes, or both. The inability to store fat in adipose tissue in patients with non-HIV lipodystrophies and in lipodystrophic mouse models results in fat accumulation in the liver and skeletal muscle, which is associated with development of insulin resistance (7,8). Whether this occurs also in HAL is not known. Adipose tissue is an active endocrine organ, which produces several proteins that regulate whole body metabolism (9). Data are sparse regarding the possible contribution of altered secretory function of the adipose tissue to the pathogenesis of HAL.

Currently there is no pharmacological treatment available for HAL. Thiazolidinediones are novel insulin-sensitizing agents, which increase subcutaneous fat mass in patients with type 2 diabetes (10). The latter is an undesirable side effect in patients with type 2 diabetes. However, in patients with HAL, both the adipose tissue-increasing and insulin-sensitizing effects of thiazolidinediones would be beneficial. Thiazolidinediones therefore appear promising drugs for the treatment of HAL, but have not been tested in a controlled trial.

The present studies were undertaken to gain insight into the pathogenesis and treatment of HAL. We examined whether the adipocyte differentiation is abnormal in lipodystrophic adipose tissue by measuring the expression of several transcription factors and other genes necessary for normal maturation of adipocytes. We also evaluated physiologic function of lipodystrophic adipose tissue by quantifying the expression of several adipocytokines, e.g. adiponectin, leptin and interleukin (IL) -6 in adipose tissue and their circulating concentrations. We studied whether liver fat content measured using proton spectroscopy is increased in HAL, and whether liver fat content is associated with features of insulin resistance. We also studied the possibility that liver fat content could be a significant correlate of the concentration of plasminogen activator inhibitor-1 (PAI-1) in plasma. Finally, we conducted a randomized, placebo-controlled, double-blind trial to

evaluate whether rosiglitazone could increase the amount of subcutaneous adipose tissue (SAT) in patients with HAL. Currently there are no human *in vivo* data available on the effects of rosiglitazone on gene expression in adipose tissue. We therefore quantified the expression of multiple genes, which could possibly be involved in the insulin-sensitizing action of rosiglitazone in subcutaneous fat of patients with HAL.

2. REVIEW OF THE LITERATURE

2.1. INSULIN RESISTANCE AND ADIPOSE TISSUE METABOLISM

2.1.1. PHYSIOLOGIC ACTIONS OF INSULIN

GLUCOSE METABOLISM

Maintenance of plasma glucose concentration within narrow limits is of vital importance to humans. Insufficient glucose availability would be deleterious especially to the brain and other neuronal tissues, which cannot use alternative energy sources. At any given moment, plasma glucose concentration represents the balance between glucose absorption from the intestine, endogenous glucose production and glucose utilization. Insulin serves as the main regulator of blood glucose concentration by inhibiting hepatic glucose production and by increasing glucose uptake primarily in skeletal muscle (11).

Endogenous glucose production

In the fasting (postabsorptive) state, an equal amount of glucose is produced and utilized. The liver produces most of the circulating glucose in the fasting state. Also the kidneys can synthesize glucose, but it is considered important only following prolonged fasting (11). The liver can produce glucose by breaking down glycogen (glycogenolysis) or by *de novo* glucose synthesis mainly from lactate, alanine, pyruvate and glycerol (gluconeogenesis) (11). The early studies suggested that glycogenolysis accounted for ~75% of glucose production after an overnight fast (11). However, novel *in vivo* measurements using ^{13}C magnetic resonance imaging (MRI) spectroscopy have shown that gluconeogenesis accounts for up to 50% of the hepatic glucose production even during early hours of fasting (12). Total depletion of hepatic glycogen (70 to 150 g) occurs within 24-64 hours depending on the method used for quantification of glycogen stores (13).

Insulin inhibits both gluconeogenesis and glycogenolysis. In normal subjects, serum insulin concentration of ~30 mU/l halve hepatic glucose production and complete suppression is achieved at insulin concentrations of 50-60 mU/l in studies employing [3-^{3}H] glucose under non-steady state conditions (14). Insulin induces the transcription of sterol regulatory element binding protein 1c (SREBP-1c) by a phosphatidylinositol 3 (PI 3)-kinase dependent mechanism (*vide infra*) (15). After the proteolytic cleavage of the precursor SREBP-1c, the truncated, mature form of SREBP-1c translocates into the nucleus, where it activates transcription of glucose kinase, an enzyme that increases glucose phophorylation and glycogen repletion (15). Mature form of SREBP-1c also inhibits the transcription of phosphoenolpyruvate carboxykinase (PEPCK), an important enzyme in gluconeogenesis (15). Insulin also decreases the activity of the enzyme glycogen phosphorylase, which stimulates breakdown of glycogen to glucose (11,13). Furthermore, insulin indirectly decreases gluconeogenesis by suppressing lipolysis and proteolysis, thus reducing peripheral release of gluconeogenic precursors (11). An increase in plasma glucose concentration regulates hepatic glucose production by

inhibiting both gluconeogenesis and glycogenolysis, independent of changes in glucoregulatory hormones (11).

Glucagon rapidly increases both glycogenolysis and gluconeogenesis (16). Catecholamines also rapidly stimulate glycogenolysis and gluconeogenesis. However, their role for preventing hypoglycemia is considered significant only as a compensatory mechanism if glucagon secretion is deficient (17). Also glucocorticoids enhance hepatic glucose production, but in contrast to the acute stimulatory effects of glucagon and catecholamines, the effects of corticosteroids take several hours to occur. Corticosteroids activate gluconeogenic enzymes and augment the transfer of free fatty acids (FFA) to the liver (11). Growth hormone impairs the ability of insulin to suppress hepatic glucose production (18). In addition, a complex paracrine signaling system operates between Kuppfer cells, hepatocytes and endothelial cells and may, at least judging from animal data, regulate glucose production (13).

Other factors involved in hepatic glucose production include fat accumulation in the liver (Chapter 2.1.4), which is associated with hepatic insulin sensitivity in several animal models (Chapter 2.1.5.) and in humans (19). Adiponectin is an adipocyte-derived protein (Chapter 2.1.3.), which *in vitro* and in animal models has been shown to increase the ability of insulin to suppress glucose production and to downregulate the expression of enzymes involved in gluconeogenesis (20,21). Interestingly, adiponectin infusion in animals increases insulin sensitivity and decreases liver fat content (22).

Glucose utilization

Insulin regulates glucose utilization mainly by increasing glucose uptake in skeletal muscle. Under fasting conditions, when circulating concentration of insulin is low, glucose utilization occurs mainly in insulin-independent tissues, such as the brain, renal medulla and erythrocytes, which cannot use alternative energy sources. According to various studies, it has been estimated that the brain accounts for ~50%, splanchnic area (the liver and gut) ~25%, skeletal muscle and fat ~10%, kidneys ~6% and heart ~5% of the basal glucose disposal (14). Under fasting conditions, insulin-dependent tissues, such as skeletal muscle and splanchnic tissues use FFA as the main source of energy (11).

After oral glucose administration, insulin-dependent tissues switch their energy supply from FFA to glucose. Consequently, one third of glucose is taken up by skeletal muscle, one third by the splanchnic tissues and one third by other tissues, especially the brain (14,23).

Under intravenously maintained normoglycemic hyperinsulinemia, e.g. during hyperinsulinemic euglycemic clamp, glucose utilization can increase up to 6-fold compared to glucose utilization rate after an overnight fast (14). Under these experimental conditions, skeletal muscle by far accounts for most of glucose

utilization (~70%), the brain for 14%, heart 6%, splanchnic area 6%, kidneys 2%, and adipose tissue for 1% (14).

In order to exert its effect on cells, insulin must first bind to an extracellular α-subunit of its cell membrane-associated receptor. This binding leads to autophosphorylation of the intracellular β-subunit of the receptor, which consequently results in activation of the tyrosine kinase activity of the receptor (24). Tyrosine kinase catalyzes phosphorylation of several insulin receptor substrate (IRS) proteins. IRS-1 is the main IRS in skeletal muscle (25). Intracellular insulin signaling involves two major pathways: the mitogen-activated protein (MAP) kinase and the PI 3-kinase pathway. The MAP kinase pathway mediates growth-promoting effects of insulin and PI 3-kinase most of the metabolic responses to insulin, such as translocation of intracellular glucose transport protein 4 (GLUT4) (*vide infra*) to the cell membrane, and glycogen and protein synthesis (24).

Specific glucose transport proteins are needed for glucose entry into the cells. Seven functional isomers of glucose transport proteins are known today (11). GLUT4 is the main insulin-dependent glucose transport protein expressed in skeletal muscle and adipose tissue (26,27). Insulin-induced intracellular signaling results in translocation of the intracellular GLUT4 to the cell membrane and also enhances GLUT4 activity (16). GLUT1 is the main insulin-independent glucose transporter. It is expressed ubiquitously and is present on the cell surface (16). GLUT2 is present on the plasma membrane and mediates glucose entry into the hepatocytes (15). GLUT2 also mediates the export of glucose out of hepatocytes during gluconeogenesis (11).

LIPID METABOLISM

Lipoproteins are particles that transport hydrophobic lipids in the blood and mediate their delivery to various tissues. Dietary fat enters circulation in chylomicrons, which are triglyceride-rich lipoproteins synthesized by enterocytes in the small intestine (28). On the vascular endothelium, lipoprotein lipase (LPL) releases fatty acids from chylomicrons (28). FFA can then be taken up by tissues, such as skeletal muscle and adipose tissue. The resulting chylomicron remnant particles are cleared from the circulation by the liver (28).

The liver synthesizes both triglyceride and cholesterol, which are released into the circulation as very low density lipoproteins (VLDL) (28). Following the release of fatty acids from VLDL by endothelial LPL, VLDL are converted into VLDL remnants, intermediate density lipoproteins and finally into low density lipoproteins (LDL) (28). High density lipoprotein (HDL) particles can originate from the liver and the gut, and hydrolysis of chylomicrons and VLDL yield components which can form HDL particles (28).

Insulin suppresses VLDL secretion by directly inhibiting the assembly and production of VLDL particles (29). In addition, insulin suppresses VLDL production indirectly by decreasing FFA availability for VLDL

assembly by inhibiting lipolysis in adipose tissue (29). Insulin acutely increases the activity of LPL in adipose tissue (30), but normally decreases the activity of LPL in skeletal muscle (29,31). Lipolysis in adipose tissue is a very insulin sensitive process. Insulin inhibits lipolysis primarily through inhibiting hormone sensitive lipase (HSL), the rate-limiting enzyme of intracellular triglyceride hydrolysis in adipose tissue (32,33). These combined effects of insulin tend to "keep fat where it belongs", i.e. in adipose tissue (29).

FIBRINOLYSIS AND OTHER EFFECTS

PAI-1 is an inhibitor of fibrinolysis. Plasma PAI-1 concentrations are increased in insulin resistant subjects (34). *In vitro*, insulin increases the synthesis of PAI-1 in human vascular endothelial and smooth-muscle cells, and in hepatoma HepG2 cells (34,35). Insulin also increases PAI-1 expression in human subcutaneous adipocytes *in vitro* (36). The relative contributions of these tissues *in vivo* to PAI-1 production in different physiological and pathological situations are unknown.

Physiologic concentrations of insulin acutely decrease the stiffness of large arteries measured using pulse wave analysis (37). Insulin has also been shown to cause vasodilatation in peripheral resistance vessels, but this effect requires prolonged or high doses of insulin and its physiologic relevance has therefore been questioned (29). In hypothalamus, insulin stimulates sympathetic nervous system resulting in e.g. increases in sympathetic nervous activity in muscle (29). Insulin also regulates the autonomic control of heart rate by decreasing vagal and increasing sympathetic tone (29).

2.1.2. INSULIN RESISTANCE

Insulin resistance is defined as the inability of insulin to produce its usual biological actions at circulating concentrations that are effective in normal subjects (29). Insulin resistance can develop to any of the metabolic actions of insulin.

CAUSES OF INSULIN RESISTANCE

Obesity

Obesity is associated with an impaired action of insulin to inhibit glucose production and to increase glucose uptake (29). Body mass index (BMI), however, accounts only for a part of the variance in insulin sensitivity in the normal population, and the mechanisms by which obesity induces insulin resistance are poorly understood (29). Recent data would suggest that the amount of fat stored within the liver and skeletal muscle is the most proximal correlate of insulin resistance in obesity (38). In fact, fat may also accumulate in the liver and skeletal muscle in the absence of subcutaneous fat, in lipodystrophic conditions in humans and animals, as will be discussed later.

Physical inactivity

Several prospective epidemiological studies have shown an inverse correlation between physical activity and the incidence of type 2 diabetes (29,39). Physical inactivity increases the risk of diabetes, even after adjusting for age, smoking, alcohol consumption, family history of diabetes, BMI, HDL-cholesterol, triglycerides and hypertension (29). Studies on the effects of physical exercise training in diabetic and non-diabetic subjects suggest a preferential loss of visceral fat over total fat and a decrease in inflammatory markers, such as C-reactive protein (CRP) and tumor necrosis factor (TNF) α (40,41).

Insulin and contractions of muscle fibers stimulate glucose uptake in skeletal myocytes through independent mechanisms (42). Contractions of the myocytes increase glucose uptake by stimulating the adenosine monophosphate-activated protein kinase (AMPK) (43). AMPK is an energy-sensing enzyme, which is activated in response to cellular fuel depletion, hypoxia and contraction (44). AMPK activation leads to increased glucose uptake, enhanced insulin sensitivity and increased oxidation of fatty acids in skeletal muscle, and to an increase in hepatic fatty acid oxidation and inhibition of glucose production in the liver (45,46).

Gender

The glucose uptake is 45% higher in women than in men when expressed per kilogram of muscle tissue after controlling for age and maximal oxygen uptake (47). Female sex steroids are unlikely to be responsible for this gender difference, since estradiol does not improve insulin sensitivity in postmenopausal women (48).

Age

Several factors, such as increasing adiposity, a reduction in muscle mass, physical inactivity, medications and coexisting illnesses may contribute to age-related insulin resistance (49). In a recent report, increased insulin resistance in healthy elderly people was associated with increased fat accumulation in skeletal muscle and the liver, and with a ~40% reduction in mitochondrial oxidative and phosphorylative activity in the muscle when compared to healthy young people matched for body composition and physical activity (50). These data would support the hypothesis that an inability of skeletal muscle and the liver to metabolize fatty acids, possibly because of mitochondrial dysfunction, may lead to intracellular accumulation of fatty acid metabolites and defects in insulin signaling and action in these tissues (51).

2.1.3. ADIPOSE TISSUE

Traditionally, adipose tissue was regarded merely as a passive energy reserve capable of storing lipids in the form of triacylglycerol at times of energy surplus, and releasing FFA and glycerol at times when energy expenditure exceeds energy intake. A grown-up person has usually 10 - 25 kg of fat, which stores 90 000 to 225 000 kcal energy in the form of triglyceride (11). However, it is now recognized that adipose tissue has a wide range of endocrine and paracrine functions, and participates in the regulation of metabolism in other tissues. It is also important to bear in mind that adipose tissue does not consist of adipocytes only but also of

a variety of other functionally active cells such as preadipocytes, vascular endothelial and smooth muscle cells, fibroblasts, mast cells and macrophages (52).

DIFFERENTIATION AND FUNCTION OF ADIPOCYTES

Adipocytes originate from pluripotent mesenchymal stem cells, which can differentiate to adipocytes, myocytes, chondrocytes or osteoblasts (**Fig. 1**) (52,53). Stem cells first develop into preadipocytes and so become committed to the adipocyte lineage (54). The regulation of this first step is poorly known (54). Interestingly, it has recently been shown that under experimental conditions in mice preadipocytes can be converted also into macrophages (55).

After being committed to the adipocyte lineage, the preadipocytes have an exponential growth phase, which leads to cell confluence and subsequently to a cell cycle arrest usually achieved through contact inhibition (54). Thereafter contact-inhibited preadipocytes re-enter the cell cycle due to hormonal induction and undergo a limited number of cell divisions known as the clonal expansion of preadipocytes (52).

In the final step of differentiation, fibroblast-like preadipocytes accumulate intracellular lipids and become typical round adipocytes. The main regulators of the terminal differentiation are three classes of transcription factors: CCAAT/enhancer-binding proteins (C/EBPs), peroxisome proliferator-activated receptor (PPAR) γ and SREBP-1c (**Fig. 1**) (52). These transcription factors act in a sequential cascade. First, C/EBPβ and δ are transiently induced and seem to have a direct transcriptional effect through C/EBP binding sites in the PPARγ promoter. PPARγ is then responsible for inducing C/EBPα. PPARγ and C/EBPα reinforce the expression of each other, thus ensuring sufficient expression of the two major stimulators of adipocyte differentiation (53). PPARγ and C/EBPα synergistically activate differentiation-linked gene expression. Many of these genes are known to have binding sites for both C/EBP proteins and PPARγ (53). In addition to C/EBPβ- and δ-dependent induction, PPARγ expression can also be induced by SREBP-1c, which may additionally be involved in the production of an endogenous PPARγ ligand and consequently increase PPARγ activity (53). SREBP-1c stimulates adipogenesis not only via inducing PPARγ, but also by directly activating expression of adipogenic genes (56). Eventually, the activation of the transcription factors results in *de novo* or enhanced expression of genes that characterize the mature adipocyte phenotype along with massive triglyceride accumulation. The products of these genes include e.g. fatty acid synthase (FAS), GLUT4, insulin receptor and adipocyte lipid binding protein (ALBP) (53).

Factors stimulating adipogenesis

The combination of insulin, dexamethasone and cyclic adenosine monophosphate (cAMP) is conventionally used to stimulate adipocyte differentiation *in vitro* (57). Insulin increases the percentage of preadipocytes



Figure 1. *Differentiation of an adipocyte from a multipotent mesenchymal stem cell. After the clonal expansion of preadipocytes a cascade of several transcription factors gets activated. PPARγ is the major transcription factor for the activation of adipogenic genes, which results in lipid accumulation and final maturation of the adipocyte.*

that differentiate, adipocyte lipogenesis and it also has antiapoptotic activity (53). Glucocorticoids are believed to stimulate adipogenesis through binding to glucocorticoid receptor. Glucocorticoid-induced transcriptional effects in adipocyte differentiation may include induction of C/EBPδ expression and reduction of the expression of preadipocyte factor-1, which is a negative regulator of adipogenesis (53). Increase in cellular cAMP concentration promotes adipocyte differentiation at least in part, by inducing C/EBPβ, but may also act through the cAMP response element binding protein (CREB) (53).

Factors inhibiting adipocyte differentiation

Inflammatory cytokines, such as TNFα, IL-1, IL-6, IL-11 and interferon γ inhibit adipocyte differentiation *in vitro*, and may contribute to atrophy of adipose tissue in cancer cachexia, inflammatory and chronic infectious diseases (56). Exposure of preadipocytes to TNFα or to other inflammatory cytokines inhibits adipogenesis by blocking induction of PPARγ and C/EBPα (56). Growth hormone has been shown to

decrease adiposity *in vivo* through activation of lipolysis (56). However, *in vitro* growth hormone can both promote and inhibit adipocyte differentiation (58).

Physiology of mature adipocytes

Surplus energy is stored in adipocyte lipid droplets as triglycerides. Depending on the size of the lipid droplet, the mature adipocyte can change its diameter by 20-fold and the volume by several thousand-fold (9).

Adipocytes synthesize triglycerides from fatty acids. In order to enter the adipocytes, fatty acids must first be released from circulating triglyceride-rich lipoproteins, chylomicrons and VLDL (**Fig. 2**). The release of fatty acids from circulating lipoproteins is catalyzed by LPL, which is located on the adipose tissue capillary endothelium (11). The activity of LPL is regulated mainly by insulin, but is also controlled by the removal rate of liberated fatty acids from the capillary, i.e. if fatty acids are not taken up by adipocytes, LPL activity decreases (59). The less fatty acids are taken up by the adipocytes, the more fatty acids enter the general circulation and reach the liver and skeletal muscle (59).

Entry of fatty acids into the adipocyte is likely to occur both by passive diffusion and active transport (**Fig. 2**) (60). Three groups of proteins have been implicated in the transport process: fatty acid transport proteins (FATPs), CD36 also known as fatty acid translocase (FAT), and plasma membrane-associated fatty acid binding protein (FABPpm). Their expression is upregulated during adipocyte differentiation (60). Acylation stimulating protein (ASP) is another protein regulating the uptake of fatty acids by the adipocyte. ASP is formed via posttranslational interactions of three proteins secreted by adipocytes: factor B, adipsin (factor D) and the third component of complement C3 (61).

Once inside the adipocyte, fatty acids are bound to cytoplasmic fatty acid-binding proteins (FABP). Two FABPs are expressed in human white adipose tissue, ALBP (the human homologue of the mouse aP2) and keratinocyte lipid binding protein (KLBP) (**Fig. 2**) (62). Acyl coenzyme A synthase (ACS) in turn catalyzes the conversion of long-chain fatty acids to their acyl CoA esters than can then be used either for the synthesis of triglycerides or for oxidation in mitochondria (63).

The breakdown of adipocyte intracellular triglycerides, lipolysis, is catalyzed by HSL (**Fig. 2**). Insulin and ASP decrease lipolysis by increasing re-esterification of fatty acids and inhibiting HSL activity (61,64). Other regulators of lipolysis include TNFα, which increases lipolysis (65), and autonomous nervous system, which increases lipolysis via β1- and β2- receptors, or decreases lipolysis via α2-receptors (66).



Figure 2. *Schematic picture of FFA trafficking in the adipocyte. FFA (•) are released from triglyceride-rich lipoproteins (VLDL, chylomicrons) on capillary endothelium by LPL. FFA can then enter the adipocyte via passive diffusion or by using transport proteins (FATP-1 and -4, FAT/CD36, FABPpm). Intracellular FFA are bound to ALBP or KLBP. ACS catalyzes the formation of AcylCoA, which can either be oxidized in mitochondria or used for triglyceride synthesis. Glucose uptake via GLUT4 and GLUT1 transporters is needed for glycerol formation. HSL catalyzes breakdown of intracellular triglycerides.*

In addition to storing and releasing fatty acids, adipose tissue is capable of producing a large number of proteins such as adiponectin, leptin, TNFα, IL-6, LPL, PAI-1, tissue factor, angiotensinogen, adipsin, ASP, some of which are important in the regulation of whole body metabolism (Chapter 2.1.3.). Of note, some of these proteins do not exclusively originate from adipocytes, but also from other cells such as macrophages and endothelial cells present in adipose tissue.

Brown adipose tissue

The primary function of brown adipose tissue is not to store energy but to produce heat. Brown adipocytes differ from white adipocytes morphologically: brown adipocytes are rich in mitochondria and store lipids in small droplets instead of one large droplet as seen in white adipocytes (67). In rodents, brown and white adipocytes have specific tissue distribution; inguinal, epididymal and retroperitoneal depots contain mainly white adipocytes, whereas interscapular and perirenal depots contain mainly brown adipocytes (68).

Abundant brown adipose tissue is present in human newborns, primarily in the thoracic cavity surrounding the great vessels (53). In healthy human adults, there are no specific brown fat depots, but occasional brown adipocytes can be detected within normal white adipose tissue (68). Expression of uncoupling protein-1 (UCP-1), which confirms the presence of brown adipocytes, has been found to be significantly increased in omental vs. subcutaneous fat both in lean and obese subjects (69). It has been estimated that in omental fat approximately 1 in 100-200 adipocytes is brown (69).

The PPARγ coactivator –1 (PGC-1) is expressed in brown fat, skeletal muscle, heart, kidney and brain, but not in white fat in mice (53). PGC-1 may preferentially direct preadipocytes to a brown adipocyte phenotype, since overexpression of PGC-1 in human and mouse white adipocytes in culture induces endogenous UCP-1 expression and mitochondrial biogenesis (53,70).

PGC-1 expression has not been measured in patients with HAL, but is an interesting protein in this context for multiple reasons. As a co-activator of PPARγ (71), it may affect adipogenesis via PPARγ activation. In addition, PGC-1 has been shown to regulate mitochondrial biogenesis (72), which may have impact in the pathogenesis of the mitochondrial alterations observed in HAL (Chapter 2.3.4.). Furthermore, in muscle cells *in vitro*, adenovirus-mediated PGC-1 expression results in increased GLUT4 expression (73). PGC-1 expression in transgenic mice has been shown to convert type II muscle fibers into type I which are rich in mitochondria, express more GLUT4 and are more dependent in oxidative metabolism than type II fibers (74).

ADIPOSE TISSUE AS A REGULATOR OF WHOLE BODY INSULIN RESISTANCE

Mechanisms of insulin resistance in adipose tissue

The mechanisms underlying insulin resistance in adipocytes are not fully understood. Subcutaneous adipocytes from patients with type 2 diabetes have reduced IRS-1 protein expression and reduced PI 3-kinase activity when compared to adipocytes from non-diabetic subjects (75). Low messanger RNA (mRNA) and protein levels of IRS-1 in subcutaneous adipocytes have also been found in healthy individuals with an increased risk of type 2 diabetes, i.e. in massively obese subjects and subjects with first-degree relatives with type 2 diabetes (76). Those healthy adults, who had low IRS-1 expression in subcutaneous adipocytes had also impaired downstream insulin signaling, reduced PI 3-kinase activation, GLUT4 expression and insulin-stimulated glucose transport in adipocytes (77). Low IRS-1 expression in subcutaneous adipocytes of insulin resistant subjects was associated with decreased expression of genes related to fat cell differentiation, such as adiponectin, ALBP, PPARγ and LPL (77,78). Women with gestational diabetes have been reported to have a decreased cellular content of GLUT4, but normal content of GLUT1 in isolated omental adipocytes (79). Similarly, GLUT4 expression in SAT has been reported to be reduced both in obese patients with type 2 diabetes and in obese non-diabetic subjects when compared to lean controls (80).

Free fatty acids

FFA have emerged as a major link between obesity and insulin resistance (81). In normal subjects, an acute elevation of FFA by a lipid infusion decreases insulin-stimulated glucose uptake (82,83). It has been demonstrated using MRI spectroscopy that FFA infusion into healthy humans causes a decrease in intracellular glucose-6-phosphate concentration in skeletal muscle (84). This decrease was a consequence of reduced insulin-stimulated glucose transport and insulin-stimulated induction of PI 3-kinase activity (84).

Acute elevation of FFA in the plasma inhibits the ability of insulin to suppress glucose production in the liver (82,85). Although data are somewhat contradictory, increased plasma FFA may reduce hepatic insulin clearance (86). Because approximately half of the insulin secreted by β-cells is removed on first pass by the liver, this reduction in clearance may contribute to peripheral hyperinsulinemia in insulin resistance (86).

Adipocytokines

The term adipocytokine is used to describe a wide range of proteins produced by adipose tissue. Adipocytokines include both classical cytokines such as TNFα and IL-6, and other proteins, such as adiponectin and leptin (87). Adipocytokines may act locally as autocrine or paracrine factors, or have remote-acting endocrine functions.

Adiponectin

In 1995, a novel 30-kDa secretory protein, which was later named adiponectin, was described in 3T3-L1 adipocytes (88). The protein was expressed exclusively in adipocytes and its mRNA was induced 100-fold during adipocyte differentiation (88). Adiponectin was originally named Acrp30 (adipocyte complement-related protein of 30 kDa) and later was also called AdipoQ, apM1, GBP28 (89).

Since adiponectin is exclusively expressed in adipocytes, it was surprising that the plasma concentrations in humans were inversely rather than directly correlated with BMI both in women and men, although women had higher plasma concentrations than men (90). Adiponectin concentrations have also been shown to increase after weight loss (91). Adiponectin seems to act as a metabolically protective adipocytokine, since age- and BMI-matched diabetic patients have lower serum adiponectin concentrations than non-diabetic subjects (91). Furthermore, diabetic and non-diabetic patients with coronary artery disease have lower adiponectin concentrations than diabetic or non-diabetic subjects without coronary artery disease, respectively (91,92). Adiponectin mRNA levels were significantly reduced in omental adipose tissue of obese patients with type 2 diabetes compared with lean and obese normoglycemic subjects (93). Although less pronounced, adiponectin mRNA levels were reduced also in SAT of type 2 diabetic patients (93).

In addition to the cross-sectional studies listed above, the role for adiponectin in the development of insulin resistance has been evaluated in some longitudinal animal and human studies. In a prospective study with

rhesus monkeys, decrease in plasma adiponectin concentration paralleled with the development of insulin resistance and this decrease preceded overt hyperglycemia (94). In apparently healthy humans, high concentrations of adiponectin seem to be associated with a substantially reduced relative risk of developing type 2 diabetes even after adjusting for age, sex, waist to hip ratio (WHR), BMI, smoking, exercise, alcohol consumption, education and HbA1c concentration at baseline (95). Similarly, baseline plasma adiponectin concentration was lower in those Pima Indians who after a mean follow-up of 6.7 years developed diabetes than in those who did not develop diabetes matched for age, sex, BMI (96).

Further evidence for an antidiabetic and cardioprotective role of adiponectin has been obtained in animal and *in vitro* studies. Infusion of adiponectin reverses insulin resistance both in obese and lipoatrophic mouse models (22). *In vitro* adiponectin has been shown to inhibit the TNFα-induced expression of endothelial adhesion molecules (97). Furthermore, adiponectin suppresses the *in vitro* transformation of human monocyte-derived macrophages into foam cells (98).

Regulation of adiponectin expression has recently been evaluated in several studies. Known inhibitory regulators of adiponectin expression in 3T3-L1 adipocytes include TNFα and dexamethasone (99), IL-6 (100) and ghrelin (101). TNFα also decreases adiponectin expression in differentiating primary human adipocytes (102). Both TNFα and IL-6 decrease adiponectin mRNA levels also in cultured human SAT (103). In non-diabetic subjects, adiponectin expression in SAT has been shown to have an inverse correlation with the expression of TNFα, but not with the expression or plasma levels of IL-6 concentration (104). The effect of insulin on adiponectin expression remains controversial even in 3T3-L1 cell line; one study showed an insulin-induced inhibition of adiponectin expression (99), whereas in another study insulin enhanced the secretion of adiponectin (105). In humans, insulin appears to decrease circulating levels of adiponectin (106). β-Adrenergic stimulation inhibits adiponectin expression in human visceral adipose tissue (VAT) explants (107) and 3T3-L1 adipocytes (108). In mice, castration increases plasma adiponectin concentrations and improves insulin sensitivity (109). Treatment with thiazolidinediones increases adiponectin plasma concentrations in humans (110) and adiponectin mRNA concentrations in adipose tissue of obese mice (111). A functional PPAR-responsive element was recently identified in the human adiponectin promoter (112).

The molecular mechanisms by which adiponectin enhances insulin sensitivity are still incompletely understood. Infusion of adiponectin decreases insulin resistance and triglyceride content in skeletal muscle and in the liver both in obese and lipoatrophic mice (22). Adiponectin increases fatty acid oxidation in isolated muscle in mice (113). Both globular and full-length adiponectin stimulate phosphorylation and activation of AMPK in skeletal muscle (21). In parallel with the activation of AMPK, adiponectin stimulates phosphorylation and thereby inhibition of acetyl coenzyme A carboxylase (ACC) activity (21). Lower ACC activity leads to a fall in malonyl-CoA content and relieves the inhibitory effect of malonyl-CoA on carnitine

palmitoyl transferase 1, which results in enhanced entry of fatty acids into mitochondria for oxidation (21,114). In isolated rat hepatocytes, adiponectin increases the ability of insulin to suppress glucose production (20). Full-length adiponectin, but not the globular domain was capable of activating AMPK in the mouse liver and subsequently reduced expression of molecules involved in gluconeogenesis, such as PEPCK and glucose-6 phosphatase (21).

Very recently, two adiponectin receptors (AdipoR) have been cloned (115). Human and mouse AdipoR1 share 96.8% and AdipoR2 95.2% identity (115). In mice, AdipoR1 is abundantly expressed in skeletal muscle, whereas AdipoR2 is predominantly expressed in the liver (115).

Leptin

Leptin is the protein product of the obese (ob) mouse gene cloned in 1994 (116). Leptin is expressed mainly, but not exclusively in white adipocytes (117). Originally leptin was thought to act merely as a satiety hormone (118) and reduce food intake via central mechanisms. Today, however, it is clear that leptin has multiple other functions, such as regulation of the hypothalamic-pituitary-endocrine axes, hematopoiesis, angiogenesis, immune functions, osteogenesis, and wound healing (117).

Since leptin expression in adipose tissue is increased in obese humans (119), and serum leptin concentration and mRNA in adipocytes are positively correlated with total body fat, it has been suggested that obese people are resistant to the effects of leptin (120). Since leptin treatment induces weight loss in leptin-deficient (*ob/ob*) obese mice (121), exogenous leptin therapy has also been tested in human obesity. However, leptin treatment in normal obese humans with high leptin concentrations, induced only modest weight loss in a few subjects and had no effect on glycemic control (122). However, in patients with different forms of non-HIV lipodystrophy with low baseline leptin levels, leptin treatment induced a marked improvement in glycemic control (123). In this study, the improvements in hepatic and skeletal muscle insulin sensitivity were associated with a decrease in hepatic and muscle triglyceride content (124).

Pro-inflammatory cytokines

TNFα has been suggested to contribute to obesity-induced insulin resistance. TNFα is overexpressed in adipose tissue of obese humans and its expression is decreased by weight loss (125). Although TNFα appears to be secreted into conditioned media of human adipose tissue explants (126), the release of TNFα from adipose tissue to the circulation has not been shown *in vivo* (127). TNFα mRNA levels in human adipose tissue have been shown to correlate closely with the level of hyperinsulinemia (126). However, correlations between TNFα expression in SAT and BMI or insulin sensitivity have not been found in all studies (128).

The cellular actions of TNFα are mediated through two receptors, TNFα receptor 1 (TNFR1 or p60 in humans, and p55 in rodents), and TNFR2 (p80 in humans and p75 in rodents) (129). The suggested mechanisms of TNFα to cause insulin resistance involve increased lipolysis and a consequent increase in circulating FFA levels, decrease in GLUT4, insulin receptor and IRS-1 synthesis, inhibition of PPARγ synthesis and/or function, and serine phosphorylation of IRS-1 (130). However, the contribution of TNFα to insulin resistance in humans still remains to be defined; the first trial using TNFα-neutralizing antibodies failed to change insulin sensitivity in patients with type 2 diabetes (131).

IL-6 is secreted from SAT to the circulation and adipose tissue-derived IL-6 is estimated to account for 15-35% of its total circulating concentration in humans (127). Serum concentrations of IL-6 are increased in obesity (132) and in type 2 diabetes (133), and correlate with the degree of insulin resistance in non-diabetic subjects (134,135). IL-6 protein content in adipose tissue has been found to be inversely correlated with *in vivo* insulin-stimulated glucose uptake, and *in vitro* glucose uptake in human subcutaneous adipocytes (136). Weight loss enhances insulin sensitivity and is associated with a decrease in IL-6 protein levels in both SAT and serum (137). Furthermore, the change in circulating IL-6 level has been found to correlate with the improvement in insulin sensitivity after weight loss (138).

The mechanisms linking IL-6 to insulin resistance are not fully understood. In the human hepatocarcinoma cell line, HepG2, IL-6 decreases tyrosine phosphorylation of IRS-1 and the association of the p85 subunit of PI 3-kinase with IRS-1, and inhibits insulin-dependent activation of protein kinase B (139). IL-6 does not cause an acute lipolytic effect in human adipocytes (140). In 3T3-L1 adipocytes, IL-6 decreases transcription of IRS-1, GLUT4 and PPARγ genes, and insulin-stimulated glucose transport (140).

Resistin

Resistin is a peptide hormone, which has been shown to impair glucose tolerance and insulin action in normal mice (141). Administration of anti-resistin antibody has been shown to improve glycemia and insulin action in mice with diet-induced obesity (141). However, several studies have later reported an association between decreased rather than increased resistin expression and insulin resistance in various rodent models (142). Resistin mRNA (143) and protein (144) concentrations were significantly increased in abdominal subcutaneous and omental fat when compared with breast and thigh subcutaneous fat in non-diabetic subjects. However, the role of resistin in human insulin resistance remains elusive, since several studies have not been able to detect resistin mRNA in human adipocytes (142).

METABOLIC CHARACTERISTICS OF DIFFERENT ADIPOSE TISSUE DEPOTS

Already in the 1950s, the association between android, i.e. upper body obesity and type 2 diabetes was recognized (145). In 1985, Ashwell et al. studied fat distribution using computed tomography (CT) and

suggested that the metabolic complications of obesity may relate specifically to the amount of intra-abdominal fat (146). Intra-abdominal fat can be further divided into an intraperitoneal depot (omental [0.5-3 kg] and mesenteric [0.5-2 kg]) and retroperitoneal, i.e. perirenal fat (0.5-2 kg) (147). Omental and mesenteric fat depots are also referred to as visceral fat since their venous drainage is mainly through the portal vein (147). However, subcutaneous fat is the largest abdominal fat depot with an estimated weight of 1-20 kg (147). Of the whole body adipose tissue mass, subcutaneous fat constitutes at least 80% in both lean and obese subjects (148).

Intra-abdominal fat

VAT constitutes less than 20% of the whole body adipose tissue. Thus, for VAT to be more important than SAT in the pathogenesis of insulin resistance, there should be significant differences in the metabolic activity of VAT vs. SAT. Indirect evidence in favor of major functional differences between fat depots comes from a study, in which obesity was treated surgically with adjustable gastric binding (AGB) only, or with AGB and removal of the greater omentum fat which represented less than 1% of total fat mass (149). After 24 months, improvements in insulin sensitivity, and decreases in fasting plasma glucose and insulin concentrations were 2-3 times greater in omentectomized subjects as compared to those treated with AGB only (149).

The anatomic location of VAT may make it more important than SAT in the development of insulin resistance. Due to the portal venous drainage of visceral fat, the liver may get exposed to high concentrations of FFA and adipocytokines released from VAT, which could then stimulate hepatic glucose production and triglyceride synthesis, and decrease insulin clearance by the liver (147,150).

Gene expression in VAT vs. SAT in humans has been evaluated in several studies (**Table 1**). Omental fat secretes more IL-6 than subcutaneous fat, although IL-6 secreted from the isolated adipocytes is estimated to account only for ~10% of the total adipose tissue release (151). By contrast, leptin expression is higher in SAT than VAT (152,153). Some other adipocytokines, such as TNFα are similarly expressed in both SAT and VAT (148). It is impossible to draw firm conclusions regarding the expression of most genes, since they have only been evaluated in a single study or because the results from diverse studies show conflicting results. Furthermore, since many of these studies have included morbidly obese subjects, the results may not be generalizable to people with normal or moderately increased body weight.

Table 1. *Comparisons of gene expression in human subcutaneous (SAT) vs. visceral adipose tissue (VAT).*

	Number of subjects (F/M)	BMI (kg/m^2)	Measurement	Result	Ref.
Adiponectin	6	28-29	Protein from adipose tissue sample.	VAT < SAT	(154)
Adiponectin	9	41	Secretion of protein from isolated adipocytes.	VAT = SAT	(155)
Adipsin	31 (19/12)	28 (Female) 24 (Male)	mRNA from isolated adipocytes (n=12).	VAT = SAT	(156)
ALBP	29 (20/9) total 20 (13/7) obese 9 (7/2) lean	44 (Obese) 23 (Lean)	mRNA from adipose tissue samples in obese only. Protein from adipose tissue samples in all subjects.	VAT < SAT (both mRNA and protein, but in obese only)	(62)
Angiotensinogen	20 (8/12)	41	mRNA from adipose tissue sample (n=16).	VAT > SAT	(157)
Angiotensinogen	9 (5/4)	34	mRNA from adipose tissue sample.	VAT > SAT	(158)
ASP / C3a	9 (5/4)	34	mRNA from adipose tissue sample.	VAT > SAT	(158)
CETP	9 (5/4)	34	mRNA from adipose tissue sample.	VAT < SAT	(158)
cIAP2	31 (19/12)	28 (Female) 24 (Male)	mRNA from isolated adipocytes (n=8).	VAT > SAT	(156)
cIAP2	11 (9/2)	24	mRNA from preadipocytes.	VAT > SAT	(159)
Complement components:C2, C3,C4,C7,Factor B	10 (0/10)	42	mRNA from adipose tissue sample.	VAT > SAT	(160)
Glucocorticoid receptor	14 (14/0)		mRNA from adipose tissue sample.	VAT > SAT	(161)
GLUT4	12 (7/5)	20-53	mRNA from adipose tissue.	VAT < SAT	(162)
GLUT4	9 (9/0)	45	mRNA (n=6-8) and protein from isolated adipocytes from 3 sites: round ligament,. greater omentum, subcutaneous fat.	Round ligament > omentum or subcutaneous fat	(163)
Glycerol-3-phosphate dehydrogenase	24 (15/9)	20-34	mRNA from isolated adipocytes (n=20).	VAT = SAT	(152)
Glycogen synthase	12 (7/5)	20-53	mRNA from adipose tissue.	VAT < SAT	(162)
11β-HSD-1	16 (7/9)	Weight 78kg	mRNA and enzyme activity in isolated preadipocytes.	VAT > SAT in enzyme activity	(164)
HSL	31 (19/12)	28 (Female) 24 (Male)	mRNA from isolated adipocytes (n=12).	VAT = SAT	(156)
HSL	21 (12/9)	32	mRNA and HSL activity in isolated adipocytes.	VAT < SAT	(165)
HSL	12 (7/5)	20-53	mRNA from adipose tissue.	VAT = SAT	(162)

IL-6	10 (6/4)	52	Protein release into media from adipose tissue fragments (n=6) or isolated adipocytes (n=3).	VAT > SAT	(151)
Insulin receptor	12 (7/5)	20-53	mRNA from adipose tissue. Most mRNA from insulin receptor lacking exon 11.	VAT > SAT	(162)
Insulin receptor	55 (28/27)	19-37	mRNA (n=20) and protein (n=9) from isolated adipocytes.	VAT = SAT	(166)
IRS-1	12 (7/5)	20-53	mRNA from adipose tissue.	VAT = SAT	(162)
IRS-1	55 (28/27)	19-37	Protein (n=5) from isolated adipocytes.	VAT < SAT	(166)
KLBP	29 (20/9) total 20 (13/7) obese 9 (7/2) lean	44 (Obese) 23 (Lean)	mRNA from adipose tissue samples in obese only. Protein from adipose tissue samples in all subjects.	VAT > SAT (protein level in lean only)	(62)
Leptin	31 (19/12)	28 (Female) 24 (Male)	mRNA from isolated adipocytes (n=12).	VAT < SAT	(156)
Leptin	24 (15/9)	20-34	mRNA from isolated adipocytes.	VAT < SAT	(152)
Leptin	9 (5/4)	34	mRNA from adipose tissue sample.	VAT < SAT	(158)
Leptin	12 (7/5)	20-53	mRNA from adipose tissue.	VAT < SAT	(162)
Leptin	23 (23/0) 15 obese 8 lean	28-60 (obese) 20-27 (lean)	Protein secretion from adipose tissue samples (in all subjects) and mRNA in obese women.	VAT < SAT	(153)
LPL	31 (19/12)	28 (Female) 24 (Male)	mRNA from isolated adipocytes (n=11).	VAT = SAT	(156)
LPL	63 (45/18)	46 (Female) 50 (Male)	mRNA from adipose tissue samples (n=12 women and 5 men).	VAT < SAT in women VAT = SAT in men	(167)
LPL	12 (7/5)	20-53	mRNA from adipose tissue.	VAT = SAT	(162)
PAI-1	22 (14/8)	43	mRNA from adipose tissue and protein secretion from adipose tissue samples.	VAT < SAT	(168)
PAI-1	28 (28/0)	28	mRNA from adipose tissue samples.	VAT = SAT	(169)
PAI-1	26 (22/4)	41	mRNA from adipose tissue samples.	VAT > SAT	(170)
PAI-1	7 (3/4)	18-28	Protein secretion from adipose tissue explant.	VAT > SAT	(171)
PAI-1	40	28	Protein (n=7) and mRNA release from adipose tissue samples.	VAT > SAT	(172)
PAI-1	18 (10/8) total 11 (8/3) obese 7 (2/5) non-obese	45 (obese) 24 (non-obese)	Protein release from adipose tissue culture.	VAT > SAT	(173)
6-Phosphofructo-1-kinase	12 (7/5)	20-53	mRNA from adipose tissue.	VAT = SAT	(162)
PI 3-kinase	12 (7/5)	20-53	mRNA from adipose tissue.	VAT = SAT	(162)

p85-subunit					
PPARα	12 (7/5)	20-53	mRNA from adipose tissue (n=6).	VAT = SAT	(162)
PPARδ	12 (7/5)	20-53	mRNA from adipose tissue (n=6).	VAT = SAT	(162)
PPARγ	12 (7/5)	20-53	mRNA from adipose tissue.	VAT < SAT in those with BMI < 30 only	(162)
PPARγ	31 (19/12)	28 (Female) 24 (Male)	mRNA from isolated adipocytes (n=11).	VAT = SAT	(156)
Resistin	10	26	Protein from adipose tissue sample.	VAT > thigh or breast SAT VAT = abdominal SAT	(144)
SREBP-1c	20 (14/6)	51	mRNA from adipose tissue.	VAT < SAT	(174)
TNFα			Reviewed by Arner (148).	VAT = SAT	(148)
TNF receptors p60 and p80	40 (40/0) 28 obese 12 non-obese	48 (obese) 26 (lean)	mRNA from adipose tissue samples.	VAT < SAT only obese subjects included.	(175)

Omental and mesenteric adipocytes have higher rate of lipolysis, i.e. FFA release, than subcutaneous adipocytes, and their lipolysis is more readily stimulated by catecholamines and less readily suppressed by insulin (147,150,176). Unexpectedly, in one study the mRNA expression and the activity of HSL, which is the major determinant of the maximum lipolytic capacity of human fat cells (177), was found to be higher in SAT than in VAT (165). In two other studies available, HSL expression was not different between VAT and SAT (152,162).

In the view of stable or increasing amount of VAT in obese subjects, increased lipolysis in VAT should be compensated by increased lipogenesis. This has been shown in a study, where the uptake of orally administered fatty acids was ~50% higher in VAT than in SAT (178). However, *in vitro* triacylglycerol synthesis was greater in human SAT fragments and subcutaneous preadipocytes than in omental adipose tissue and preadipocytes (179). LPL regulates hydrolysis of plasma triglycerides and consequently FFA availability for deposition in adipose tissue. LPL mRNA expression has either been reduced in VAT compared to SAT (167) or it has been similar in both fat depots (152,162).

Subcutaneous fat

The origin and concentration of FFA in the human portal vein are poorly known due to the difficult anatomic accessibility of the portal vein. According to catheterization studies, only ~10% of the FFA reaching the liver originate from VAT (147,180). Postprandial FFA delivery to the liver is greater in women with upper than lower body obesity (181). The excess FFA, however, seem to originate from the non-splanchnic adipose tissues rather than from VAT (181).

Paucity rather than excess of lower body subcutaneous fat may independently contribute to the development of insulin resistance and diabetes. In a cross-sectional study, a narrow hip circumference adjusted for age, BMI and waist circumference was associated with features of insulin resistance (182). Conversely, the protective role of abundant lower body subcutaneous fat was demonstrated in a recent prospective study where large hip and thigh circumferences at baseline were associated with a lower risk of development of type 2 diabetes, independently of BMI, age and waist circumference (183).

Taken together, there are differences in the metabolic activity of VAT vs. SAT. However, the exact mechanisms of these different fat depots to contribute to insulin resistance in humans *in vivo* are currently not fully understood.

2.1.4. FAT IN INSULIN SENSITIVE TISSUES OTHER THAN ADIPOSE TISSUE

Patients with excess (the obese) or too little (the lipoatrophic) adipose tissue are insulin resistant and at increased risk of developing type 2 diabetes. A common denominator for both groups appears to be excessive deposition of lipids in the liver and skeletal muscle (38).

THE LIVER

The term “nonalcoholic fatty liver disease” (NAFLD) is used to describe a spectrum of abnormalities ranging from simple steatosis to nonalcoholic steatohepatitis (NASH) (184). The term “nonalcoholic steatohepatitis” was originally used to describe liver disease that histologically mimicked alcoholic hepatitis and that could progress to cirrhosis (185). Steatosis without inflammation seems to be a benign condition (186). It has been suggested that the development of NASH requires two pathogenic steps: hepatic fat accumulation and thereafter oxidative stress capable of initiating significant lipid peroxidation and cytokine induction (187,188).

Both steatosis and NASH are associated with obesity and diabetes (189). Subjects with normal glucose tolerance, who had biopsy-proven NAFLD with or without steatohepatitis had central fat accumulation, increased triglycerides and uric acid, and a low HDL cholesterol irrespective of BMI (190). In the same study, patients with NAFLD had impaired insulin-induced suppression of hepatic glucose production, and reduced glucose disposal rate when compared to healthy subjects even after adjusting for age, BMI and WHR (190).

Liver fat content measured using spectroscopy has been found to be more closely correlated with insulin-induced suppression of hepatic glucose production in type 2 diabetic patients than any other measure of body composition (191). In healthy non-diabetic men, liver fat content was associated with several features of insulin resistance, including hyperinsulinemia, hypertriglyceridemia, a low HDL cholesterol concentration and high 24-h systolic blood pressure, and impaired insulin-induced suppression of hepatic glucose production and of serum FFA concentration (19). Similarly in obese non-diabetic women, those with higher liver fat content had an increased serum triglyceride and insulin concentrations, a lower HDL cholesterol concentration, higher 24-h systolic and diastolic blood pressure, and lower glucose uptake during hyperinsulinemic euglycemic clamp than women with lower liver fat content but similar BMI (192).

SKELETAL MUSCLE

With MRI proton spectroscopy it is possible to non-invasively differentiate intramyocellular lipid (IMCL) from extramyocellular lipid (193,194). Using spectroscopy, a group of healthy men with higher IMCL have been shown to have reduced glucose uptake when compared to healthy men with lower IMCL independent of BMI and physical fitness (195). In obese subjects with unaltered insulin sensitivity, the preservation of insulin sensitivity has been associated with unaltered IMCL content, but increased fat oxidation when compared to lean subjects (196).

Aerobic fitness and recent strenuous exercise are important confounding factors when interpreting the relationship between IMCL and insulin resistance. A 2-week training program has been shown to

significantly increase IMCL whereas insulin sensitivity tended to improve (197). On the other hand, a 3-hour cycling exercise has been found to acutely decrease IMCL content (197).

MECHANISMS OF INSULIN RESISTANCE WITH FAT ACCUMULATION IN THE LIVER AND SKELETAL MUSCLE

Since triglycerides themselves are inert, increased intracellular triglyceride content is likely to be merely a surrogate marker of some other fatty acid-derived factor(s), such as long chain acyl-CoA, which can induce insulin resistance by multiple mechanisms, including diacylglycerol formation, activation of protein kinase C-theta, and ultimately serine, instead of tyrosine, phosphorylation of IRS-1, and reduction in PI 3-kinase activity (84,198,199). Other potential mechanisms of long chain acyl-CoA to induce insulin resistance include inhibition of insulin signaling via *de novo* ceramide synthesis and direct inhibition of hexokinase and glycogen synthase (200).

2.1.5. MOUSE MODELS OF LIPODYSTROPHY

Several mouse models of lipodystrophy with varying severity of fat loss have been reported in recent years. These models have been crucial in understanding the deleterious effects of the accumulation of lipids in insulin sensitive tissues, such as the liver and skeletal muscle, when adipose tissue cannot normally store fat.

Adipocyte specific-expression of diphtheria toxin A chain virtually eliminates white and brown fat in mice (8). Histologic examination of fat revealed atrophy, necrosis and monocytic infiltration, livers were enlarged and filled with fat, and mice developed diabetes (8). Troglitazone significantly decreased serum glucose, insulin, triglyceride, FFA and cholesterol concentrations, but did not change serum leptin concentration, or liver or muscle fat content in these mice (8).

Another model of fatless mouse was developed by expressing a truncated nuclear version of SREBP-1c in adipocytes (201,202). Surprisingly, overexpression of truncated SREBP-1c, a known adipogenic transcription factor, reduced adipose tissue mass and induced hypoleptinemia, hepatic steatosis and type 2 diabetes (201,202). Continuous leptin infusion decreased liver fat content and corrected insulin resistance (202).

A fatless mouse has also been developed by expressing a dominant-negative protein, termed A-ZIP/F (203). These A-ZIP/F-1 transgenic mice have no white fat, dramatically reduced brown fat, severe hepatosteatosis, diabetes, reduced serum leptin and increased glucose, insulin, triglyceride and FFA concentrations (203). Transplantation of wild-type fat tissue to A-ZIP/F-1 fatless mice reversed hyperglycemia, lowered insulin concentrations, improved muscle insulin sensitivity, corrected insulin signaling defects and normalized fat content in the liver and muscle (204,205).

2.1.6. NON-HIV HUMAN LIPODYSTROPHIES

Human lipodystrophies are rare genetic or acquired disorders characterized by total or partial loss of adipose tissue (lipoatrophy) and occasionally by local accumulation of fat (lipohypertrophy). The prevalences for the congenital forms have been estimated to be in the range of 1:10 million people (7). Of note, lipodystrophy must be differentiated from paucity of adipose tissue due to negative energy balance, e.g. due to starvation or extreme physical training. In contrast to lipodystrophies, in the latter condition the remaining adipocytes are functionally normal and retain the ability to store lipids during periods of energy surplus.

Human lipodystrophies can be classified according to the presumed etiopathogenesis, i.e. genetic, presumed inflammatory or autoimmune, and acquired lipodystrophies; or according to the severity of fat loss, i.e. generalized or partial (206). Various forms of congenital lipodystrophies have been described, such as congenital generalized (Berardinelli-Seip syndrome) and familial partial (Dunnigan and Köbberling variety) lipodystrophies (7,206). Presumed inflammatory or autoimmune lipodystrophies include acquired generalized (Lawrence syndrome), acquired partial (Barraquer-Simons syndrome) and injection site - associated lipodystrophy e.g. due to insulin injections before the availability of purified or human insulin (7,206).

Mutations causing Dunnigan-type partial lipodystrophy have recently been described (207). These mutations are found in the LMNA gene, which encodes type A lamins (207). Nuclear lamins are filament-type proteins that are the major building blocks of the nuclear lamina, a fibrous proteinaceous meshwork underlying the inner nuclear membrane thereby giving the cell nucleus its shape and interacting with proteins that regulate gene expression (206,208). The binding of lamin A to SREBP-1 is reduced by mutations causing lipodystrophy (209). Since SREBP-1 is a transcription factor, which promotes adipocyte differentiation, this defective interaction has been suggested to, at least partly, cause loss of fat in Dunnigan lipodystrophy (209).

Clinical and laboratory findings of lipodystrophic patients vary considerably, but they usually include insulin resistance and type 2 diabetes, hypertriglyceridemia, low HDL-cholesterol concentration, hypertension and a fatty liver (7,206). Women may suffer from oligo-amenorrhea and polycystic ovaries. Severe hypertriglyceridemia may cause pancreatitis, and fatty liver may lead to cirrhosis (7). Early onset diabetes and dyslipidemia are likely to accelerate atherosclerosis (7,210).

There are only limited data regarding treatment of lipodystrophy and its complications. Metformin may work in lipoatrophic diabetic patients, but the efficacy has been described in a single case report only (206,211). Insulin at very large doses may correct metabolic abnormalities in lipodystrophic patients with diabetes, whereas sulfonylureas have not been useful (206). Thiazolidinediones would seem ideal to treat lipodystrophy since they both improve insulin sensitivity and increase adipose tissue mass (212). In an open-label, uncontrolled study including 20 patients with various forms of lipodystrophy, use of troglitazone for

six months was shown to significantly decrease HbA1c levels, triglyceride and FFA concentrations (213). The respiratory quotient decreased significantly suggesting increased fat oxidation. Body fat measured by dual-energy x-ray absorptiometry (DEXA) increased significantly and MRI showed an increase in subcutaneous but not visceral fat. The size of the liver measured using MRI decreased (213). The effect of leptin has been studied in a small open-label, uncontrolled study in nine lipodystrophic patients with low serum leptin concentrations at baseline (123). Treatment with subcutaneous recombinant leptin injections for four months decreased HbA1c, triglyceride and FFA concentrations. Liver size decreased on the average by 28%. Body weight decreased in all but one patient. The effects on body composition were not reported (123). Leptin treatment in three of these patients significantly reduced hepatic and intramyocellular lipid content, and enhanced the insulin-induced suppression of hepatic glucose production and the insulin-stimulated peripheral glucose disposal (124).

2.2. HIV INFECTION AND ANTIRETROVIRAL THERAPY

2.2.1 HISTORY OF THE HIV EPIDEMIC

On June 5, 1981 Centers for Disease Control published a report of five cases of Pneumocystis carinii pneumonia among previously healthy young men in Los Angeles (214); this report is often referred to as the beginning of general awareness of acquired immunodeficiency syndrome (AIDS). It was soon realized that a new acquired disease of cellular immunodeficiency that manifested as Pneumocystis carinii pneumonia, Kaposi’s sarcoma, mucosal candidiasis and other opportunistic infections had emerged among gay men, intravenous drug users and hemophiliacs (215). By 1982, the new disease was being referred to by its new name “AIDS” (216). In May 1983, Dr Montagnier’s group from France reported an isolation of a new virus, which they believed was the cause of AIDS (217). In 1984, Dr Gallo’s group reported isolation of a new human retrovirus from blood samples of patients with AIDS and at risk for AIDS (218). It was later shown that LAV (lymphadenopathy-associated virus) described by Dr Montagnier and HTLV-III (human T-cell leukemia virus III) described by Dr Gallo were the same virus, and in 1986 the virus was renamed HIV (Human Immunodeficiency Virus) (219).

By 1999, according to World Health Organization, HIV infection had become the fourth leading cause of death worldwide after ischemic heart disease, cerebrovascular disease and acute lower respiratory infections (220). Among infectious disease pathogens, HIV causes more deaths than any other single agent (220). In 2002, 42 million people were estimated to live with HIV, the vast majority of them in sub-Saharan Africa, and in 2002 alone, 3.1 million people died from HIV/AIDS (221).

2.2.2. PATHOGENESIS

CD4+ T LYMPHOCYTES

Loss of immune system competence, and in particular, loss of cellular immunity is the major cause of clinical symptoms of HIV infection. T-lymphocytes expressing a CD4-receptor (CD4+ cells) are a critical component of intact cellular immunity. Loss of CD4+ cells occurs throughout HIV disease with an approximate decline of 80-90 cells/mm^3 per year (222). Since the beginning of the HIV epidemic, the blood CD4+ count has been used to indicate disease stage. CD4+ counts of healthy subjects are in the range of 500 to 1300 cells/mm^3 (223). A patient with a CD4+ cell count below 200 cells/mm^3 is at substantial risk of developing opportunistic infections and malignancies, and according to classification by Centers for Disease Control, is categorized as having AIDS even in the absence of opportunistic infections (224).

VIRAL LIFE CYCLE (**Fig. 3**)

Binding of the virus to the CD4 molecule on the host cell surface initiates a complex mechanism of viral entry, which leads to fusion of the viral lipid envelope with the cell membrane. The core of the virus penetrates into the cytoplasm and liberates viral genomic RNA. Viral reverse transcriptase enzyme converts RNA into double-stranded DNA, which is transported to the nucleus. In the nucleus, a viral enzyme called integrase mediates the integration of the viral DNA into the host chromosomal DNA. Thereafter viral DNA functions as a mammalian gene resulting in production of viral RNA and proteins. The viral structural proteins assemble around viral genomic RNA at the plasma membrane to produce new viruses. The final stage of the viral life cycle consists of proteolytic cleavage of precursor molecules by the viral protease enzyme (225).

During its clinical latency, HIV infection was earlier considered to be a relatively static infection. However, it is currently known that as many as 10^{10} virion particles are produced and cleared daily in an untreated individual (226). Rapid rate of virus production and high mutation rate create genetically diverse virus population within an individual patient. It is estimated that every possible point mutation will occur at least once daily in an HIV-infected non-treated person (227). The diversity of the viral population places high requirements for the potency of antiretroviral treatment.

2.2.3. CLINICAL COURSE

HIV is transmitted either through unprotected sexual contact, contaminated blood products, contaminated needles or injection equipment, or through mother-to-child transmission as transplacental or intra-partum infection or during breast-feeding (228). Symptomatic primary infection develops in ~50% of infected persons, usually 2-8 weeks after contracting the virus, and is characterized by fever, lymphadenopathy, pharyngitis and morbilliform skin eruption (222). The natural course of HIV infection thereafter is variable, but chronic HIV infection can remain clinically latent for years with minimal or no symptoms (229). With



Figure 3. *Schematic picture of the life cycle of HIV and the site of action of antiretroviral agents. HIV enters the human host cell by using the CD4- and co-receptors (1). The released viral single-stranded RNA is converted into double-stranded DNA by the viral reverse transcriptase (2). Double-stranded viral DNA enters the cell nucleus and is incorporated into the cell DNA in a reaction catalyzed by the viral integrase enzyme (3). Viral proteins and RNA are synthesized (4) and new viruses assembled (5). Viral proteins are modified by the viral protease. Fusion inhibitors block the viral entry into the cell, NRTIs and NNRTIs inhibit the reverse transcriptase and PIs the protease enzyme.*

advancing immunodeficiency, patients often develop nonspecific symptoms such as fever, night sweats, mucosal and dermatological manifestations (229). The final stage of the infection is named AIDS and is defined by the occurrence of an opportunistic infection or tumor considered indicative of advanced infection with HIV. In untreated individuals, the median time for progression from contracting HIV to the development of AIDS is ~10 years (223).

2.2.4. TREATMENT

HISTORY OF ANTIRETROVIRAL THERAPY

Until late 1980s, the only therapeutic interventions available for HIV-infected persons were prophylaxis and treatment of opportunistic diseases. Since the treatment of opportunistic diseases does not affect the gradual loss of CD4+ T cells, patients remained at constant risk for further opportunistic diseases and the overall prognosis remained poor. The first antiretroviral agent to decrease mortality among patients with AIDS was

zidovudine (230). The superiority of a dual nucleoside combination over zidovudine monotherapy on survival and disease progression was shown later (231).

After mid 1990s it became possible to monitor the progression of HIV infection not only by measuring the CD4+ count but also by quantifying the amount of HI-virus in plasma (viral load). Viral load was soon shown to independently predict disease progression (232) and, even more importantly, the measurement of viral load made it possible to monitor the virologic efficacy of antiretroviral treatment. In 1995-96, it was understood that mono and dual therapies could only transiently suppress viral replication, whereas the introduction of triple-drug regimens resulted in durable virologic suppression and lead to enormous positive impact on the prognosis of HIV-infected people (233,234). The acronym HAART, originally referring to triple combination therapy, was widely used already in 1996. After the introduction of HAART, the mortality rates declined by ~60-80% (**Fig. 4**) (1). Improved prognosis was based on the recovery of immune system after the viral replication was controlled for by the combination therapy. Successful HAART is not only able to stop the gradual loss of CD4+ cells, but it also allows the regeneration of these cells. Prophylaxis for opportunistic infections can be successfully discontinued after sustained increase in CD4+ count (235). However, since it is impossible to eradicate the virus with present antiretroviral agents (236), HAART most likely needs to be continued permanently.

ANTIRETROVIRAL AGENTS

Nucleoside reverse transcriptase inhibitors (NRTI)

NRTIs are structurally similar to the natural building blocks of nucleic acids, but are unable to form phosphodiester linkage essential for deoxyribonucleic acid (DNA) elongation. They compete with the natural substrates of reverse transcriptase enzyme and when incorporated into the viral DNA, they terminate further elongation of DNA (**Fig. 3**) (237). NRTI-associated adverse events include e.g. polyneuropathy, gastrointestinal side effects, myositis, lipodystrophy, and in rare cases lactic acidosis (237,238). As of summer 2003, there are six NRTIs available in Finland: abacavir, didanosine, lamivudine, stavudine, zalcitabine, zidovudine (**Table 2**). These agents require intracellular activation through incorporation of three phosphate groups into the molecule before they can function as NRTIs. A novel agent, tenofovir, has one phosphate group bound to it, and hence it only requires two additional intracellular phosphorylations (239). Tenofovir is therefore regarded a nucleotide analogue instead of a nucleoside analogue, albeit eventually the mechanism of action is identical to that of other NRTIs.

Non-nucleoside reverse transcriptase inhibitors (NNRTI)

NNRTIs bind reversibly at a non-substrate binding site in the reverse transcriptase enzyme (**Fig. 3**). They inhibit non-competitively the function of reverse transcriptase by causing a change in the shape of the enzyme or blocking the polymerase active site (240). Rash is the most common side effect of NNRTIs, in



Figure 4. *Trends in annual rates of death per 100 000 population due to the leading causes of death among persons 25-44 years of age in the United States 1987-2000. HAART became widely available in 1996. Modified from http://www.cdc.gov/hiv/graphics/images/l285/l285-10.htm.*

addition, nevirapine is associated with liver toxicity and efavirenz with central nervous system symptoms (237). Currently there are three NNRTIs available in Finland: delavirdine, efavirenz and nevirapine (**Table 2**).

Protease inhibitors (PI)

The HIV protease, the target molecule of the PIs, is a 99 –amino-acid protein with aspartyl protease activity (241). PIs hinder the cleavage of the viral precursor proteins and therefore the released viral particles remain non-infectious to uninfected cells (**Fig. 3**). Mammalian cells also contain aspartyl proteases, but they do not efficiently cleave the viral polyproteins. PIs used for the treatment of HIV infection are inactive or only weakly active against human aspartyl proteases (241). All PIs may cause gastrointestinal side effects, other adverse events include elevations in liver function tests, hyperlipidemia (with the exception of atazanavir), glucose intolerance and fat redistribution (241,242). There are currently 8 PIs available in Finland: amprenavir, atazanavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir (**Table 2**).

Table 2. *Antiretroviral agents available in Finland as of autumn 2003.*

Nucleoside reverse transcriptase inhibitors NRTI	Non-nucleoside reverse transcriptase inhibitors NNRTI	Protease inhibitors PI	Fusion inhibitor
Zidovudine AZT/ ZDV	Nevirapine NVP	Saquinavir SQV	Enfuvirtide T-20
Lamivudine 3TC	Efavirenz EFV	Ritonavir RTV	
Didanosine ddI	Delavirdine DLV	Indinavir IDV	
Stavudine d4T		Nelfinavir NFV	
Zalcitabine ddC		Amprenavir APV	
Abacavir ABC		Lopinavir LPV	
Tenofovir TDF		Fosamprenavir fAPV	
		Atazanavir ATZ	

Fusion inhibitors

Fusion inhibitors are the newest class of antiretroviral agents. They block the viral entry into the host cell by preventing fusion of the viral envelope with the cell membrane (**Fig. 3**) (243). The only fusion inhibitor available today for clinical use, enfuvirtide, is a synthetic peptide and must be administered by subcutaneous injections. The most common adverse events include injection site complications and gastrointestinal disturbances (244,245). Due to its parenteral administration and high cost, enfuvirtide is currently used in salvage regimens of patients who harbor viruses resistant to other antiretroviral agents (246).

INITIATION OF THERAPY

HAART is recommended for HIV-infected patients with severe symptoms and also for asymptomatic patients with CD4+ cell counts less than 200/mm^3 (247,248). Treatment should be considered in patients with CD4+ counts between 200-350/mm^3, but is rarely indicated in patients with CD4+ counts above 350/mm^3 (248). The first-line alternatives are the combinations of two NRTIs with either a NNRTI or a PI (248). The success of the initial treatment is mainly determined by the patient's adherence to the medication. The combination of drugs must be individualized, since different combinations have different dosing patterns, dietary restrictions, and antiretroviral agents may have interactions with concurrent illnesses and medications. It is estimated that at least 90-95% of the doses must be taken at correct times with drug-specific eating or fasting requirements to maintain optimal drug concentrations in plasma and complete virologic suppression (247). Since the eradication of the virus is not possible with current regimens (2), high level of adherence must be maintained permanently.

2.3. HAART-ASSOCIATED LIPODYSTROPHY

2.3.1. METABOLIC ALTERATIONS OF HIV INFECTION BEFORE HAART

BODY COMPOSITION

Before HAART was available, the progression of HIV infection was often accompanied by loss of body weight. In its most severe form, loss of body weight results in HIV wasting syndrome, which is recognized as one of the AIDS-defining conditions (224). The wasting syndrome is characterized by loss of both lean body mass and fat mass (249). Loss of lean body mass makes the wasting syndrome distinctly different from lipodystrophy, which affects fat tissue only.

FEATURES OF INSULIN RESISTANCE

Before the HAART era, diabetes was rare in HIV-infected patients (250). The observed disturbances in glucose metabolism were often considered to be induced by medications, such as pentamidine (251), corticosteroids or megestrol acetate (250). Prior to HAART, patients with advanced HIV infection typically had increased serum concentrations of triglycerides, but decreased concentrations of total, LDL and HDL cholesterol (252).

2.3.2. CLINICAL AND METABOLIC CHARACTERISTICS OF HAL

HAART became widely available in 1996. The first case reports describing HAART-associated buffalo humps (253) and thinning of the buttocks and thighs together with hypertrophy of breasts (254) were published as early as 1997. Soon thereafter, accumulation of intra-abdominal fat (255) and facial lipoatrophy (256) were reported in patients using HAART. Today, these features are recognized as symptoms of HAL, which has also been named fat redistribution or fat maldistribution syndrome. Patients with HAL often have also hyperlipidemia and insulin resistance (257).

2.3.3. DEFINITION OF HAL

The main clinical features of lipodystrophy are subcutaneous fat loss and fat accumulation intra-abdominally, within breasts or over the dorsocervical spine (**Fig. 5**) (3,258,259). However, as of today there is no uniformly approved definition for lipodystrophy. Recently, an objective case definition of lipodystrophy has been suggested (260). However, despite its relatively complex composition (the definition requires DEXA scan, abdominal CT scan, measurement of HDL cholesterol and anion gap in blood) the model reaches only 79% sensitivity and 80% specificity in diagnosing lipodystrophy.



Figure 5. *Abdominal MRI scan of a person with normal fat distribution characterized by abundant subcutaneous and little intra-abdominal fat (left), and of a person with HAL (right) with almost complete loss of subcutaneous and severe accumulation of intra-abdominal fat. Fat is shown in white in these MRI scans.*

2.3.4. PATHOGENESIS AND ETIOLOGY OF HAL

LIPODYSTROPHIC HUMAN ADIPOSE TISSUE

There are limited *in vivo* human adipose tissue data describing changes in lipodystrophic adipose tissue. Morphology of lipoatrophic tissue is characterized by a greater variation in adipocyte size with an increased number of small adipocytes when compared to HIV-infected treatment naive patients or HIV negative controls (261-263). Adipocytes have been found to contain clusters of small lipid droplets instead of a single large droplet (264). Lipogranulomata with lipid-laden macrophages and vascular proliferation have been reported (261,263). Also apoptosis has been present in lipoatrophic adipose tissue (263).

Gene expression in SAT in patients with HAL has only been evaluated in a single study (262). Patients with HAL had decreased mRNA concentrations of PPARγ, SREBP-1c, C/EBPα, C/EBPβ, HSL, GLUT4, leptin, but increased mRNA concentration of TNFα (262). At the protein level, SREBP-1 was increased, although SREBP-1c mRNA was decreased. Protein levels of the β-subunit of insulin receptor and the insulin-signaling kinase protein kinase B were decreased. Protein concentration of PPARγ was also decreased in keeping with its decreased mRNA concentration. SREBP-1c mRNA concentration correlated negatively with insulin resistance, and weaker inverse correlations were found between insulin resistance and PPARγ, leptin and GLUT4 mRNA concentrations. The mRNA concentrations of TNFα correlated positively with insulin resistance (262). In this study patients with HAL are compared to a group of healthy HIV negative subjects. It therefore remains uncertain to what extent the observed alterations are due to lipodystrophy, HAART *per se* or HIV-infection (262).

NRTI-induced mitochondrial toxicity due to inhibition of mitochondrial DNA polymerase γ has been suggested to cause lipodystrophy, especially lipoatrophy (265). In keeping with this hypothesis, mitochondrial DNA (mtDNA) has been found to be reduced in SAT of patients with HAL when compared to HAART-treated patients without lipodystrophy, HIV-infected treatment-naive patients or HIV negative controls (264,266). The number of mtDNA copies per cell has been shown to be decreased in adipocytes from patients with HAL when compared to treatment naive HIV-infected patients or healthy controls (261). Loss of mtDNA was more severe in stavudine- than zidovudine-treated patients (261). Electron microscopy has revealed abnormal cristae and inclusions in mitochondria in lipoatrophic adipose tissue (264). No large mitochondrial deletions, insertions or point mutations have been found in these studies (264,266).

There are no tissue data on the hypertrophic intra-abdominal fat in patients with HAL. In a single case report of a patient with HAART-associated buffalo hump, gross pathological examination revealed unremarkable adipose tissue with a few septae and the microscopic appearance was consistent with non-encapsulated mature fat tissue (267).

INSULIN RESISTANCE IN PATIENTS WITH HAL

In one of the most comprehensive studies on insulin resistance in patients with HAL, multiple alterations in glucose metabolism were detected: lipodystrophic patients had increased post-absorptive glucose production, decreased insulin-induced suppression of endogenous glucose production and lipolysis, and decreased insulin-stimulated glucose disposal when compared to healthy subjects (268). In a longitudinal study, 12 weeks of PI-containing treatment reduced insulin-stimulated glucose disposal implying insulin resistance in skeletal muscle, but did not affect the ability of insulin to suppress hepatic glucose production (269). Insulin resistance was also suggested to affect adipose tissue, since insulin-induced suppression of lipolysis was impaired after 12 weeks of treatment (269). In keeping with insulin resistance in skeletal muscle, IMCL content is increased in patients with HAL and correlates with insulin resistance (270,271). Increased circulating FFA concentrations may also contribute to HAART-associated insulin resistance. Two doses of acipimox were used as an inhibitor of lipolysis in a pilot study of seven men with HAL (272). Acipimox decreased FFA concentrations significantly and resulted in a significant increase in insulin sensitivity compared to placebo (272).

ETIOLOGY OF HAL

Since HAART usually consists of at least three drugs, it is difficult, if not impossible to assess the effect of an individual antiretroviral agent on lipodystrophy in HIV-infected patients. PIs were primarily suspected to cause lipodystrophy and other metabolic abnormalities. However, since basically all PI-treated patients receive also two or more NRTIs, their potential contribution to the development of adverse events must be taken into account. Furthermore, HIV infection itself, nadir CD4+ count, degree of the HAART-induced

viral suppression, older age, gender and ethnicity may play a role in the development of lipodystrophy and metabolic abnormalities (273).

PROTEASE INHIBITORS

Effects of PIs in vitro

Several PIs have been shown to inhibit differentiation of various adipocyte cell lines (**Table 3**). The proposed mechanisms include both PPARγ-dependent (274,275) and –independent (276,277) mechanisms. The earlier events of differentiation, such as mitotic clonal phase of preadipocytes does not seem to be affected (274,275). PIs have also been shown to increase lipolysis (278) and decrease LPL expression (279) and activity (280). Nelfinavir has been associated with increased apoptosis in mature adipocytes (274). Pre- or co-treatment of cells with rosiglitazone or troglitazone has been shown to reverse the PI-induced inhibition of adipocyte differentiation and the increased basal lipolysis (275,281,282), whereas concomitant treatment with TNFα has been shown to exacerbate the suppressive effects of PIs on adipogenesis (281). Although patients with HAL often present with both subcutaneous lipoatrophy and hypertrophy of visceral fat, there are hardly any data suggesting mechanism(s) for fat hypertrophy. Stimulation of differentiation of 3T3-L1 adipocytes by a PI has been reported in a single study, which showed increased expression of the active, mature SREBP-1 protein, but decreased expression of PPARγ and C/EBPα (283).

PIs have been shown to decrease insulin-stimulated glucose uptake in several models, but there is no consensus regarding the mechanisms of insulin resistance. In some (282), but not all models (284), PIs seem to inhibit GLUT4 translocation. PIs inhibit the action of insulin also in HepG2 hepatoma cells, which express no or almost no GLUT4 (285). PIs have caused inhibition of early insulin signaling in HepG2 hepatoma cells (286), but not in 3T3-L1 adipocytes (284). It has also been shown that different PIs and different exposure times result in different effects on glucose transport (287). Troglitazone pre- and co-treatment with nelfinavir had no effect on the impairment in insulin-stimulated glucose uptake induced by nelfinavir (282).

Effects of PIs in animal models

There are limited data from animal models evaluating metabolic adverse events of PIs. In Wistar rats, a single intravenous dose of indinavir decreased glucose uptake in the muscle but did not alter the suppression of hepatic glucose output under hyperinsulinemic conditions (288). Ritonavir has been shown to increase plasma triglyceride and cholesterol levels, and liver fat content (289). These abnormalities were due to accumulation of the active SREBP-1 protein, but not mRNA of SREBP in the liver and white adipose tissue (289). The increase of the active form of SREBP-1 was suggested to be due to its decreased degradation (289). However, in another model ritonavir treatment in rats decreased serum triglyceride concentration, increased body fat and caused no change in insulin sensitivity (290).

Table 3. *In vitro effects of PIs on cell and tissue models.*

Protease inhibitor	Cell / tissue	Effect	Ref.
APV, IDV, NFV, RTV	3T3-L1	Inhibition of differentiation, but not via inhibition of PPARγ-mediated gene transcription.	(276)
IDV, SQV	Cultured primary human preadipocytes	Inhibition of differentiation via PPARγ-independent mechanism.	(277)
IDV	3T3-F442A	Decrease in protein expression of SREBP-1, PPARγ and insulin receptor. Defective maturation and altered localization of SREBP-1.	(275)
IDV	Human embryonic kidney and hepatoma cells	Inhibition of SREBP-1c –dependent genes, such as LPL and FAS, but no effect on SREBP-1c independent gene encoding LDL receptor.	(279)
IDV	3T3-L1	Inhibition of insulin-stimulated glucose uptake, but no effect on early insulin signaling or translocation of GLUT4 or GLUT1.	(284)
IDV	Xenopus oocytes	Inhibition of the activity of glucose transporter isoforms in decreasing order GLUT4 >> GLUT2 > GLUT3 > GLUT1 ~ GLUT8.	(291)
IDV	L6 skeletal muscle cells	Stronger inhibition of GLUT4 over GLUT1.	(292)
IDV	Rat skeletal muscle	Decrease in both insulin- and contraction-stimulated glucose transport, decrease in cell surface GLUT4. No effect on insulin stimulation of PI 3-kinase and phosphorylation of protein kinase B.	(293)
IDV	HepG2 hepatoma cells	Reduced insulin effect on IRS-1 tyrosine phosphorylation, on the association of PI 3-kinase with IRS-1 and phosphorylation of protein kinase B. Impaired insulin-stimulated glycogen synthesis.	(285,286)
APV, IDV, NFV, SQV, RTV	C3H10T1/2 stem cells	Inhibition of lipogenesis and increased acute lipolysis (APV and IDV had only little effect). Only SQV inhibited ligand-binding to PPARγ.	(278)
NFV, IDV, SQV	3T3-L1, L6 myotubes	Acute exposure to NFV, IDV or SQV: decreased insulin-stimulated glucose uptake through direct interaction with GLUT4. Prolonged exposure to NFV (but not IDV or SQV): increased basal lipolysis and glucose uptake with elevated GLUT1 expression and decreased insulin-stimulated	(287)

		glucose transport and protein kinase B phosphorylation.	
NFV	3T3-L1	Decrease in the expression of C/EBPα, PPARγ. Reduced level of active, but not the precursor protein of SREBP-1c. Increased apoptosis in differentiated adipocytes.	(274)
NFV	3T3-L1	Decreased insulin-stimulated glucose uptake and impaired GLUT4 translocation and increased basal lipolysis.	(282)
RTV	3T3-L1	Enhancement in adipocyte differentiation. Increase in active SREBP-1 protein, blunted upregulation of PPARγ and C/EBPα during differentiation.	(283)
SQV	3T3-F442A	Inhibition of synthesis of lipids, increase in lipolysis. Inhibition of LPL activity, but no effect on LPL mRNA. Increase in basal glucose transport, but decrease in insulin-stimulated glucose transport.	(280)

For abbreviations of antiretroviral agents, see Table 2.

These discrepant *in vitro* and animal data regarding the metabolic effects of HAART underscore the importance of defining *in vivo* effects of antiretroviral agents on gene expression in humans.

Effects of PIs in humans

Lipodystrophy was originally described as an adverse event of PIs (257,294). Although lipodystrophy has been described in patients not receiving PIs (295), the prevalence of lipodystrophy is greater in patients receiving PIs than in PI-naive or antiretroviral therapy-naive HIV-infected patients (296). In a study with 655 HIV-infected patients receiving first-line antiretroviral therapy and followed for a median of 86 weeks, indinavir exposure significantly increased the risk of developing combined form of both lipoatrophy and fat accumulation (297). In another report with 366 patients receiving their first antiretroviral therapy, lipoatrophy and lipohypertrophy were independently associated with the initiation of a PI-containing regimen (298). One study found an association between high nelfinavir trough concentrations in plasma and overall lipodystrophy and peripheral fat wasting scores (299), and another study found an increased risk of lipodystrophy with increasing duration of PI therapy (300).

In cross-sectional studies, PI-treated patients have higher prevalence of insulin resistance than non-PI-treated (301,302), treatment-naive HIV-infected patients (302) or healthy subjects (257). In longitudinal studies, treatment with a PI-containing HAART for 3 months increased fasting serum insulin concentration by 96% (303), and diabetes was diagnosed in 6% of 117 patients after a 12-month treatment with a PI-containing regimen (304). In a cohort of 1785 women, the use of PIs was associated with a threefold increase in the risk of developing diabetes (305).

Most of the studies evaluating the effects of PIs on insulin resistance have compared PI-treated patients with either HIV-infected drug naive or healthy subjects. Therefore it remains unknown to what extent PI treatment *per se* and to what extent PI-associated lipodystrophy contribute to insulin resistance. There are some data demonstrating the development of insulin resistance in PI-treated patients in the absence of changes in body composition. The effects of a single antiretroviral drug can be evaluated in HIV negative subjects, since there is no risk for development of viral resistance due to suboptimal HIV therapy. In these studies, a 4-week treatment with indinavir or even a single dose of it decreased insulin sensitivity without changes in circulating lipoproteins or FFA concentrations, or in the amount of intra-abdominal or subcutaneous fat (306,307). However, several studies have shown that PI-treated patients with lipodystrophy are more insulin resistant than PI-treated patients without lipodystrophy (257,308,309). Patients with both subcutaneous lipoatrophy and intra-abdominal fat accumulation have been found to be more insulin resistant than those with atrophy only or those with no lipodystrophy (302,309). Taken together, it seems likely that both PI treatment *per se* and lipodystrophy may contribute to the development of insulin resistance in HIV-infected patients.

NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

Effects of NRTIs in vitro and in animal models

There are substantially less *in vitro* data on the effects of NRTIs than of PIs on adipocyte differentiation. When 3T3-F442A cells were treated either with zidovudine, stavudine, didanosine or lamivudine, only zidovudine exerted a significant antiadipogenic effect (310). NRTI-associated lipoatrophy has been suggested to result from NRTI-induced inhibition of mitochondrial DNA polymerase γ (265). *In vitro* studies of the NRTIs demonstrate the following hierarchy of mitochondrial DNA polymerase γ inhibition: zalcitabine > didanosine > stavudine > lamivudine > zidovudine > abacavir (311). In lean mice, stavudine decreased hepatic and muscle mtDNA, but only in obese (*ob/ob*) mice stavudine decreased mtDNA in white adipose tissue (312).

Effects of NRTIs in humans

Lipodystrophy, especially lipoatrophy, has been described in HIV-infected patients who have been treated with NRTIs only (295,313,314). Trunk-to-extremity fat ratio was increased and extremity-to-total fat ratio decreased in NRTI-treated, PI-naive patients when compared with BMI-matched HIV-infected, treatment naive controls (315). In addition, lipodystrophy was significantly more common among patients randomized to receive two PIs and stavudine than among patients who received dual PI therapy without stavudine (316). Of the various NRTIs, stavudine has most commonly been associated with lipodystrophy (295,297,317-319). The use of lamivudine has been associated with the development of lipodystrophy in one study (319).

There are only limited and contradictory data regarding insulin resistance and the use of NRTIs. In a cross-sectional study with 45 patients, NRTI treated patients were not more insulin resistant than HIV-infected therapy-naive patients (302). In a small longitudinal study with 9 subjects, dual NRTI therapy for 5 months did not change serum glucose, insulin or lipid concentrations (303). However, the duration of NRTI treatment has independently predicted fasting hyperinsulinemia (309), and the use of stavudine and the rate of lipolysis have been strong independent predictors of insulin resistance (320). The use of stavudine has also been associated with an increased risk of developing diabetes in a large retrospective study with 1011 patients (321). However, when therapy naive patients were compared with PI-naive, but either zidovudine or stavudine treated patients, those on stavudine had lower total body fat, markedly reduced subcutaneous-to-visceral fat ratio and higher serum triglycerides, but plasma glucose, insulin and C-peptide concentrations were not different between the groups (295).

NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

There are limited human and no *in vitro* data on the effects of NNRTIs on HAL and metabolic adverse effects. In a longitudinal study using DEXA scans, the use of nevirapine has been associated with a reduced rate of loss of subcutaneous fat when compared with PI-containing regimens (322). Favorable effects of

nevirapine on blood lipids have been reported in a study comparing three different first-line antiretroviral combinations: in addition to 2 NRTIs, patients were randomized to receive nevirapine, indinavir or lamivudine. The nevirapine group had a 49% increase from baseline in HDL-cholesterol concentration after 24 weeks of treatment as opposed to 16% increase in the lamivudine and indinavir groups (323).

HOST-ASSOCIATED FACTORS

Patients with older age (317,324) and female gender appear to have an increased risk for developing lipodystrophy (297,298,324). Co-infection with hepatitis C (325), male gender (326) and white race (322) have been associated with an increased risk of developing lipoatrophy.

Preliminary data suggest that genetic susceptibility may influence the development of HAART-associated metabolic adverse events. TNFα polymorphism has been evaluated in two studies. Data from a genetic case-control study suggest that a G to A substitution in the –238 position in the promoter region of the TNFα gene predisposes to HAL (327). Similarly, the TNFα -238G/A promoter polymorphism has been found to independently enhance the progression of lipodystrophy in a cohort of HAART-recipients (328). A single-nucleotide polymorphism (3'322C/G) in the SREBP-1c gene was found to be predictive of HAART-related dyslipidemia in a group of 67 patients, although it did not alter the amino acid sequence of the protein (329). A larger study with 355 HAART-treated patients, however, could not confirm the association of this SREBP-1c polymorphism and dyslipidemia (330).

2.3.5. PREVALENCE OF HAL

LIPODYSTROPHY

The reported prevalences of lipodystrophy vary from as low as 2% among 272 PI-treated patients (331) up to 83% among 113 PI-treated patients (332) depending on the age and sex of the patients, type and duration of HAART, and the different definitions of lipodystrophy. Estimates from large surveys indicate a 50% prevalence of at least one physical abnormality after 12-18 months of therapy (3,273).

ABNORMALITIES IN GLUCOSE METABOLISM

It is difficult to compare the results from different studies examining glucose metabolism in patients with HAL due to differences in the methods used. In oral glucose tolerance test (OGTT), 35% of patients with HAL had impaired glucose tolerance (IGT), and an additional 7% had diabetes (309). These prevalences of IGT and diabetes were 7-fold higher than those in age- and BMI-matched controls (309). Other studies have reported a 17 - 46% prevalence of IGT and a 7 - 13% prevalence of diabetes measured using the OGTT (301,332), and up to a 61% prevalence of peripheral insulin resistance measured using the intravenous insulin tolerance test (333) among patients using PIs. In a retrospective study of 1011 patients followed for a median of 289 days, 16 new cases of diabetes were diagnosed; the risk for developing diabetes was significantly increased in patients receiving indinavir or stavudine (321). A large cohort study with 17 852

HIV-infected subjects with or without antiretroviral therapy has found only a 2.5% -prevalence of diabetes (334). NNRTI and a combination of NNRTI and PI therapy were independently associated with the presence of diabetes in this large cohort (334).

LIPID ABNORMALITIES

The prevalence of hyperlipidemia among HIV-infected patients using PIs is in the range of 30-75% (301,332,334). Among patients receiving non-PI containing HAART, 11% had cholesterol levels >6.5 mmol/l and 26% triglycerides >2.2 mmol/l (335). In a longitudinal study, treatment with HAART including a PI for a mean of 3.4 months increased serum total cholesterol by 23% and triglyceride concentration by 48% (303).

IMPAIRED FIBRINOLYSIS

In addition to having altered glucose and lipid metabolism, patients with HAL have also been found to have increased plasma PAI-1 and tPA antigen levels when compared to HIV negative controls (336). PAI-1 and fibrinogen levels were also significantly higher in 266 patients (42% with lipodystrophy) receiving PI-containing HAART when compared to 97 treatment naive HIV-infected subjects (337). In this study, the plasma PAI-1 concentration was independently correlated with the use of PI-containing HAART, serum triglyceride and insulin concentrations, and BMI (337).

2.3.6. SIGNIFICANCE OF HAL

Lipodystrophy has a variety of physical and psychological effects, ranging from bodily discomfort to low self-esteem and depression (338,339). Especially facial lipoatrophy may be a visible marker of HIV infection (340) and may lead to social isolation (338). In addition, self-perceived lipodystrophy is an independent cause of nonadherence to HAART (5).

Due to the short history of HAART, long-term effects of HAART-associated insulin resistance and dyslipidemia on cardiovascular morbidity still remain unknown. Dyslipidemias have been associated with an increased intima-media thickness of the carotid artery suggesting an increased risk of atherosclerosis in HIV-infected patients (341,342), but in a multivariate analysis HAART or lipodystrophy were not independent risk factors for the increased intima-media thickness (342). HIV-infected patients may have a high prevalence of conventional cardiovascular risk factors, such as cigarette smoking (343). Also dietary habits may be inappropriate especially among individuals with long history of HIV infection, since dietary advice given to HIV-infected persons prior to mid 1990s was targeted to prevent wasting by increasing caloric, especially fat intake.

Data from large cohort studies are inconsistent regarding the risk of cardiovascular events in HAART-treated patients. In the Veterans Affairs Cohort with follow-up of 36 766 HIV-infected persons, the introduction of

HAART was associated with a reduction, and not an increase, in the rate of hospital admission for cardio- or cerebrovascular disease (344). However, these patients had been exposed to combination antiretroviral therapy for relatively short duration: the median exposure time for NRTIs was 17 months, for PIs 16 months and for NNRTIs 9 months (344). In the HOPS cohort (HIV Outpatient Study) with 5672 HIV-infected patients, the frequency of myocardial infarction increased significantly after the introduction of PIs, and the use of PIs was strongly associated with the likelihood of having a myocardial infarction (345). In the DAD cohort (Data collection on Adverse events of anti-HIV Drugs) with 23 468 HIV-infected people, each year of exposure to antiretroviral therapy increased the risk of myocardial infraction by 26% even after adjusting for known cardiovascular risk factors such as age, gender and smoking (6).

2.3.7. TREATMENT OF HAL

Attempts to treat HAL are based either on the modification of HA ART, or on the addition of another agent to treat the metabolic complication. Simple removal of an agent from HAART has been shown to lead to an unacceptably high risk of virologic failure (346). Therefore, in the so called "switch-studies" the suspected toxic antiretroviral agent is usually replaced by another agent, which is believed to be metabolically less toxic .

If adverse events are severe, discontinuation of all antiretroviral agents may be considered. Development of viral resistance is unlikely to occur, if all agents are discontinued simultaneously (347). However, due to the inevitable rebound in viral replication and the consequent decrease in the CD4+ cell count, it is usually not possible to discontinue HAART for a long time. In an uncontrolled study, 7-week interruption of all antiretroviral agents caused a significant decrease in triglyceride, total and LDL cholesterol concentration, but there were no significant changes in glucose or insulin levels or anthropometric measurements(348).

SWITCHING ANTIRETROVIRAL AGENTS

It is difficult to draw firm conclusions regarding the switch studies due to differences in study population, study design and methods applied (**Table 4**). Most of the published studies have evaluated the effect of replacing a PI by a NNRTI. There are no constant beneficial effects on body composition in these studies. However, blood lipids have improved in most (349-353), but not all (354-356) studies after commencing a NNRTI. Although the effects on glucose metabolism are less pronounced, some studies report an improvement (349,350,356). Another approach is to replace a PI by a NRTI, mainly by abacavir. This switch does not appear to correct body composition, but is associated with improvements in blood lipids (357-359). Data regarding effects on glucose metabolism are very limited.

A couple of studies have evaluated the effect of replacing a thymidine analogue NRTI, i.e. stavudine (or zidovudine), by abacavir. This switch seems to result in an increase in the amount of limb fat measured using

DEXA. However, the absolute change in fat mass has been very modest, e.g. limb fat increased by 310 g during 24 weeks of abacavir therapy compared to the control group (360), and in another study leg fat increased by 9 g and arm fat by 14 g per month after switching to abacavir (361). Although statistically significant, the increase in leg fat was not noticed either by the patients themselves or the treating physicians (360). Blood lipid and glucose concentrations have remained unchanged in these studies (360,361).

Switching of antiretroviral agents has been shown to be virologically safe in several studies in patients with no previous virologic failure (362). Virologic failure has been reported to be less or at most equally common in patients who were randomized to switch their PI to abacavir (358), nevirapine (352,353,355) or efavirenz (352) as compared to those who were randomized to continue with the PI. Switching of stavudine or zidovudine to abacavir had no effect on viral load when compared to those who continued with stavudine or zidovudine treatment (360). However, some studies have reported an increased risk of virologic failure among patients who switched their PI to abacavir (363), efavirenz or nevirapine (359), especially among patients who had received prior partially suppressive NRTI mono- or dual therapy.

MODIFICATIONS OF LIFE STYLE

The amount of aerobic, or combined aerobic and resistant training has been independently inversely associated with fasting triglyceride concentration and almost significantly associated with insulin resistance in a group of 120 HIV-infected patients and also in the subgroup of 69 patients with HAL (364). In small intervention trials involving HAART-treated patients with and without lipodystrophy, physical exercise has been shown to increase lean body mass, either to cause no change or decrease fat mass, and to decrease blood lipids, especially serum triglycerides (365-368). Taken together, physical exercise appears to improve blood lipids, and might be helpful in patients with abdominal lipohypertrophy but not with subcutaneous lipoatrophy.

The effect of diet on HAL and associated metabolic adverse events is unclear. In a study involving 100 HIV-infected subjects, there was no significant difference in the intake of total or saturated fat between patients with or without lipodystrophy (369). However, total energy intake was higher in lipodystrophic patients compared to non-lipodystrophic patients (369). Lipid-lowering diet for 6 months decreased serum cholesterol by 10% and triglycerides by 23% in those patients who self-reported good compliance with dietary advice, whereas there were no changes in blood lipids in patients who reported poor compliance (370).

Table 4. *The effects of changing antiretroviral agents on HAL.*

Intervention Group A	Control Group B	N	Baseline characteristics	Follow-up time	Results: lipodystrophy	Results: lipids	Results: glucose	Ref.
Switch PI to ABC+NVP+ADF +hydroxyurea	Continue PI	81	All with HAL	24 weeks	A > B loss of total fat and SAT, and VAT in those with moderate-severe fat accumulation at baseline	A: total chol ↓, TG ↓, HDL chol ↑ B: HDL chol ↑	No change, no change in OGTT	**(371)**
Switch PI to EFV	No control group	41	All with HAL	1 year	No change in VAT; SAT ↓ (CT); no change in WHR	No change	No change, no change in OGTT	**(354)**
Switch PI to EFV	No control group	20	All with HAL	6 months	WHR ↓, no change in SAT (ultrasonography)	TG ↓	Insulin resistance index ↓	**(349)**
Switch PI to NVP	No control group	23	All with HAL	6 months	WHR ↓	Total chol ↓, TG ↓	Glucose ↓, insulin resistance index ↓	**(350)**
Switch PI to NVP	Continue with PI	138	Simplification trial, ~72% had HAL	6 months	A: improvement in 50% as reported by the patient and doctor (no objective measurements)	No change	ND	**(355)**
Switch PI to EFV or to NVP	Continue PI	77	Simplification trial, ~75% had HAL	12 months	No change in those with HAL at baseline (DEXA, anthropometry)	NVP: total and LDL cholesterol ↓, TG ↓	No change	**(352)**
Switch PI to NVP	Continue PI	106	All with HAL	48 weeks	No change (DEXA)	A: Total chol ↓ and TG ↓	ND	**(353)**
Switch PI to NVP	Continue PI	34	All with HAL	24 weeks	No change (DEXA, anthropometry)	A: total and LDL chol ↓, VLDL-1 TG ↓, HDL chol ↑, HDL size ↑	No change	**(351)**
Switch PI to NVP	Continue PI	14	All with HAL	12 months	No change in WHR. Apoptosis in SAT did not change.	No change	A: insulin ↓	**(356)**
Switch PI to ABC (A), EFV (E) or NVP (N)		460	Simplification trial, ~30% lipoaccumulation, ~42% lipoatrophy	12 months	No change (no objective measurements)	A: total cholesterol ↓, proportion with TG>4.5 mmol/l ↓	glucose ↑ more in E than in A or N	**(359)**
Switch PI to ABC	Continue PI	211	Simplification trial, lipodystrophy not reported	48 weeks	ND	A: total chol ↓, TG ↓	ND	**(358)**

Switch PI to ABC	Continue PI	31		12 months		A: total chol ↓, TG ↓	A: insulin sensitivity ↑	**(357)**
Switch PI-containing regimen to AZT+3TC+ABC	Continue PI	163	Simplification trial, lipodystrophy not reported	84 weeks	No change in WHR	A: total chol↓, TG↓	ND	**(363)**
Switch AZT or d4T to ABC	Continue AZT or d4T	111	Moderate-severe lipoatrophy	24 week	A: Limb fat ↑ (DEXA), SAT ↑ (CT)	No change	No change	**(360)**
Switch d4T to AZT, and PI to ABC	Continue d4T and PI	37	LD not reported	48 weeks	A: limb fat ↑ (DEXA), no change in VAT (CT)	No change	No change	**(361)**
Switch d4T to ABC (A); PI or NNRTI to ABC (B); d4T+PI or d4T+NNRTI to ABC+AZT (C)		27	Patients had hypercholesterolemia and/or lipoatrophy	48 weeks	A: Total and limb fat ↑ (DEXA) No change in VAT (CT)	B: total chol ↓, LDL chol ↓, TG ↓ C: total chol ↓, LDL chol ↓	No change, no change in OGTT	**(362)**

For abbreviations of antiretroviral agents, see Table 2.

LIPID-LOWERING AGENTS

Overall, lipid-lowering agents often fail to reduce lipid concentrations to target levels in HAART-associated hyperlipidemia (372). There are several small studies reporting effects of pravastatin, atorvastatin and fluvastatin on HAART-associated hyperlipidemia. The mean decrease in total cholesterol has been in the range of 17-27%, while that in serum triglycerides has varied from no effect to a 37% decrease (372). Gemfibrozil and fenofibrate have decreased serum triglyceride concentrations by 18-54% in small trials (372).

PIs, NNRTIs and statins are all either metabolized by or affect the activity of various cytochrome P450 isoforms; therefore their concomitant use may lead to adverse pharmacological interactions (372). In healthy volunteers, the combination of ritonavir and saquinavir increased the median estimated area under the curve of simvastatin by 3059%, atorvastatin by 79% and decreased that of pravastatin by 50% (373). Pravastatin is considered safe, fluvastatin may be a safe alternative and atorvastatin can be used with caution with low initial doses in patients using PIs (372). Any statin can probably be used safely in persons using efavirenz or nevirapine, although more data are needed (372). Drug-drug interactions with fibrates and antiretroviral agents are unlikely to occur (372).

METFORMIN

The effect of metformin on HAART-associated insulin resistance and lipodystrophy has been evaluated in two studies. In a randomized, open-label study with 29 non-diabetic patients with HAART-associated insulin resistance, 2-month treatment with metformin significantly decreased plasma glucose, insulin, C-peptide and triglyceride concentrations when compared to placebo. VAT and VAT-to-total fat ratio also decreased in the metformin group (374). In a randomized, double-blind, placebo-controlled trial with 26 patients, metformin demonstrated significant reductions in insulin area under the curve during OGTT in patients with HAL with abnormal OGTT or hyperinsulinemia at baseline (375). The metformin group lost weight, and the amount of both VAT and SAT decreased (375). Metformin also decreased plasma tPA and PAI-1 concentrations (336).

THIAZOLIDINEDIONES

Thiazolidinediones (glitazones) are novel insulin-sensitizing anti-diabetic agents, two of which, rosiglitazone and pioglitazone, are available for treatment of type 2 diabetes both in Europe and the U.S. The first agent in this group, troglitazone was withdrawn due to hepatotoxicity (376). Thiazolidinediones are ligands for the transcription factor PPARγ, activation of which is critical for adipocyte differentiation (Chapter 2.1.3.) (377,378). In patients with type 2 diabetes, treatment with rosiglitazone improves insulin sensitivity despite increasing body weight and fat mass (10,379-382). The increase in fat mass amounts to 3.5-4.0 kg in 12 weeks (379,382) and appears to occur almost exclusively in SAT (380,381,383), an effect which would be desirable in patients with lipodystrophy. The expression of PPARγ in SAT has been shown to be decreased

in HIV-infected patients with lipodystrophy (262). *In vitro*, rosiglitazone has been shown to increase the expression of PPARγ (377) and to prevent the block in adipocyte differentiation induced by PIs (275).

In an uncontrolled study of patients with various forms of non-HIV lipodystrophy, troglitazone treatment improved insulin sensitivity, increased body fat % and the amount of SAT, but not that of VAT (213). Thiazolidinediones have also been used in two small, uncontrolled studies in patients with HAL. Six diabetic patients with HAL were treated with troglitazone for 3 months (384). Due to the small sample size, statistical significances were not reported, but a potential improvement in insulin sensitivity, an increase in total, LDL and HDL cholesterol concentrations, and a decrease in triglyceride concentration were reported (384). Troglitazone also appeared to decrease the amount of VAT and increase the amount of SAT (384). In another uncontrolled study involving 8 patients with HAL, rosiglitazone treatment for 6 to 12 weeks was reported to significantly improve insulin sensitivity, decrease the amount of VAT and increase the amount of SAT (385). There are, however, no controlled studies evaluating the effects of thiazolidinediones in HAL or in non-HIV lipodystrophies.

GROWTH HORMONE

Growth hormone with doses ranging from 6 mg/day to 4 mg every other day has been shown to decrease % body fat and the amount of VAT in patients with HAL (386-388). However, body composition rebounds to or near baseline after a wash out period of 12 weeks (387). Furthermore, insulin sensitivity decreased, and four out of 30 patients developed diabetes and three developed cancer of unknown relationship to treatment (387). In another study, insulin sensitivity decreased after one month of therapy, but returned to almost baseline after 6 months of treatment (388).

OTHER INTERVENTIONS

In small series of patients, topical hyaluronic acid injections for severe facial lipoatrophy have been reported to give good results (389,390). Liposuction has been used for the treatment of buffalo hump (391).

3. AIMS OF THE STUDY

The present studies were undertaken to answer the following questions:

1) Is hepatic fat content increased, and does the amount of hepatic fat correlate with features of insulin resistance in HIV-infected patients with HAL?

2) Are the circulating concentration of adiponectin and its expression in SAT decreased, and does adiponectin concentration correlate with features of insulin resistance in HIV-infected patients with HAL?

3) Is expression of genes involved in adipogenesis, fatty acid metabolism and inflammation altered in SAT in HIV-infected patients with HAL compared to HAART-treated patients without lipodystrophy?

4) Does treatment with rosiglitazone increase the amount of subcutaneous fat and improve features of insulin resistance in HIV-infected patients with HAL?

5) Does rosiglitazone treatment affect gene expression in SAT in HIV-infected patients with HAL?

6) Is plasma PAI-1 concentration increased, and does it correlate with hepatic fat content before and after rosiglitazone treatment in HIV-infected patients with HAL?

4. SUBJECTS AND STUDY DESIGNS

SUBJECTS

All HIV-infected patients were enrolled from the outpatient clinic of the Helsinki University Central Hospital. Both male and female subjects were included in the study. They had to be older than 18 years, have been treated with HAART for at least 18 months with no changes in the treatment regimen during eight weeks prior to enrollment, and did not have signs or symptoms of current opportunistic infections. Patients with HAART-associated lipodystrophy (HAART+LD+) had self-reported symptoms of loss of subcutaneous fat with or without increased abdominal girth, breast size or development of a buffalo hump. HIV-infected patients without lipodystrophy (HAART+LD-) had received HAART without developing symptoms of lipodystrophy. Both the presence and absence of the signs of lipodystrophy were confirmed by the single investigator (J.S.) before enrollment. Exclusion criteria for the rosiglitazone vs. placebo treatment study (Studies IV-VI) included serum transaminase concentrations greater than three times the upper limit of normal, heart failure, severe hypertriglyceridemia (serum triglycerides > 10 mmol/l), diabetes and pregnancy. HIV negative normal subjects (HIV-) were recruited from occupational health services in Helsinki. They were healthy as judged by history and physical examination and standard laboratory tests, and did not use any regular medication. None of the study subjects was a carrier of hepatitis B or C. Baseline characteristics of the study subjects are given in **Tables 5 and 6**.

The purpose, nature and potential risks of the study were explained to the study subjects before their written informed consent was obtained. Treatment study with rosiglitazone was investigator-initiated and not supported by the manufacturer of rosiglitazone. The study protocols were approved by the ethics committee of Helsinki University Central Hospital.

STUDY I: Hepatic fat in HAL

In this cross-sectional study, liver fat content was measured using proton spectroscopy in three age- and weight-matched groups of men: HIV-infected men using HAART who had developed lipodystrophy (HAART+LD+), HIV-infected men using HAART but without lipodystrophy (HAART+LD-) and HIV negative normal subjects (HIV-). Interrelationships between liver fat content and volumes of intra-abdominal and subcutaneous fat, and various laboratory parameters associated with insulin resistance were studied.

STUDY II: Adiponectin and HAL

Serum adiponectin and adiponectin mRNA concentration in SAT were measured in two gender-, age- and BMI-matched groups of HIV-infected, HAART-treated patients either with (HAART+LD+) or without lipodystrophy (HAART+LD-). Correlations of serum adiponectin concentration and its expression in SAT were examined with features of insulin resistance and liver fat content.

STUDY III: Gene expression in SAT in HAL

Expressions of multiple genes in SAT were compared between two gender-, age- and BMI-matched groups: HIV-infected, HAART-treated patients with lipodystrophy (HAART+LD+) and HIV-infected, HAART-treated patients without lipodystrophy (HAART+LD-). The mRNA concentrations measured using real-time PCR were determined for transcription factors (PPARγ, SREBP-1c, PPARδ) and PGC-1, for genes involved in lipogenesis and fatty acid metabolism (LPL, ACS, ALBP, KLBP, FATP-1, FATP-4), glucose transport (GLUT4, GLUT1) and inflammation (IL-6 and CD45).

STUDY IV: Treatment of HAL with rosiglitazone

Thirty HIV-infected patients with HAL participated in this randomized, double-blind, placebo-controlled study that consisted of treatment with either rosiglitazone 8 mg/d (n=15) or an identical-looking placebo (n=15) in a parallel fashion for 24 weeks. The following characteristics were considered during randomization: age, sex, BMI, fasting serum triglyceride and cholesterol concentrations, and use of PIs. The primary aim was to determine whether rosiglitazone increases the amount of subcutaneous fat in these patients. Measurements of body composition were performed at baseline and 24 weeks, and included quantification of intra-abdominal and subcutaneous fat using MRI, total body fat by bioelectrical impedance analysis (BIA), liver fat by proton spectroscopy, serum leptin concentration as a marker of adipose tissue mass and anthropometric measurements. Secondary aims included evaluation of the effects of rosiglitazone on features of insulin resistance and safety parameters. For the secondary aims of the study, blood samples were taken at outpatient visits at baseline, 2, 6, 12, 18 and 24 weeks.

STUDY V: Effects of rosiglitazone on gene expression in SAT in HAL

Thirty HIV-infected, HAART-treated patients with lipodystrophy who participated in Study IV had a subcutaneous fat biopsy performed at baseline and after 24 weeks of treatment. Effects of rosiglitazone vs. placebo on the expression of multiple genes were analyzed and these changes were correlated with the changes in features of insulin resistance and body composition.

STUDY VI: PAI-1 in HAL

In the cross-sectional part of the study, three gender- and BMI-matched groups were included: HIV-infected patients using HAART who had developed lipodystrophy (HAART+LD+), HIV-infected patients using HAART but without lipodystrophy (HAART+LD-) and HIV negative normal subjects (HIV-). In addition to measuring plasma PAI-1 and tPA concentrations, and mRNA of PAI-1 in SAT, body composition was measured using MRI and liver fat by proton spectroscopy. In the treatment part of the study, the HAART+LD+ group was treated with rosiglitazone or placebo for 24 weeks. Correlations of plasma PAI-1 concentration and its expression in SAT with features of insulin resistance were studied both before and after rosiglitazone vs. placebo treatment.

Table 5. *The number, age, body composition and metabolic characteristics of the study subjects.*

Variable	STUDY I HAART+LD+	HAART+LD-	HIV-	STUDY II-VI HAART+LD+	STUDY II,III,V,VI HAART+LD-	STUDY IV HIV-	STUDY VI HIV-
Number of subjects (f/m)	25 (0/25)	9 (0/9)	35 (0/35)	30 (5/25)	13 (4/9)	30 (5/25)	15 (3/12)
Age (years)	44 ± 2	40 ± 3	42 ± 1	43 ± 2	39 ± 2	43 ± 2	33 ± 3 ##
Body weight (kg)	75 ± 2	73 ± 4	76 ± 1	73 ± 2	69 ± 4	73 ± 2	71 ± 2
BMI (kg/m^2)	23.9 ± 0.6	23.3 ± 1.4	23.7 ± 0.3	23.6 ± 0.5	22.4 ± 1.1	23.6 ± 0.4	23.2 ± 0.6
Waist to hip ratio	1.00 ± 0.01 *	0.93 ± 0.03	0.94 ± 0.1 ##	0.99 ± 0.01 ***	0.89 ± 0.03	0.92 ± 0.01 ###	0.87 ± 0.02 ###
Total abdominal fat (cm^3)	230 ± 20	200 ± 50	220 ± 90	3100 ± 300	2700 ± 500	3200 ± 200	2700 ± 500
Subcutaneous fat (cm^3)	80 ± 10	110 ± 30	140 ± 10 ###	1100 ± 200 *	1800 ± 300	2100 ± 100 ###	1900 ± 300 #
Intra-abdominal fat (cm^3)	150 ± 20 *	90 ± 30	80 ± 20 ###	1900 ± 200 **	900 ± 300	1100 ± 100 ###	800 ± 200 ##
Liver fat (%)	8.1 ± 2.0 **	2.9 ± 1.6	5.3 ± 1.1 #	7.6 ± 1.7 ***	2.1 ± 1.1	3.2 ± 0.9 ###	3.6 ± 1.2 #
fP-glucose (mmol/l)	5.6 ± 0.3	5.2 ± 0.1	5.4 ± 0.1	5.5 ± 0.3	5.0 ± 0.1	5.3 ± 0.1	5.2 ± 0.1
fS-insulin (mU/l)	12.1 ± 1.7 *	7.1 ± 1.5	6.1 ± 0.5 ###	11.1 ± 1.2 **	6.5 ± 1.1	5.3 ± 0.5 ###	5.5 ± 0.7 ##
fS-triglycerides (mmol/l)	3.6 ± 0.4 ***	1.2 ± 0.2	1.1 ± 0.1 ###	3.4 ± 0.4 ***	1.2 ± 0.1	1.0 ± 0.1 ###	0.9 ± 0.1 ###
fS-HDL cholesterol (mmol/l)	1.1 ± 0.1 ***	1.5 ± 0.1	1.4 ± 0.1 ###	1.1 ± 0.1 ***	1.6 ± 0.1	1.5 ± 0.1 ###	1.5 ± 0.1
fS-cholesterol (mmol/l)	5.9 ± 0.2 **	4.8 ± 0.3	5.1 ± 0.2 ##	5.9 ± 0.2 **	4.9 ± 0.2	5.3 ± 0.2 #	4.6 ± 0.3 ###
S-ALT (U/l)	50 ± 5 **	28 ± 3	29 ± 2 ###	46 ± 5 **	28 ± 3	26 ± 2 ###	27 ± 3 ##

Data are shown as mean ± SEM. *<0.05, **<0.01, ***<0.001 for the comparison between HAART+LD+ vs. HAART+LD-; #<0.05, ##<0.01, ###<0.001 for the comparison between HAART+LD+ vs. HIV-. The reference intervals of the laboratory tests are: fP-glucose 4.0-6.1 mmol/l, fS-insulin 2-20 mU/l, fS-triglycerides 0.4-1.7 mmol/l, fS-HDL cholesterol >0.9 mmol/l, fS-cholesterol <5.0 mmol/l, S-ALT 10-50 U/l for men and 10-40 U/l for women.

Table 6. *HIV- and HAART-related characteristics of the study subjects.*

Variable	STUDY I HAART+LD+	STUDY I HAART+LD-	STUDY II-VI HAART+LD+	STUDY II-VI HAART+LD-
Number of subjects	25	9	30	13
Time since diagnosis of HIV (years)	8.3 ± 0.7	8.6 ± 1.9	8.4 ± 0.6	8.7 ± 1.3
Currently using PI	76%	56%	73%	69%
Currently using NNRTI	32%	44%	33%	31%
Currently using NRTI	100%	100%	100%	100%
Duration of PI therapy (months)	39 ± 4	29 ± 8	39 ± 4	39 ± 7
Duration of NNRTI therapy (months)	6 ± 2	9 ± 4	6 ± 2	9 ± 3
Duration of NRTI therapy (months)	69 ± 5 *	45 ± 11	68 ± 5	57 ± 10
Most recent CD4+ cell count (x 10^6/l)	561 ± 64	504 ± 102	572 ± 54	516 ± 70
Most recent HIV-1 RNA log 10 (copies/ml)	1.9 ± 0.2	1.8 ± 0.4	1.9 ± 0.1	1.6 ± 0.2

Data are shown as mean ± SEM. *<0.05 for the comparison between the HAART+LD+ vs. HAART+LD-.

5. METHODS

5.1. BODY COMPOSITION

The volumes of intra-abdominal and subcutaneous fat were measured using MRI. A total of 16 T1-weighted trans-axial scans extending from 8 cm above to 8 cm below the 4th and 5th lumbar interspace (a single scan at the level of the 4th and 5th lumbar interspace in Study I) were analyzed for the determination of intra-abdominal and subcutaneous fat (field of view 375 x 500 mm^2, slice thickness 10 mm, breath-hold repetition time 138.9 msec, echo time 4.1 msec). Intra-abdominal and subcutaneous fat volumes were measured using an image analysis software (Alice 3.0, Parexel, Waltham, MA). A histogram of pixel intensity of each MRI scan was displayed, and the intensity corresponding to the nadir between the lean and fat peaks was used as a cut point. First, total abdominal adipose tissue was defined as the area of pixels above this cut point. Intra-abdominal adipose tissue was thereafter manually erased and the area of subcutaneous fat was calculated. Intra-abdominal fat was finally determined by subtracting the SAT area from the total abdominal adipose tissue area. MRI analyses were performed by a single investigator (J.S.) blinded for treatment randomization (Study IV-VI). The reproducibility of intra-abdominal and subcutaneous fat measurements performed on two separate occasions in non-diabetic subjects (n=10) is 5 and 3% (coefficient of variation) at our institute.

Percentage of total body fat and body fat mass were determined using BIA (BioElectrical Impedance Analyzer System model #BIA-101A; RJL Systems, Detroit, MI). Waist circumference was measured midway between the lower rib margin and the iliac crest, and hip circumference over the great trochanters. Skinfold thicknesses (sum of mean values of triplicate measurements) were determined at 6 sites (triceps, biceps, subscapular, iliac crest, thigh and cheek). Bioelectrical impedance analyses and all anthropometric measurements were performed by a single investigator (J.S.) blinded for treatment randomization.

5.2. LIVER FAT

Liver fat content was measured using MRI proton spectroscopy. Localized single voxel (2 x 2 x 2 cm^3) proton spectra were recorded using a 1.5 T whole body system (Siemens Magnetom Vision, Erlangen, Germany), which consisted of the combination of whole body and loop surface coils for radiofrequency transmitting and signal receiving. T1-weighed high resolution MRI images were used for localization of the voxel within the right lobe of the liver. Vascular structures and subcutaneous fat were avoided in localization of the voxel. Subjects were lying on their stomach on the surface coil, which was embedded in a mattress in order to ensure a firm contact between the chest wall and the surface coil, and to minimize movement artefact caused by breathing.

The single voxel spectra were recorded using the stimulated –echo acquisition mode sequence with an echo time of 20 msec, a repetition time of 3000 msec, a mixing time of 30 msec, 1024 data points over 1000 kHz spectral width with 32 averages. Water-suppressed spectra with 128 averages were also recorded to detect weak lipid signals. The short echo time and long repetition time were chosen to ensure fully relaxed water signal, which was used as an internal standard. Chemical shifts were measured relative to water at 4.80 ppm. The methylene signal, which represents intracellular triglyceride, was measured at 1.4 ppm (**Fig. 6**) (392). Signal intensities were quantified using an analysis program VAPRO-MRUI (393). Spectroscopic intracellular triglyceride content (in percent) was expressed as a ratio of the area under the methylene peak to that under the sum of the methylene and the water peaks x 100. All spectra were analyzed by a single physicist who was unaware of any of the clinical data and treatment randomization. The reproducibility of repeated measurements of liver fat in non-diabetic subjects studied on two occasions at our institute is 11% (coefficient of variation).



Figure 6. *Spectra from the liver of a person with a 3% (left) and 21% (right) hepatic fat content measured using MRI proton spectroscopy. TG = triglyceride.*

5.3. GENE EXPRESSION IN SAT

A needle aspiration biopsy of abdominal SAT was taken under local anesthesia. The fat sample was immediately frozen and stored in liquid nitrogen until analysis. A part of the biopsy was immediately treated with collagenase for 30 min at 37 °C. From this sample, the diameter of 200 adipocytes was determined using a microscope. In order to measure blood contamination in the samples, 100 µl of supernatant was quantified for hemoglobin concentration after homogenization. Supernatant hemoglobin was measured by absorbance at 560 nm, compared to the hemoglobin standard curve and the hemoglobin reading was divided by the individual blood hemoglobin concentration.

Total RNA and cDNA preparation

Frozen fat tissue (50-150 mg) was homogenized in 2 ml of RNA STAT-60 (Tel-Test, Friendswood, TX) and total RNA was isolated according to the manufacturer's instructions. After DNase treatment (RNase-free DNase set, Qiagen, Hilden, Germany), RNA was purified using the RNeasy mini kit (Qiagen). RNA concentrations were measured using the RiboGreen fluorescent nucleic acid stain (RNA quantification kit, Molecular Probes, Eugene, OR). The quality of RNA was checked by agarose gel electrophoresis. Average yields of total RNA were 3.3 ± 0.4 µg per 100 mg of adipose tissue wet weight, and did not differ between the groups. Isolated RNA was stored at –80 ^{o}C until quantification of the target mRNAs. A total of 0.1 µg of RNA was transcribed into cDNA using M-MLV reverse transcriptase (Life Technologies, Paisley, UK) and oligo $(dT)_{12\text{-}18}$ primer.

Quantification of mRNA concentration of β-actin, adiponectin, PPARγ, LPL and SREBP-1c

Quantification of the mRNAs was performed by real-time PCR using LightCycler technology (Roche Diagnostics GmbH, Mannheim, Germany). 2 µl of 1:10 diluted cDNA was brought to a final volume of 20 µl, which contained 3 mM $MgCl_2$, 2 µl of LightCycler-FastStart DNA SYBR Green I Mix (Roche Diagnostics), and 0.5 µM of primers. After initial activation of the DNA polymerase at 95 ^{o}C for 10 min, the amplification conditions were as follows: 40 cycles consisting of denaturation at 95 ^{o}C for 15 sec, annealing for 5 sec at 57 ^{o}C (β-actin), 58 ^{o}C (adiponectin), 56 ^{o}C (PPARγ), 58 ^{o}C (LPL), or for 10 sec at 60 ^{o}C (SREBP-1c) and extension at 72 ^{o}C. The extension times (sec) were calculated from the amplicon size (base pairs/25). Fluorescent data were acquired at the end of each extension phase. After amplification, a melting curve analysis from 65 ^{o}C to 95 ^{o}C with a heating rate of 0.1 ^{o}C/sec with a continuous fluorescence acquisition was made. The primers for β-actin, adiponectin, PPARγ, LPL and SREBP-1c are listed in **Table 7**. For β-actin, adiponectin, LPL and SREBP-1c expression, standard curves were created from a specific PCR product. A standard curve for PPARγ was created using purified cloned plasmid cDNA (QIAquick PCR purification kit, Qiagen, Hilden, Germany). To account for differences in RNA loading, adiponectin, PPARγ, SREBP-1c and LPL were expressed relative to β-actin.

Quantification of mRNA concentration of β2-microglobulin, PAI-1, leptin, GLUT1, GLUT4, PGC-1, PPARδ, ALBP, KLBP, FATP-1, FATP-4, ACS, CD45 and IL-6

TaqMan real-time semiquantitative PCR was performed according to the manufacturer's protocol using ABI PRISM 7000 Sequence Detection System instrument and software (PE Applied Biosystem, Foster City, CA). Primer and probe sets were designed using the manufacturer's software and sequences available in GeneBank (**Table 7**). IL-6 was measured using Pre-Developed TaqMan Assay Reagents (PE Applied Biosystem, Foster City, CA). The GLUT4 primer set has been published (394). Expression levels were quantified (arbitrary units) by generating a six-point serial standard curve (395). The mRNA concentrations of PAI-1, leptin, GLUT1, GLUT4, PGC-1, PPARδ, ALBP, KLBP, FATP-1, FATP-4, ACS, CD45 and IL-6 were given relative to β2-microglobulin mRNA concentration.

5.4. LABORATORY ANALYSES

Serum free insulin concentrations were determined with radioimmunoassay (Phadeseph Insulin RIA, Pharmacia & Upjohn Diagnostics, Uppsala, Sweden) after precipitation with polyethylene glycol (396). Serum C-peptide concentrations were determined by a time-resolved fluoroimmunoassay (AUTOdelfia^{TM} C-peptide, Wallac, Turku, Finland). HbA_{1c} was measured by a high pressure liquid chromatography using a fully automated Glycosylated Hemoglobin Analyzer System (BioRad, Richmond, CA). Plasma glucose concentrations were measured by a hexokinase method. Serum total and HDL cholesterol, and triglyceride concentrations were measured by respective enzymatic kits from Roche Diagnostics using an autoanalyzer

Table 7. *Primers and probes used for mRNA analyses.*

Gene Bank Number	Sense primers	Antisense primers	Probe
PPARγ U79012	5’-CTCATATCCGAGGGCCAA	5’-TGCCAAGTCGCTGTCATC	*
β-actin M10277	5’-CACACTGTGCCCATCTACGA	5’-CCATCTCTGCTCGAAGTCC	*
SREBP-1c NM004176	5’-GCGGAGCCATGGATTGCAC	5’- CTCTTCCTTGATACCAGGCCC	*
LPL NM000237	5’-GGTCGAAGCATTGGAATCCAG	5’-TAGGGCATCTGAGAACGAGTC	*
Adiponectin XM 003191	5’-CAGAGATGGCACCCCTGGTG	5’-TTCACCGATGTCTCCCTTAG	*
β2-microglobulin AH002619	5’-GCCTGCCGTGTGAACCAT	5’-TTACATGTCTCGATCCCACTTAACTAT	5’-TGACTTTGTCACAGCCCA
GLUT1 NM006516	5’-CCTGTGGGAGCCTGCAAA	5’-TCTATACACAACAGGGCAGGAGTCT	5’-CACTGCTCAAGAAGAC
GLUT4 14758189	5’-GCTACCTCTACATCATCCAGAATCTC	5’-CCAGAAACATCGGCCCA	5’-CTGCCAGAAAGAGTCTGAAGCGCCT
PGC-1 AH008808	5’-AGAGACAAATGCACCTCCAAAAA	5’-AAAGTTGTTGGTTTGGCTTGTAAGT	5’-AAGTCCCACACACAGTCGCAGTCACAA
PPARδ NM006238	5’-CACACGGCGCCCTTTG	5’-CCTTCTCTGCCTGCCACAA	5’-ATCCACGACATCGAGAC
CD45 NT004612	5’-TCTTGGCATTTGGCTTTGC	5’-GGAGACTGACTGCGTGTGTGA	5’-CTGGACACAGAAGTATTT
ALBP NM001442	5’-TGATAAACTGGTGGTGGAATGC	5’-CCCTTGGCTTATGCTCTCTCA	5’-TCATGAAAGGCGTCACTTCCACGAGA
KLBP NM001444	5’-GGGAAGGAAAGCACAATAACAAGA	5’-CGAGTACAGGTGACATTGTTCATG	5’CACACTCCACCACTAATTTCCCATCTTTCAA TT
FATP-1 AX015323	5’-AGATGCCCGCTCACTTCG	5’-GCTAAGGCCCTGATCTTTGGA	5’-CCACCGCCGCCACCATTTCTC
FATP-4 AF055899	5’-CAAGACCATCAGGCGCG	5’-CGCACCTTTGCCTTCACCT	5’-TATCTTTGGCGGCCTGGTCCTCCT
ACS L09229	5’-CAAAGACGGCTGGTTACACACA	5’-TCCGGTCGATAATTTTCAAGGT	5’-CCATTTGGTAACCATTTTCCGATGTCCC
PAI-1	5´-CGCCAGAGCAGGACGAA	5´-GGAGACATCTGCATCCTGAAGTT	5´-CGCCAATCGCAAGGCACCTCTG
Leptin	5’-CCAAAACCCTCATCAAGACAATT	5’-GGAGACTGACTGCGTGTGTGA	5’-CACCAGGATCAATGACADD

(Roche Diagnostics Hitachi 917, Hitachi Ltd, Tokyo, Japan). Serum aspartate aminotransferase, alanine aminotransferase (ALT), and gamma glutamyltransferase activities were determined according to recommendations of the European Committee for Clinical Laboratory Standards using the Roche Diagnostics Hitachi 917 autoanalyzer. Venous blood gas analysis was performed using specific electrodes with a blood gas analyzer (Ciba Corning 850, Medfield, MA). Blood lactate was determined using an enzymatic method (Dade Behring ACA Analytical Test Packs, Dade Behring, Deerfield, IL).

The concentration of leptin in serum was measured by radioimmunoassay using a commercial kit (Human leptin RIA kit, Linco Research, St. Charles, MO). Serum concentration of adiponectin was measured using a commercial enzyme-linked immunosorbent assay (Human Adiponectin ELISA kit, B-Bridge International, San Jose, CA). Serum concentrations of IL-6 and TNFα were measured using commercial enzyme-linked immunoassays (Quantikine, R&D Systems, Minneapolis, MN). Serum CRP was analyzed using a commercial kit (Ultrasensitive CRP Kit, Orion Diagnostica, Espoo, Finland). Serum FFA were measured by a fluorometric assay (397). Plasma PAI-1 and tPA concentrations were measured by enzyme immunoassays TintElize PAI-1 and TintElize tPA, respectively (Biopool International, Umeå, Sweden).

HIV viral load was measured using the HIV-1 Monitor Test (Roche Diagnostics, Branchburg, NJ) with a detection limit of 50 copies/ml. Serum PI trough concentrations were determined using liquid chromatography; the assay was available for indinavir, nelfinavir, ritonavir and saquinavir.

All blood samples were drawn after an overnight fast and either analyzed immediately, or stored at –20 ºC or - 80 ºC until analyses.

5.5. STATISTICAL METHODS

The unpaired t-test or analysis of variance followed by pairwise comparison using Fisher's Least-Significant-Difference test was used to compare differences between the groups. Correlations were calculated using Spearman's rank correlation coefficient. Categorical variables were compared using Fisher's exact test. Effects of rosiglitazone and placebo treatment were calculated by comparing changes between the groups during 24 weeks using the unpaired t-test. Changes within rosiglitazone and placebo groups were calculated by the paired t-test. Repeated measurements over time were compared using analysis of variance followed by Fisher's Least-Significant-Difference test. Logarithmic transformation was performed on skewed data. All data are given as mean ± standard error of mean (SEM). Sample size for study IV was calculated based on the effects of troglitazone on the amount of subcutaneous fat measured by MRI in patients with non-HIV lipodystrophy (213). In this study, subcutaneous fat in the abdominal region increased by 837 ml after 6 months of troglitazone treatment. In the present study, a sample size of 15 in each group has 95 % power to detect a difference in means of abdominal subcutaneous fat of 450 ml assuming that the common standard

deviation is 300 ml using a two group t-test with a significance level of 0.05. All calculations were performed using the Systat statistical package, version 10.0 (Systat, Evanston, IL) or GraphPad Prism version 2.01 (GraphPad Inc, San Diego, CA). A p-value less than 0.05 was considered statistically significant.

6. RESULTS

6.1. HEPATIC FAT IN HAL (Study I)

The HAART+LD+, HAART+LD- and HIV- groups were comparable with respect to age and BMI (**Table 5**). Alcohol consumption was comparable between the groups (107 ± 27 vs. 153 ± 57 vs. 78 ± 11 grams/week in the HAART+LD+ vs. HAART+LD- vs. HIV-, non-significant [NS]). None of the subjects was a carrier of hepatitis B or hepatitis C. All HIV-infected patients had contracted HIV through sexual contact. HIV-related characteristics were comparable between the HAART+LD+ and the HAART+LD- groups with the exception of the HAART+LD+ group having had a longer duration of NRTI therapy (**Table 6**).

Body composition

The total amount of fat in the abdominal region was comparable between the groups, but its distribution was different (**Table 5**). The HAART+LD+ group had significantly more intra-abdominal fat than the HAART+LD- or the HIV- group, and significantly less subcutaneous fat than the HIV- group (**Table 5**). The ratio of intra-abdominal to subcutaneous fat was 4.4-fold higher in the HAART+LD+ group (3.1 ± 0.6) than in the HAART+LD- group (0.7 ± 0.1, $p<0.001$) and 6.2-fold higher than in the HIV- group (0.5 ± 0.1, $p<0.001$). The WHR was significantly higher in the HAART+LD+ group than in the HAART+LD- or the HIV- group (0.94 ± 0.01, $p<0.01$).

Biochemical characteristics

Serum insulin concentrations were significantly higher in the HAART+LD+ group than either in the HAART+LD- or the HIV- group (**Table 5**). Serum insulin concentrations did not correlate with the amount of intra-abdominal fat within the HAART+LD+ group ($r=0.26$, NS). The HAART+LD+ group had significantly lower serum HDL cholesterol concentration, and higher concentrations of triglyceride and total cholesterol than the HAART+LD- or the HIV- groups (**Table 5**). Serum ALT concentrations were significantly higher in the HAART+LD+ group than in the HAART+LD- or the HIV- groups (**Table 5**). Blood lactate concentrations were similar in both HIV-infected groups (1.3 ± 0.1 vs. 1.1 ± 0.2 mmol/l in the HAART+LD+ vs. HAART+LD- group, NS) and none of the patients had acidosis.

Liver fat

Liver fat content in the HAART+LD+ group was 53% higher than in the HIV- group and 179% higher than in the HAART+LD- group (**Table 5).** Liver fat content was not significantly different between the HAART+LD- and HIV- groups. Liver fat content correlated significantly with fasting serum insulin concentration in the HAART+LD+ and the HIV- group (**Fig. 7**). Similar significant relationships were observed between liver fat content and serum C-peptide concentrations (**Fig. 7**). The slopes of the regression lines relating liver fat and fasting insulin concentration were similar in the HAART+LD+ and the HIV-

groups. The intercepts of the regression lines were, however, significantly different between the HAART+LD+ and the HIV- group (p<0.001) implying that for a given percentage of liver fat, serum fasting insulin concentrations were significantly higher in the HAART+LD+ than in the HIV- group (**Fig. 7**). Liver fat did not correlate with the amount of intra-abdominal fat or WHR in the HAART+LD+, the HIV- (**Fig. 7**) or the HAART+LD- group (data not shown).



Figure 7. *Relationships between liver fat and serum fasting insulin concentration (panel A), serum C-peptide concentration (panel B), the amount of intra-abdominal fat (panel C), and the waist-to-hip ratio (panel D) in patients with HAL (•, solid line) and in HIV negative subjects (o, dotted line). r = correlation coefficient.*

Leptin

The HAART+LD+ group had significantly lower leptin concentrations than the two other groups (2.9 ± 0.3 vs. 4.0 ± 0.6 ng/ml in the HAART+LD+ vs. the two other groups, p<0.05). Serum leptin concentrations were closely correlated with the amount of SAT in both the HAART+LD+ and the HIV- groups (**Fig. 8**). Within the HAART+LD+ and the HIV- groups, serum leptin correlated with BMI, but the slopes of these relationships were different (**Fig. 8**). For the same BMI above approximately 20 kg/m^2, the HAART+LD+ group had a lower leptin concentration than the HIV- group.



Figure 8. *Relationship between the amount of abdominal subcutaneous fat and serum leptin concentration (left), and between body mass index and serum leptin concentration (right) in patients with HAL (•, solid line) and in HIV-negative subjects (o, dotted line). r = correlation coefficient.*

6.2. ADIPONECTIN IN HAL (Study II)

Body composition and biochemical characteristics of the study groups

Age and BMIs were comparable between the HAART+LD+ and the HAART+LD- groups (**Table 5**). The amount of total abdominal fat measured using MRI was similar between the groups, but the HAART+LD+ group had significantly less subcutaneous and more intra-abdominal fat than the HAART+LD- group (**Table 5**). The HAART+LD+ group had significantly higher fasting serum insulin and triglyceride, and lower HDL cholesterol concentrations than the HAART+LD- group (**Table 5**). Liver fat content was significantly higher in the HAART+LD+ group than the HAART+LD- group (**Table 5**). Among all HAART-treated patients, liver fat content correlated closely with serum fasting insulin concentration (r= 0.60, p<0.001).

Adiponectin

The mRNA concentration of adiponectin in SAT was significantly decreased in the HAART+LD+ patients when compared with the HAART+LD- patients (**Fig. 9**). Serum adiponectin concentration was significantly lower in the HAART+LD+ than in the HAART+LD- group (**Fig. 9**).

In all HAART-treated patients, adiponectin expression in SAT correlated significantly with serum concentration of adiponectin (r=0.52, p<0.001). Serum adiponectin concentrations correlated with features of insulin resistance: serum triglyceride (r=-0.52, p<0.001), HDL cholesterol (r=0.39, p<0.01), insulin (r=-0.36, p<0.05) and C-peptide (r=-0.38, p<0.05) concentrations. In addition, serum adiponectin concentrations correlated inversely with liver fat content (r=-0.50, p<0.001, **Fig. 9**) and with the amount of intra-abdominal fat (r=-0.54, p<0.001), but not with the amount of subcutaneous (r=0.20, NS) fat. Serum adiponectin concentrations also correlated inversely with those of ALT (r=-0.51, p<0.001). Similar correlations were

found between the mRNA concentration of adiponectin in SAT and features of insulin resistance: fasting serum triglycerides (r=-0.65, p<0.001), HDL cholesterol (r=0.44, p<0.01), insulin (r=-0.43, p<0.01), C-peptide (r=-0.44, p<0.01), liver fat (r=-0.55, p<0.001, **Fig.9**) and intra-abdominal fat content (r=-0.68, p<0.001), but not with the amount of subcutaneous fat (r=0.27, NS).



Figure 9. *Serum adiponectin and adiponectin mRNA concentration in SAT (upper panels) and their relationships with liver fat content (lower panels). Error bar = SEM, r = correlation coefficient. ***p<0.001.*

6.3. GENE EXPRESSION IN SAT IN HAL (Study III)

Body composition and biochemical characteristics of the study groups

The study subjects were the same as in Study 2 and their clinical and biochemical characteristics are given in **Table 5**. HIV- and HAART-related characteristics did not differ between the groups (**Table 6**).

Adipose tissue gene expression

The mRNA concentrations of control genes were not different between the groups (β-actin 217 ± 44 vs. 180 ± 40 in the HAART+LD+ vs. HAART+LD-, NS; β2-microglobulin 606 ± 71 vs. 645 ± 73, respectively, NS). The blood contamination percentage did not differ significantly between the groups (17.2 ± 2.2 vs. 14.3 ± 2.1% volume/weight, HAART+LD+ vs. HAART+LD-, NS).

Transcription factors and coactivator: PPARγ, SREBP-1c, PPARδ and PGC-1

The mRNA concentrations of PPARγ, SREBP-1c, PPARδ and PGC-1 are shown in **Table 8**. Expressions of all these genes were significantly lower in the HAART+LD+ than in the HAART+LD- group. PPARγ and SREBP-1c expressions were significantly interrelated within the HAART+LD+ group ($r = 0.68$, $p<0.0001$).

Table 8. *The expression of the defined genes in SAT in the HAART+LD+ and the HAART+LD- groups.*

Variable	HAART+LD+	HAART+LD-
PPARγ	$13 \pm 2 \times 10^{-3}$ **	$28 \pm 6 \times 10^{-3}$
SREBP-1c	1.8 ± 0.2 **	3.1 ± 0.5
PGC-1	$19 \pm 4 \times 10^{-3}$ *	$27 \pm 7 \times 10^{-3}$
PPARδ	$15 \pm 3 \times 10^{-3}$ *	$20 \pm 3 \times 10^{-3}$
LPL	$7 \pm 1 \times 10^{-3}$ ***	$19 \pm 3 \times 10^{-3}$
ACS	$10 \pm 2 \times 10^{-4}$ *	$15 \pm 3 \times 10^{-4}$
FATP-1	$16 \pm 3 \times 10^{-4}$	$15 \pm 2 \times 10^{-4}$
FATP-4	$13 \pm 2 \times 10^{-4}$	$12 \pm 1 \times 10^{-4}$
KLBP	$13 \pm 1 \times 10^{-3}$	$10 \pm 2 \times 10^{-3}$
ALBP	0.26 ± 0.03	0.27 ± 0.02
GLUT4	0.8 ± 0.2 *	1.6 ± 0.3
GLUT1	$10 \pm 1 \times 10^{-3}$	$13 \pm 2 \times 10^{-3}$
IL-6	0.8 ± 0.3 *	0.2 ± 0.1
CD45	$16 \pm 3 \times 10^{-4}$ *	$9 \pm 1 \times 10^{-4}$
Adiponectin	$68 \pm 10 \times 10^{-5}$ ***	$242 \pm 62 \times 10^{-4}$

Data are shown as mean ± SEM.
*p<0.05, **p<0.01, ***p<0.001 for comparisons between HAART+LD+ and HAART+LD-.

Lipogenesis and fatty acid metabolism: LPL, ACS, ALBP, KLBP, FATP-1 and FATP-4

Expression of LPL and ACS were significantly decreased in the HAART+LD+ group compared to the HAART+LD- group (**Table 8**). The mRNA concentrations of the fatty acid transport proteins FATP-1 and FATP-4, or the fatty acid intracellular binding proteins ALBP and KLBP did not differ between the groups (**Table 8**).

Glucose transport proteins: GLUT4 and GLUT1

The mRNA concentration of GLUT4 was significantly decreased in patients with lipodystrophy (**Table 8**). Expression of PGC-1 correlated closely with that of GLUT4 within the HAART+LD+ group (**Fig. 10**). The mRNA concentration of GLUT1 was not different between the groups (**Table 8**).



Figure 10. *Relationship between mRNA concentration of PGC-1 and GLUT4 in SAT in patients with HAL. r = correlation coefficient.*

Markers of inflammation: CD45 and IL-6

The mRNA concentrations of CD45 and IL-6 were significantly higher in the HAART+LD+ than the HAART+LD- group (**Table 8**). Serum IL-6 concentration (2.2 ± 0.3 vs. 1.9 ± 0.6 pg/ml, HAART+LD+ vs. HAART+LD-, NS) did not differ between the groups. There was no correlation between serum IL-6 and adipose tissue mRNA concentration of IL-6 (r=0.24, p=0.14).

6.4. TREATMENT OF HAL WITH ROSIGLITAZONE (Study IV and V)

Body composition and biochemical characteristics at baseline

At baseline, the placebo and rosiglitazone groups were similar with respect to age, gender, body weight and composition (**Table 9**). The HIV-related characteristics of the subjects are given in **Table 6**. There were no significant differences between the rosiglitazone and the placebo group with respect to HIV-related characteristics at baseline (data not shown). None of the patients changed any of the antiretroviral agents during the study.

Compared to the age- and weight-matched HIV- group, the HAART+LD+ group had significantly less subcutaneous and more intra-abdominal fat, and higher WHR (**Table 5**). Fasting serum insulin and triglyceride concentrations were significantly higher and HDL cholesterol concentrations lower in the HAART+LD+ than in the HIV- group (**Table 5**). Plasma glucose (**Table 5**) or HbA_{1c} (5.2 ± 0.2 vs. 5.5 ± 0.1 %, HAART+LD+ vs. HIV-, NS) concentrations were not different between the groups.

Table 9. *The number, age, body composition and laboratory characteristics of the subjects in the rosiglitazone and the placebo groups at baseline and at 24 weeks.*

Variable	Rosiglitazone		Placebo	
	0 weeks	**24 weeks**	**0 weeks**	**24 weeks**
Number of patients	15	15	15	15
Males / females	12 / 3		13 / 2	
Age (years)	44 ± 3		42 ± 2	
Body mass index (kg/m^2)	23.7 ± 0.7	23.9 ± 0.6	23.6 ± 0.8	23.9 ± 0.9
Body weight (kg)	73.0 ± 2.5	73.7 ± 2.5	73.3 ± 3.4	74.4 ± 3.6
Subcutaneous fat (cm^3)	980 ± 200	1040 ± 230	1300 ± 250	1330 ±250
Intra-abdominal fat (cm^3)	2000 ± 250	2030 ± 260	1830 ± 330	1780 ± 320
Total body fat (%)	17.6 ± 1.6	18.0 ± 1.6	17.4 ± 1.9	18.0 ± 1.9
Skinfolds (mm)	38 ± 4	36 ± 4	38 ± 4	38 ± 3
Serum leptin (ng/ml)	4.2 ± 1.0	3.8 ± 0.9	3.8 ± 0.8	3.9 ± 0.9
Serum insulin (mU/l)	12.6 ± 1.5	9.3 ± 0.6 * †	9.6 ± 1.8	16.3 ± 5.7
Serum HDL cholesterol (mmol/l)	1.0 ± 0.1	0.9 ± 0.1	1.1 ± 0.1	1.2 ± 0.1
Liver fat content (%)	7.3 ± 1.6	6.2 ± 1.3 †	8.0 ± 3.1	10.1 ± 3.3
Serum CRP (mg/l)	1.5 ± 0.3	1.0 ± 0.3 *	1.6 ± 0.4	1.6 ± 0.3
Serum IL-6 (pg/ml)	2.0 ± 0.3	1.8 ± 0.3	2.4 ± 0.4	2.1 ± 0.4
B-leukocytes (x 10^9/l)	5.6 ± 0.3	5.0 ± 0.3 * †	5.9 ± 0.6	6.1 ± 0.6
Serum FFA (µmol/l)	550 ± 35	422 ± 36 *	572 ± 64	516 ± 55
Serum TNFα (pg/ml)	1.7 ± 0.2	1.7 ± 0.2	1.5 ± 0.2	1.8 ± 0.3
Serum adiponectin (ug/ml)	3.6 ± 0.5	6.2 ± 1.1 * †	3.1 ± 0.6	3.6 ± 0.6

Data are shown as mean ± SEM. *$p<0.05$ for the change between 0 and 24 weeks within rosiglitazone or placebo group. † $p<0.05$ for the comparisons of changes between the rosiglitazone and placebo group.

Clinical effects of rosiglitazone

After 24 weeks of treatment, there were no significant changes in body weight or in the amount of intra-abdominal or subcutaneous fat as determined by MRI, serum leptin concentrations, the sum of skinfold thicknesses or other measures of adiposity in either placebo or rosiglitazone group (**Table 9**).

Serum insulin concentrations and liver fat content decreased in the rosiglitazone group, but increased in the placebo group (**Table 9**); the changes between the groups were statistically significant. In the rosiglitazone group, the change in serum insulin concentration correlated with the change in the liver fat content ($r=0.52$, $p<0.05$), but not with any other measure of body composition. Serum triglyceride concentrations increased significantly during rosiglitazone treatment (**Fig. 11**). Serum total cholesterol concentrations also increased

significantly (**Fig. 11**). Serum HDL cholesterol did not change significantly in either group (**Table 9**). Plasma glucose concentration decreased non-significantly in both groups: by 0.01 ± 0.2 in the placebo and 0.15 ± 0.1 mmol/l in the rosiglitazone group. Serum CRP and FFA concentrations, and total white blood cell count decreased significantly in the rosiglitazone group (**Table 9**). Serum adiponectin concentration increased significantly in the rosiglitazone group, but remained unchanged in the placebo group (**Table 9**).



Figure 11. *The effect of rosiglitazone vs. placebo on serum triglyceride and total cholesterol concentration. Error bars = SEM. Dashed line = mean value of HIV negative normal subjects. *p<0.05, **p<0.01 for comparisons vs. baseline. #p<0.05 for comparisons between the rosiglitazone and the placebo groups.*

Serum ALT and hemoglobin concentrations decreased significantly in the rosiglitazone group and remained stable in the placebo group (**Fig. 12**). One patient in the rosiglitazone group discontinued the study after 12 weeks of treatment due to increased triglyceride concentration (32.5 mmol/l). None of the patients developed hypoglycemia or clinically detectable edema. Venous blood pH and bicarbonate concentrations did not change significantly in either group (data not shown). CD4+ cell counts and serum PI concentrations did not change significantly in either group (data not shown). None of the patients lost virologic control during the study.

Effects of rosiglitazone on gene expression in SAT

There were no significant differences in the mRNA concentrations for any of the genes at baseline between the placebo and rosiglitazone group (**Table 10**). Rosiglitazone induced a significant increase in the expression of adiponectin and PGC-1, and a significant decrease in the expression of IL-6. In addition, the expression of PPARγ was increased in the rosiglitazone group when compared with the placebo group. Expression of other genes involved in lipogenesis, fatty acid metabolism or glucose transport remained unchanged in both groups.



Figure 12. *The effect of rosiglitazone vs. placebo on serum ALT and hemoglobin concentration. Error bars = SEM. Dashed line = mean value of HIV negative normal subjects. *p<0.05, **p<0.01, ***p<0.001 for comparisons vs. baseline. $^{\#}$p<0.05, $^{\#\#}$p<0.01 for comparisons between the rosiglitazone and the placebo groups.*

Interrelationships between gene expression and features of insulin resistance

Among lipodystrophic patients at baseline, the mRNA concentration of adiponectin in SAT correlated with that of SREBP-1c (r=0.69, p<0.0001) and LPL (r=0.95, p<0.0001), and with liver fat content (r=-0.39, p<0.05). Similar correlations were also found after 24 weeks between adiponectin expression and the liver fat content (r=-0.34, p=0.07), and between adiponectin and SREBP1-c (r=0.79, r<0.0001) and LPL (r=0.94, p<0.0001) expression in SAT. Serum adiponectin concentration at 24 weeks but not at baseline correlated significantly with the liver fat content (r=-0.36, p<0.05) and the fasting serum insulin concentration (r=-0.38, p<0.05).

In all patients with HAL, the change in the concentration of adiponectin mRNA in SAT correlated closely with the corresponding changes in the concentrations of LPL mRNA (r=0.89, p<0.0001) and SREBP-1c mRNA (r=0.47, p<0.05). The change in serum adiponectin concentration was inversely correlated with the change in fasting serum insulin concentration (r=-0.49, p<0.01), the liver fat content (r=-0.45, p<0.05) (**Fig. 13**) and serum ALT concentration (r=-0.38, p<0.05). The change in fasting serum insulin concentration and the change in liver fat content correlated significantly (r=0.45, p<0.05).

The change in the mRNA concentration of IL-6 in adipose tissue correlated positively with the changes in fasting serum FFA (r=0.52, p<0.01) and serum CRP (r=0.40, p<0.05) concentrations. The change in the serum concentration of CRP also correlated inversely with the changes in mRNA concentrations of SREBP-1c (r=-0.45, p<0.05) and LPL (r=-0.45, p<0.05) in SAT.

Table 10. *The expression of the defined genes in the rosiglitazone and the placebo group at baseline and at 24 weeks.*

	Rosiglitazone		Placebo	
	0 weeks	**24 weeks**	**0 weeks**	**24 weeks**
PPARγ	12.5 ± 3.3 x 10^{-3}	13.3 ± 2.4 x 10^{-3} †	13.9 ± 2.6 x 10^{-3}	12.0 ± 2.4 x 10^{-3}
SREBP-1c	1.7 ± 0.4	1.7 ± 0.2	1.8 ± 0.3	1.7 ± 0.3
PGC-1	15 ± 4 x 10^{-3}	20 ± 4 x 10^{-3} *	23 ± 7 x 10^{-3}	23 ± 6 x 10^{-3}
PPARδ	14 ± 4 x 10^{-3}	14 ± 3 x 10^{-3}	16 ± 4 x 10^{-3}	12 ± 3 x 10^{-3}
Adiponectin	62 ± 16 x 10^{-5}	72 ± 14 x 10^{-5}*	73 ± 18 x 10^{-5}	74 ± 16 x 10^{-5}
GLUT1	9 ± 2 x 10^{-3}	12 ± 2 x 10^{-3}	10 ± 2 x 10^{-3}	10 ± 1 x 10^{-3}
GLUT4	0.64 ± 0.15	0.66 ± 0.16	0.96 ± 0.26	0.67 ± 0.12
IL-6	1.05 ± 0.60	0.33 ± 0.08 ** †	0.56 ±0.33	0.43 ± 0.12
CD45	19 ± 6 x 10^{-4}	19 ± 5 x 10^{-4}	14 ± 2 x 10^{-4}	15 ± 2 x 10^{-4}
LPL	7 ± 2 x 10^{-3}	7 ± 1 x 10^{-3}	7 ± 2 x 10^{-3}	7 ± 2 x 10^{-3}
ACS	7 ± 1 x 10^{-4}	7 ± 1 x 10^{-4}	13 ± 3 x 10^{-4}	10 ± 3 x 10^{-4}
FATP-1	14 ± 4 x 10^{-4}	13 ± 3 x 10^{-4}	18 ± 4 x 10^{-4}	13 ± 2 x 10^{-4}
FATP-4	12 ± 3 x 10^{-4}	10 ± 2 x 10^{-4}	15 ± 3 x 10^{-4}	10 ± 2 x 10^{-4}
KLBP	11 ± 2 x 10^{-3}	9 ± 1 x 10^{-3}	14 ± 2 x 10^{-3}	11 ± 1 x 10^{-3}
ALBP	0.24 ± 0.04	0.25 ± 0.03	0.27 ± 0.05	0.22 ± 0.03
Leptin	0.078 ± 0.025	0.061 ± 0.023	0.052 ± 0.020	0.046 ± 0.019

Data are shown as mean ± SEM. *p<0.05 and **p<0.01 for the change between 0 and 24 weeks within the rosiglitazone or placebo group. † p<0.05 for the comparisons of changes between the rosiglitazone and placebo group.

6.5. PAI-1 IN HAL (Study VI)

Body composition and biochemical characteristics of the groups

Clinical and biochemical characteristics of the study groups are given in **Table 5.**

Circulating PAI-1, tPA and cytokine concentrations

Plasma PAI-1 antigen concentrations were significantly increased in the HAART+LD+ group (28.4 ± 2.4 ng/ml) compared with the HAART+LD- (17.8 ± 2.6, p<0.05) and the HIV- groups (10.4 ± 2.7, p<0.001) as were plasma tPA concentrations (10.7 ± 0.6 vs. 7.3 ± 0.6 vs. 6.1 ± 0.8 ng/ml, p<0.01 for HAART+LD+ vs. HAART+LD-, p<0.001 for HAART+LD+ vs. HIV-). These differences persisted even after age was included as a covariate in the analysis of variance.



Figure 13. *Relationship between the change in serum adiponectin concentration and the change in serum insulin concentration (left), and between the change in serum adiponectin concentration and the change in liver fat content (right) in patients with HAL. r = correlation coefficient..*

Serum TNFα concentrations were not significantly different between the groups (1.6 ± 0.1 vs. 1.5 ± 0.2 vs. 2.0 ± 0.8 pg/ml, HAART+LD+ vs. HAART+LD- vs. HIV-). Serum IL-6 concentrations, on the other hand, were increased in both HIV-infected groups relative to the HIV- group (2.2 ± 0.2 vs. 1.9 ± 0.6 vs. 0.7 ± 0.2 pg/ml, p<0.05 for HIV-infected groups vs. HIV-).

PAI-1 and leptin expression in SAT

In SAT, PAI-1 mRNA concentration averaged 0.019 ± 0.003 in the HAART+LD+ group, which was significantly higher than in the HAART+LD- (0.007 ± 0.002, p<0.005) and the HIV- (0.006 ± 0.001, p<0.005) groups (**Fig. 14**). Fat cell diameter was greater in the HIV- (94 ± 3 µm) than in the HAART+LD+ (74 ± 3 µm, p<0.01) or in the HAART+LD- group (80 ± 4 µm, p<0.05). Leptin mRNA concentration in SAT was significantly lower in the HAART+LD+ group (0.06 ± 0.02) when compared to the HAART+LD- (0.17 ± 0.03, p<0.005) or the HIV- (0.28 ± 0.06, p<0.001) group.

Relationships between PAI-1 and physical and biochemical characteristics before rosiglitazone therapy

Fig. 15 depicts the relations of plasma PAI-1, and **Fig. 16**, those of plasma tPA antigen concentrations to liver fat content, and to the amount of subcutaneous and intra-abdominal fat in all study groups. Within the HAART+LD+ group, plasma PAI-1 antigen concentration correlated with liver fat content before rosiglitazone therapy (r=0.49, p<0.01, **Fig. 15**) but not with serum TNFα (r=-0.03, NS) or IL-6 (r=0.18, NS) concentrations, the amount of subcutaneous (r=-0.05, NS**, Fig. 15**) or intra-abdominal fat (r=0.33, NS, **Fig. 15**), serum C-peptide (r=0.33, NS) or insulin (r=0.26, NS) concentrations, or body weight (r=0.26, NS). Within the HAART+LD+ group, the correlation coefficient between PAI-1 mRNA concentrations in SAT and plasma PAI-1 concentrations before rosiglitazone therapy was 0.39 (p<0.05).



Figure 14. *The mRNA concentration of PAI-1 in SAT in the HAART+LD+, HAART+LD- and HIV- groups (left); the change by rosiglitazone vs. placebo treatment in PAI-1 mRNA concentration in SAT (middle) and plasma PAI-1 antigen concentration (right). Error bars = SEM. *p<0.05, ***p<0.005.*

Effects of rosiglitazone treatment

Compared with baseline, PAI-1 mRNA concentration in SAT decreased slightly in the placebo group (p<0.05 for before vs. after) but not in the rosiglitazone group (p>0.1); the changes between the groups were not statistically significant (**Fig. 14**). Rosiglitazone treatment was associated with a decrease in plasma PAI-1 concentration from 30 ± 4 to 23 ± 2 ng/ml (p<0.05; **Fig. 14**). Plasma PAI-1 remained unchanged in the placebo group (27 ± 3 vs. 26 ± 3 ng/ml, before vs. after, NS; **Fig. 14**). The mean size of the adipocytes or the distribution of cell sizes were not changed by placebo or rosiglitazone treatment (data not shown). Plasma tPA decreased from 11.3 ± 0.8 to 10.5 ± 0.8 ng/ml (p<0.05) in the rosiglitazone group but remained unchanged in the placebo group (10.1 ± 0.7 vs. 9.8 ± 0.7 ng/ml, NS). Serum IL-6 concentration did not change with rosiglitazone treatment when compared to placebo (**Table 9**). Serum TNFα concentration increased almost significantly in the placebo group (p=0.06), but remained unchanged in the rosiglitazone group (**Table 9**). Leptin expression remained unchanged in both rosiglitazone and placebo groups (**Table 10**).

The change in plasma PAI-1 concentration within the HAART+LD+ group was significantly correlated with the change in serum insulin concentration (r=0.42, p<0.05), which in turn was significantly correlated with the change in liver fat content (r=0.49, p<0.01). The correlation coefficient between the change in plasma PAI-1 concentration and the change in liver fat content was 0.37 (p<0.05). Except for the latter correlation, there were no significant correlations between the change in plasma PAI-1 concentration and changes in body composition, nor were there any significant correlations between the change in plasma PAI-1 concentration and the changes in serum TNFα or IL-6 concentrations (data not shown). The change in plasma PAI-1 concentration did not correlate with the change in PAI-1 mRNA concentration in SAT (r=-0.04, NS).



Figure 15. *Relationships between liver fat (LFAT), subcutaneous and intra-abdominal fat, and plasma PAI-1 antigen concentrations in HAART-treated patients with (closed circles, HAART+LD+) and without (open triangles, HAART+LD-) lipodystrophy, and in HIV-negative normal subjects (open circles, HIV-). The correlation coefficients and the corresponding p-values were for LFAT: r = 0.49, p<0.01 in the HAART+LD+ group, r = 0.54, p<0.05 in the HAART+LD- group, r = -0.17, NS in the HIV- group; for subcutaneous fat: r = -0.05, NS in the HAART+LD+ group, r = 0.17, NS in the HAART+LD- group, r = 0.19, NS in the HIV- group; for intra-abdominal fat: r = 0.33, NS in the HAART+LD+ group, r = 0.45, NS in the HAART+LD- group, r = 0.63, p<0.05 in the HIV- group.*



Figure 16. *Relationships between liver fat (LFAT), subcutaneous and intra-abdominal fat, and plasma tPA antigen concentrations in HAART-treated patients with (closed circles, HAART+LD+) and without (open triangles, HAART+LD-) lipodystrophy, and in HIV-negative normal subjects (open circles, HIV-). The correlation coefficients and the corresponding p-values were for LFAT: $r = 0.65$, $p<0.0001$ in the HAART+LD+ group, $r = 0.65$, $p<0.05$ in the HAART+LD- group, $r = 0.03$, NS in the HIV- group; for subcutaneous fat: $r = 0.02$, NS in the HAART+LD+ group, $r = -0.30$, NS in the HAART+LD- group, $r = 0.36$, NS in the HIV- group; for intra-abdominal fat: $r = 0.33$, NS in the HAART+LD+ group, $r = 0.49$, NS in the HAART+LD- group, $r = 0.71$, $p<0.05$ in the HIV- group.*

7. DISCUSSION

7.1. SUBJECTS AND METHODS

7.1.1. SUBJECTS

In the current study, three groups of subjects were included. Most of the comparisons were made between the HAART+LD+ and the HAART+LD- groups in order to distinguish findings associated with lipodystrophy from those associated with HIV and HAART. This is important, since a chronic HIV infection *per se* induces expression of inflammatory cytokines (398,399). Furthermore, it has recently been shown that human preadipocytes express CD4, CXCR4 and CCR5 receptors, which are necessary for entry of HIV into inflammatory host cells (400). At least *in vitro*, adipocytes can actually express viral proteins (400). Therefore the mere presence of HIV may influence gene expression in adipocytes. When two HIV-infected, HAART-treated groups were compared, these potential interferences could be avoided.

There is no international consensus regarding the diagnosis of lipodystrophy. Therefore clinical criteria, i.e. presence of symptoms (HAART+LD+) or lack thereof (HAART+LD-) reported by the patients and the findings confirmed by the single investigator (J.S.), were used for grouping of the HIV-infected patients. The clinical criteria classified the patients correctly as was later shown by objective measurements of body composition: regardless the similar body weight and total body fat, the HAART+LD+ group had significantly less subcutaneous fat and more intra-abdominal fat than the HAART+LD- group (**Table 5**). The HAART+LD+, HAART+LD- and HIV- groups were matched for gender and BMI, and also for age with the exception of Study VI, in which the HIV- group was somewhat younger than the HAART+LD+ group. However, the results of Study VI did not change when age was included as a covariate in the analyses.

At the time of the initiation of Study IV, there were no data available regarding the use of rosiglitazone in HAL. Patients with serum transaminase concentrations higher than three times the upper limit of normal, patients with heart failure and with severe hypertriglyceridemia were excluded from the study in order to minimize the risk of potential side effects due to rosiglitazone. These exclusion criteria must be taken into account before generalizing the results. Although there were no interaction studies available evaluating concomitant use of thiazolidinediones and antiretroviral agents, harmful interactions were considered unlikely, since rosiglitazone does not interact with other cytochrome P450 3A4 substrates (401,402). As expected, there were no significant changes in PI concentrations and none of patients who had undetectable amount of the virus in plasma at baseline lost virologic control during the study.

7.1.2. LIVER FAT

MRI proton spectroscopy is a novel method that allows non-invasive quantification of liver fat without radiation exposure. Other common non-invasive methods for evaluating liver fat content, such as ultrasound are at best only semi-quantitative (403). The recorded methylene signal from the liver specifically represents intrahepatocellular triglyceride, since there is no extrahepatocellular fat in the liver. Quantification of hepatic fat by proton spectroscopy correlates closely with that determined histologically from liver biopsies and with liver density measurements calculated by CT (191,404,405), although the units of measurement are different. In our hands, the spectroscopic fat percentage is about half of the histologic fat percentage (Vehkavaara S et al, unpublished data). Spectroscopy has also the advantage that a larger volume of liver (8 cm^3) can be analyzed than by performing a liver biopsy (406). An important limitation of all non-invasive methods is their inability to differentiate benign fat accumulation (hepatosteatosis) from steatohepatitis, which has a significantly worse prognosis as a liver disease (407).

7.1.3. BODY COMPOSITION

Body composition was measured using MRI, BIA and anthropometric measurements. MRI and CT imaging allow depot-specific quantification of abdominal subcutaneous vs. intra-abdominal fat in contrast to DEXA, which can measure total truncal fat, but not separate the two depots (408). This limitation of DEXA is of great significance in patients with lipodystrophy (409) since, as in the present study, the total amount of abdominal fat does not necessarily differ between lipodystrophic and non-lipodystrophic subjects (**Table 5**). Abdominal subcutaneous and intra-abdominal fat depots are most commonly measured using a single CT or MRI scan at the level of L4-L5. Even though a good correlation has been shown between the fat mass measured by MRI covering total abdominal cavity and the fat mass from a single MRI scan (410), we preferred to quantify adipose tissue mass by using a total of 16 slices 1 cm apart to increase the accuracy of the measurement.

BIA is a non-invasive, inexpensive method for determining total, but not compartment-specific body composition, and has been validated in HIV-infected patients before the era of HAART (411). However, the method may not be reliable in patients with HAL and the predictive equations should be developed specifically for patients with lipodystrophy (412). Reliability of anthropometric measurements could perhaps also be questioned. However, in the current study anthropometry was considered useful, since measurements are known to be more reliable in lean subjects with thin subcutaneous fat layer than in obese subjects (408). The inter-observer error was eliminated by having a single investigator to perform all measurements. The coefficient of variation of repeated skinfold measurements by the same trained observer is approximately only 5%, but it rises to 10-20% between different observers (408).

Lack of DEXA imaging should be considered a limitation of the current study, since DEXA would have provided an additional measure of total limb fat mass. This would have been useful when evaluating the

effects of rosiglitazone on the amount of SAT. However, since rosiglitazone is not known to affect lean body mass, an increase in the amount of subcutaneous fat should either have caused an increase in total body weight, or alternatively it should have been compensated by a reciprocal decrease in the amount of intra-abdominal fat if the body weight remained unchanged. The lack of change in body weight or in the amount of intra-abdominal fat measured by covering almost all abdominal cavity (16 MRI scans), makes it unlikely that such a significant increase in the amount of subcutaneous fat remained unnoticed.

7.1.4. GENE EXPRESSION

Gene expression was quantified using real-time polymerase chain reaction (PCR). Because RNA cannot serve as a template for PCR, mRNA must first be converted into cDNA. DNA is thereafter amplified by a PCR reaction. Real-time PCR is currently the most sensitive method for quantification of mRNA (414).

PCR reaction generates copies of the DNA template in an exponential fashion. Due to various limiting factors, the reaction eventually does not remain exponential, but reaches a ”plateau phase”; some reactions reach a higher plateau than others (415). The variability of the plateau level reached makes the end-point quantification of PCR products unreliable (415). With the ability to follow the concentration of the PCR product as they are accumulating, i.e. in ”real time”, it is possible to measure the amount of the PCR product at a point in which the reaction is still in the exponential range. It is only during this exponential phase of the PCR reaction that it is possible to extrapolate back to determine the starting amount of the template (415).

Measurements of gene expression in adipose tissue in humans are often limited by the size of the sample and by the high lipid content of adipose tissue samples (416). The extreme paucity of subcutaneous fat in patients with severe lipodystrophy limited the size of fat samples also in the current study. Protein expression could not be evaluated in these small samples, which is a limitation of the current study. One must also keep in mind, when interpreting results of gene expression in adipose tissue samples that adipose tissue is not composed of adipocytes only, but also of other cells, such as endothelial cells and macrophages (52), which contribute to the total mRNA and protein concentrations of the adipose tissue samples.

7.2. GENE EXPRESSION IN SAT AND ADIPOCYTOKINE PRODUCTION

Lipodystrophy in its most typical form is characterized not only by a loss of subcutaneous fat but also by an accumulation of intra-abdominal fat and occasionally by a development of a buffalo hump or an increase in breast size. There are, however, no human or animal data regarding the effects of antiretroviral agents on gene expression in the hypertrophic adipose tissue. Although also non-HIV human data are limited, there is some evidence that differences in gene expression exist between different fat depots even in non-lipodystrophic conditions (**Table 1**).

Prior to the current study, gene expression in SAT of patients with HAL had been evaluated in one study (262). Since the subjects in the control group of this study were not HIV-infected and did not use HAART, it remained unclear as to whether the differences between the groups were due to the HIV infection, HAART or lipodystrophy.

7.2.1. TRANSSCRIPTION FACTORS AND CO-ACTIVATOR **(Table 8)**

The mRNA concentrations of PPARγ, SREBP-1c, PPARδ and PGC-1 in SAT were decreased in patients with HAL when compared to HIV-infected, HAART-treated patients without lipodystrophy. Since PPARγ is considered the main adipogenic transcription factor, and its expression is decreased also when patients with HAL are compared to HIV negative subjects (262), it seems likely that defective PPARγ expression plays a role in the development of lipodystrophy. Upstream regulators of PPARγ in the cascade of adipocyte differentiation include C/EBPβ, δ and α (53). These transcription factors were not measured in the current study, but C/EBPβ and α expressions were reported to be decreased in patients with HAL in the study of Bastard et al (262). PPARγ can also be activated by SREBP-1c, the expression of which was decreased in patients with HAL compared to the HAART+LD- group in the current study and compared to healthy controls in the study of Bastard et al (262). We also found a close correlation between PPARγ and SREBP-1c mRNA concentrations. The expression of PPARδ, which may play a role in the earlier events of adipocyte differentiation, such as proliferation of adipocyte precursor cells (417), was found to be decreased in patients with HAL and may contribute to the reduction in adipocyte differentiation.

The expression of PGC-1 has not previously been evaluated in patients with HAL. PGC-1 is an interesting protein in this context, since it was originally identified as a co-activator of PPARγ (71), but has also been found to be involved in the biogenesis of mitochondria (72). In the present study, PGC-1 expression in SAT was decreased in patients with HAL. Low expression of PGC-1 may therefore have contributed both to the low transcriptional activity of PPARγ and to the mitochondrial alterations in SAT described earlier in patients with HAL (264,266). As mitochondrial dysfunction may lead to apoptosis (418), mitochondrial damage in adipose tissue may, at least partly, explain the apoptotic findings in SAT of patients with HAL (263). PGC-1 expression in adipose tissue was closely correlated with that of GLUT4 in patients with HAL (**Figure 10**). This is in keeping with a recent report, which found PGC-1 expression in SAT to be reduced in the insulin-resistant subjects and its expression to correlate with the expression of GLUT4, IRS-1, UCP-1 and insulin sensitivity (419). In the same study, a correlation between PGC-1 and GLUT4 expression was found also in skeletal muscle (419). Currently there are no data regarding PGC-1 expression in the liver in man, but hepatic expression of PGC-1 in mice somewhat surprisingly has resulted in increased gluconeogenesis (420).

7.2.2. GENES OF LIPOGENESIS AND FATTY ACID METABOLISM **(Table 8)**

The expression of fatty acid transport proteins (FATP-1, FATP-4) and intracellular binding proteins (ALBP, KLBP) were similarly expressed in the HAART+LD+ and the HAART+LD- groups. The expression of most fatty acid transport proteins are known to be upregulated by PPARγ in mice *in vivo* and *in vitro* (60,421). However, the lower expression of PPARγ in patients with HAL in the current study was not associated with reduced levels of expression of fatty acid transport or intracellular binding proteins. Whether this is due to different regulation of the expression of these genes in man when compared to mice is unclear.

Both ALBP and KLBP, and at least CD36 of the fatty acid transport proteins, are also expressed in human macrophages (422,423). It is thus possible that the unchanged expression of these genes in SAT of patients with HAL could reflect a decrease in the expression in adipocytes and an increase in macrophages. A recent mouse model, in which macrophages were deficient in aP2 (corresponding human ALBP), expressed low levels of pro-inflammatory cytokines (TNFα, IL-1β, IL-6) (422). If ALBP expression was increased in macrophages in the current study, this might have contributed to the increased expression of IL-6. Interestingly, incubation of human peripheral blood mononuclear cells (PBMCs) with PIs increased the expression of CD36, which may increase the rate of lipid accumulation in macrophages and development of atherosclerosis (424). Human data in this regard are, however, as yet inconclusive. Seven to 30 day treatment of healthy volunteers and HIV-infected subjects with HAART has been shown to decrease rather than increase CD36 expression in PBMCs (425).

Expression of ACS and LPL genes were reduced in the HAART+LD+ group compared with the HAART+LD- group. PPARγ is known to increase the expression of ACS both in preadipocytes *in vitro* and in adipose tissue in the rat *in vivo* (426). Pro-inflammatory cytokines decrease the expression of ACS in the liver and adipose tissue of hamsters (427). The low ACS expression in patients with HAL may therefore be a consequence of downregulation of PPARγ and upregulation of inflammatory cytokines, i.e. IL-6 and TNFα (262). Regulation of LPL expression resembles that of ACS in adipose tissue. Both SREBP-1 and PPARγ increase LPL expression *in vitro* and in rat adipose tissue (428,429), whereas pro-inflammatory cytokines decrease LPL expression (9). Thus, both the decreases in PPARγ and SREBP-1, and the increases in IL-6 and TNFα (262) expressions could have contributed to the low LPL expression.

7.2.3. MARKERS OF INFLAMMATION **(Table 8)**

In the present study, the expression of IL-6 in SAT was increased in the HAART+LD+ group when compared to the HAART+LD- group. IL-6 is a multifunctional cytokine produced by several different cell types including immune cells, adipocytes, fibroblasts, stromal-vascular cells, endothelial cells, myocytes, and a variety of endocrine cells (9). As much as a third of the total circulating concentration of IL-6 has been estimated to originate from adipose tissue (9), but only ~10% of the IL-6 secreted from adipose tissue

originates from adipocytes (9). The HAART+LD+ group had a higher number of white blood cells capable of IL-6 production in SAT as judged from the significantly higher concentration of the mRNA coding for CD45. CD45 is a tyrosine phosphatase, which is expressed exclusively in white blood cell lineage (430). The expression of a specific macrophage marker, CD68 (431), is of great interest in these patients regarding the source of inflammatory cytokines. The expression of CD68 appears to be increased in patients with HAL (Sutinen J et al., unpublished). TNFα has considerable catabolic effects in adipose tissue, including inhibition of CEBPα, PPARγ and LPL expression, and induction of apoptosis (9). TNFα and IL-6 may also inhibit the expression of adiponectin (Chapter 7.2.4.). Increased inflammation in lipodystrophic adipose tissue may therefore have multiple direct and indirect effects in the pathogenesis of lipodystrophy and the associated insulin resistance.

Because of the cross-sectional design of the current study, the results are limited to show associations between altered gene expression and lipodystrophy in the pathogenesis of HAL. Only prospective studies can prove the cause and effect. In addition, the role of a specific drug or even a drug class cannot be evaluated due to the small number of subjects and the large variety of HAART-combinations used by the patients. Taken together, multiple alterations have been found to characterize gene expression in SAT of patients with HAL compared with HIV-infected, HAART-treated patients without lipodystrophy implying that the changes were attributable to or responsible for lipodystrophy.

7.2.4. ADIPONECTIN

In the present study, adiponectin expression in SAT and its serum concentration (**Fig. 9**) were significantly decreased in the HAART+LD+ when compared to the HAART+LD- group. Both serum concentration and adipose tissue mRNA concentration of adiponectin correlated closely with features of insulin resistance including liver fat content, suggesting that adiponectin deficiency may contribute to hepatic insulin resistance in these patients.

The expression of adiponectin in SAT of patients with HAL was measured for the first time in the current study. Low expression of adiponectin in lipodystrophic adipose tissue has thereafter been reported by Lihn et al (432). The low serum adiponectin concentration in HAL in the current study is in keeping with findings of other recent reports comparing patients with HAL with HIV-infected subjects without HAL or with HIV negative healthy controls (432-435). All of these studies have also found an inverse correlation between circulating adiponectin concentrations and features of insulin resistance (432-436). In one study, adiponectin concentration was inversely correlated with the use of NRTI, and was suggested to mediate the worsening of insulin resistance during NRTI therapy (435). Serum adiponectin concentrations are decreased also in the generalized vs. the partial forms of non-HIV lipodystrophies and correlate with features of insulin resistance (437). Taken all data together, there is striking consistency, in contrast to data with leptin (Chapter 7.2.5.),

demonstrating adiponectin deficiency in human lipodystrophy. Even though cross-sectional studies cannot define the cause and effect, adiponectin is a candidate link between adipose tissue dysfunction and disturbances in whole body metabolism.

The serum concentrations of adiponectin correlate inversely with BMI in persons with normal body weight and in obese individuals (90). However, body weight did not explain low adiponectin levels in the current study, since the HAART+LD+ and the HAART+LD- groups had comparable BMIs. Because in general population lean subjects have increased adiponectin, the paucity of subcutaneous fat *per se* in the HAART+LD+ group is not sufficient to explain low expression of adiponectin. Since adiponectin expression is induced 100-fold during adipocyte differentiation (88), the decrease in the expression of PPARγ and other transcription factors may have contributed to the low adiponectin expression.

Current data are controversial regarding the expression of adiponectin in SAT vs. VAT (**Table 1**). Visceral fat has also been suggested to produce an as-yet unidentified substance, which may destabilize adiponectin mRNA (438). The significantly decreased serum adiponectin concentration together with significantly increased intra-abdominal fat mass in the HAART+LD+ group and the strong inverse correlation between the serum adiponectin concentration and the intra-abdominal fat mass, would suggest an inhibitory rather than stimulatory effect of intra-abdominal fat on adiponectin production.

In the present study, serum adiponectin concentrations correlated closely with liver fat content, and liver fat content correlated with serum insulin concentrations. Currently there are no other human data available relating liver fat content and adiponectin concentrations. However, adiponectin has been found to be negatively correlated with IMCL in the oxidative soleus muscle, but not in the non-oxidative tibialis anterior muscle in healthy volunteers (439,440). Serum adiponectin concentration has also been shown to correlate positively with the increase in insulin-stimulated insulin receptor tyrosine phosphorylation in human skeletal muscle (441).

In mice, adiponectin infusion enhances insulin sensitivity, fat oxidation in muscle and decreases liver and muscle fat content (22). In another mouse model, adiponectin inhibits the expression of hepatic gluconeogenic enzymes PEPCK and glucose 6 phosphatase and the rate of endogenous glucose production (442). In isolated primary rat hepatocytes, physiologic doses of adiponectin have been shown to enhance insulin-induced suppression of glucose production (20). Adiponectin treatment of mice with alcohol- or obesity-induced fatty livers has been shown to alleviate hepatomegaly, steatosis and decrease ALT concentrations (443). These therapeutic effects resulted partly from an increase in the carnitine palmitoyltransferase-1 activity and hepatic fatty acid oxidation, and from a decrease in the activities of enzymes involved in fatty acid synthesis in the liver, including ACC and FAS (443). These data strongly suggest that adiponectin regulate hepatic lipid accumulation and endogenous glucose production.

Adiponectin has also anti-inflammatory properties antagonizing the effects of TNFα (444), which may contribute to the insulin-sensitizing effects of adiponectin. Disruption of the adiponectin gene in mice is associated with high levels of TNFα in adipose tissue and plasma (445). Adenovirus-induced adiponectin expression in these mice normalized the increased TNFα expression (445). In mice with a fatty liver, adiponectin treatment suppresses hepatic production of TNFα and its plasma concentrations (443). On the other hand, TNFα has been shown to decrease the expression of adiponectin in 3T3-L1 adipocytes (99), and both TNFα and IL-6 have been found to decrease the expression of adiponectin in human adipose tissue culture *in vitro* (103). Plasma TNFα and its expression in SAT have been shown to be increased, and to correlate negatively with plasma adiponectin concentration in patients with HAL (432). IL-6 expression is also increased in SAT in patients with HAL as shown in the current study and by Lihn et al (432). It is therefore possible that increased TNFα and/or IL-6 contribute to the decreased adiponectin expression in HAL or *vice versa*. Very recently, the expression of CRP has been demonstrated in human SAT (446). The expression of CRP in SAT correlated inversely with that of adiponectin (446).

Adiponectin deficiency may also enhance atherosclerosis by increasing the rate of foam cell formation, since *in vitro* adiponectin has been shown to reduce human macrophage-to-foam cell transformation (98). In this study, adiponectin suppressed the expression of the class A macrophage scavenger receptor without affecting the expression of CD36 (98). *In vitro* data therefore suggest that HAART may increase macrophage lipid accumulation by two mechanisms, i.e. by a direct PI-induced increase in the expression of CD36 in human PBMCs (424) and by an adiponectin deficiency-mediated increase in the expression of macrophage scavenger receptor (98).

7.2.5. LEPTIN

The HAART+LD+ group had a significantly lower serum leptin concentration than the HAART+LD- or the HIV- group (Study I). These data are consistent with data comparing patients with HAL to HIV negative controls (447). In some studies, however, serum leptin concentrations have not been different between lipodystrophic and non-lipodystrophic HIV-infected patients (270,433,448), and HAL has also been associated with an increased leptin concentration when compared to non-lipodystrophic HIV-infected patients (449). The reasons for the contrasting results between the current study and some previous studies are not clear, but may include lack of statistical power due to a smaller sample size (270), or less severe lipoatrophy of study subjects as judged from BMI (433) than in the current study. The latter hypothesis is supported by the findings of a study, in which only patients with pure lipoatrophy, as opposed to patients with pure lipohypertrophy or mixed form of lipodystrophy, had decreased circulating leptin concentrations when compared to non-lipodystrophic subjects (450). Large variation in the results regarding leptin in these studies also raises the question whether altered leptin expression is at all a characteristic feature of HAL.

In the current study, serum leptin concentration correlated with BMI and especially with the amount of subcutaneous fat both in the HAART+LD+ and the HIV- group (**Fig. 8**). The slope of the relationship between BMI and serum leptin concentration was significantly different between the HAART+LD+ and the HIV- groups; for a given BMI above 20 kg/m^2 the lipodystrophic patients had a lower leptin concentration than the HIV negative subjects. This could be explained by increased leptin expression in SAT vs. VAT (**Table 1**), since for the same BMI lipodystrophic patients have less SAT and more VAT than non-lipodystrophic subjects. When the relationship between subcutaneous fat mass and serum leptin concentration was evaluated in the lipodystrophic and HIV negative subjects, the relationships had similar slopes in both groups (**Fig. 8**). But again, for the same amount of SAT, the lipodystrophic patients have additionally more VAT than the non-lipodystrophic patients. The contribution of the additional VAT to serum leptin concentration in the HAART+LD+ group should be compensated by a decreased leptin expression in SAT when compared to HIV-group. This was later directly shown when leptin expression was measured by quantifying mRNA concentration in SAT: patients with HAL had lower leptin expression than HAART-treated patients without lipodystrophy or HIV negative subjects (Study VI) (262).

Data from lipodystrophic mouse models suggest that leptin can reverse insulin resistance when normal adipose tissue is absent (202). Leptin treatment has also been shown to decrease serum cholesterol and triglyceride concentrations and interscapular fat mass, and to improve liver steatosis in a ritonavir-induced lipodystrophic mouse model (451). In non-HIV lipodystrophic humans with a low baseline leptin concentration, leptin-replacement therapy for four months has been shown to improve glycemic control and to decrease triglyceride concentrations and liver volume (123). As of today there are no data regarding the effect of leptin therapy in HAL.

7.2.6. PAI-1

The increased plasma PAI-1 and tPA concentrations in the HAART+LD+ group when compared to the HAART+LD- or the HIV- group (Study VI) are in keeping with a previous study comparing patients with HAL to HIV negative subjects (336). PAI-1 expression in adipose tissue of patients with HAL has not been previously reported.

PAI-1 mRNA concentrations in SAT are approximately 2-fold increased in obese as compared to lean subjects (452,453). Given that the obese subjects in the latter studies had mean BMIs of 42.6 kg/m^2 (452) and 35.6 kg/m^2 (453), adipose tissue mass was markedly increased and thus SAT probably contributed substantially to the increase in plasma PAI-1 concentrations. We found a 2-3 -fold increase in PAI-1 gene expression in SAT in the HAART+LD+ group compared with the HAART+LD- and the HIV- groups (**Fig. 14**). However, SAT was almost 2-fold reduced in the abdominal region (**Table 5**). This implies that even though the concentration of PAI-1 mRNA was 2-3 -fold increased in subcutaneous fat, this increase, in the

face of a 2-fold reduction in total SAT mass, is unlikely to explain the greater than 2-fold increase in plasma PAI-1 antigen concentration. Another factor worth considering is that PAI-1 has been suggested to originate from stromal cells rather than adipocytes in adipose tissue (170). There are more inflammatory cells in the lipodystrophic than in the non-lipodystrophic adipose tissue as judged from the increased CD45 expression (**Table 8**). The lack of a correlation between the size of the SAT depot and plasma PAI-1 (**Fig. 15**) could therefore be due to altered composition of adipose tissue. Again, even here opinions are divided as some authors have suggested that SAT does not contribute to circulating plasma PAI-1 concentrations (454).

Significant associations between plasma PAI-1 concentrations and the amount of VAT rather than SAT have been found (455). Visceral fat may produce more PAI-1 than subcutaneous fat (170,455). In the present study within the HAART+LD+ group, which had a 2-fold increase in intra-abdominal fat (**Table 5**), there was no correlation between the amount of intra-abdominal fat and plasma PAI-1 concentration (**Fig. 15**) suggesting that other factors are important in the regulation of plasma PAI-1 concentration (Chapter 7.4.3).

7.3. LIVER FAT

In the current study, the liver fat content was significantly higher in the HAART+LD+ group when compared to the HAART+LD- and the HIV- group (**Table 5**). Liver fat has not been previously quantified in patients with HAL.

The increased hepatic fat content of the patients with HAL could not be explained by alcohol consumption, which was comparable in all groups (Study I). Hepatitis C has recently been shown to increase the risk for severe liver damage (456) and insulin resistance (325) during HAART. This association, however, cannot explain the findings in the current study, since none of the subjects had serologic evidence of hepatitis C or B. The HAART+LD+ and the HAART+LD- groups were comparable with respect to the HIV-related characteristics with the exception of the HAART+LD+ group having a longer exposure to NRTIs (**Table 6**). Even though this is unlikely to alone explain lipodystrophy and insulin resistance, we cannot exclude the possibility that NRTI-specific effects, such as mitochondrial toxicity (265) could have contributed to these side effects. NRTI-induced mitochondrial toxicity has been suggested to cause lactic acidosis and hepatic steatosis in some patients using HAART (457,458). None of the subjects in the current study had symptoms of lactic acidosis and serum lactate concentrations were similar in the HAART+LD+ and the HAART+LD- groups (Study I). However, in the absence of liver biopsies, we cannot exclude the possibility that mitochondrial abnormalities, such as those described in insulin resistant patients with non-alcoholic steatohepatitis (459), characterized also the present participants. Very recently, mild to diffuse steatosis and ultrastructural mitochondrial abnormalities have been found in liver biopsies of HIV-infected patients who had been treated with NRTI-based regimens and had only mildly elevated transaminases (460) suggesting that mitochondrial abnormalities may contribute to liver steatosis also in the absence of lactic acidosis.

Data are limited regarding the direct effects of HAART on the liver. Treatment of monkeys with stavudine has been shown to deplete mtDNA and disturb oxidative phosphorylation in the liver (461). The effects of stavudine in the human liver are not known, but the use of stavudine has been associated with the loss of mtDNA in subcutaneous adipocytes in patients with HAL (261). In mice, ritonavir caused enlargement of the liver and hepatic lipid accumulation especially when fed with a high fat diet (289). The proposed mechanism was an excessive accumulation of SREBP-1 and –2 in the nucleus of hepatocytes. These data in mice would suggest that features of insulin resistance in patients with HAL were a consequence of a primary effect of PIs in the liver. This is, however, controversial. At least in adipocytes, PIs have been shown both to decrease and to increase the expression of SREBP (**Table 3**). In human SAT, SREBP-1 mRNA concentration is decreased in patients with HAL when compared to HAART-treated patients without lipodystrophy (**Table 8**) and to HIV- negative subjects (262).

It is also possible that steatosis is not due to a direct effect of the drugs in the liver, but is a consequence of the inability of the adipose tissue to store triglycerides (38). Furthermore, the dysfunction of the remaining lipoatrophic subcutaneous fat and hypertrophic intra-abdominal fat may result in upregulation of insulin resistance-inducing cytokines, such as TNFα (432), and downregulation of beneficial adipocytokines, such as adiponectin (**Table 8**).

In the current study, liver fat content correlated with fasting serum insulin and C-peptide concentrations, but not with the amount of intra-abdominal fat or WHR (**Figure 7**). Furthermore, the amount of intra-abdominal fat did not correlate with serum insulin concentrations (Study I). The lack of this correlation challenges the idea that accumulation of fat intra-abdominally is, at least alone, responsible for insulin resistance in HAL. For a given amount of liver fat, serum insulin concentrations were higher in the lipodystrophic patients than the HIV negative subjects (**Fig. 7**) implying that liver fat alone was insufficient to explain all the variation in serum insulin concentrations. Fat may not be deposited only in the liver but also in skeletal muscle cells. The amount of IMCL has been shown to correlate negatively with insulin sensitivity in HIV negative subjects (195,462-465). IMCL is also increased in patients with HAL when compared to HIV negative controls (271) or to HIV-infected non-lipodystrophic patients (270), and correlates inversely with insulin sensitivity (270,271). In humans, HAART-associated insulin resistance is most likely caused by a combination of direct and indirect mechanisms, e.g. indinavir has been shown to induce an acute decrease in glucose disposal even after a single dose in healthy subjects (307).

Accumulation of liver fat may not only affect patients' health via contributing to insulin resistance, but may also lead to steatohepatitis and eventually to cirrhosis (407). The presence of steatohepatitis can only be confirmed by performing liver biopsies. Since this is an invasive procedure and places the subjects at risk for

bleeding complications, biopsies were not performed in the current study. Fatty liver disease is a significant contributor to morbidity in patients with non-HIV lipodystrophy (206) and NAFLD is the most common cause of cryptogenic cirrhosis, which is the third leading cause of liver transplantation in the United States (466). It has also recently been shown that patients who have hepatitis C and NAFLD have an increased risk of advanced fibrosis when compared to hepatitis C patients without NAFLD (467). This additive effect may be especially important in patients with HAL, since co-infections with HIV and hepatitis C are common.

7.3.1. LIVER FAT AND PAI-1

A striking finding in the present study was the close correlation of plasma PAI-1 concentrations with liver fat content in the HAART+LD+ and the HAART+LD- groups (**Fig. 15**). It can be concluded that plasma PAI-1 concentration is likely to be regulated directly via changes in production or uptake of PAI-1 by the liver, or indirectly via alterations in serum insulin concentrations due to changes in hepatic insulin sensitivity (19,191). This interpretation is also supported by the intervention study (Chapter 7.4.3.).

In the normal human liver, PAI-1 mRNA has been localized to endothelial cells but not to hepatocytes (468). On the other hand, PAI-1 synthesis in hepatocytes is induced by specific mediators and under certain pathological conditions. Mediators of the acute phase response (IL-1 alone and in combination with IL-6) stimulate PAI-1 gene transcription in HepG2 hepatoma cells (469,470). Insulin can increase PAI-1 production in cultured hepatocytes and HepG2 cells (471,472). Hepatosteatosis is associated with increased synthesis of a variety of proteins including hepatic enzymes and coagulation factors (188). The latter include PAI-1 and tPA, which are increased in men with steatosis, independently of obesity (473). Liver enzymes are also correlated with plasma PAI-1 concentrations, independently of serum triglycerides in hypertriglyceridemic subjects (474), and independently of triglycerides, insulin and obesity in asymptomatic hyperlipidemic men (475). Recently, increases in PAI-1 mRNA concentrations were found in hepatocytes of rabbits with a fatty liver after high fat feeding (476). These studies support the notion that the liver may be a source of circulating PAI-1 in subjects with a fatty liver. Whether it is the simultaneous increase in serum triglycerides or insulin, or perhaps changes in circulating FFA or some other factor, which increases PAI-1 under such conditions remains unclear. Since PAI-1 is cleared by the liver (477), fat accumulation in the liver could increase PAI-1 concentration in plasma by impairing its clearance.

7.4. TREATMENT OF HAL WITH ROSIGLITAZONE

7.4.1. CLINICAL EFFECTS

This is the first controlled study evaluating the efficacy and safety of a thiazolidinedione in patients with HAL. In contrast to results in type 2 diabetic patients (10,379-382), in non-HIV lipodystrophic patients (213) and *in vitro* data (275), treatment with rosiglitazone did not increase any of the several measures of adiposity. The results of the current study contrast also those of an uncontrolled study evaluating the effects of

rosiglitazone in HAL. In the latter study, treatment of 8 patients with 8 mg of rosiglitazone for 6-12 weeks significantly increased the amount of SAT and decreased the amount of VAT measured using a single CT scan (385). Peripheral SAT was measured at baseline using DEXA. Body weight or DEXA results after rosiglitazone treatment were not reported (385). Possible explanations for the different results may arise from the differences in study design, i.e. open-label uncontrolled vs. double-blind placebo-controlled, or possibly from differences in the background HAART regimens.

The lack of effect of a 24-week treatment with rosiglitazone on body fat in the present study demonstrates that either rosiglitazone is unable to increase adipose mass in patients with HAL, or these patients require much longer treatment than HIV negative patients. It can also be hypothesized that rosiglitazone caused a stimulatory effect on adipocyte differentiation, but this beneficial effect was neutralized by the unaltered use of HAART. It therefore remains to be studied, whether thiazolidinediones could increase fat mass under the circumstances that the concomitant HAART could be simultaneously modified to exert a less deleterious effect on the differentiating adipocytes, or if thiazolidinediones were given prophylactically.

In HIV negative subjects, rosiglitazone lowers or has neutral effects on serum triglyceride concentrations (10,379-382,478). Both LDL and HDL cholesterol concentrations generally increase by rosiglitazone (380,478). In the study by Gelato et al., rosiglitazone increased serum triglycerides non-significantly by 1.5 mmol/l in patients with HAL (385). In the current study, serum triglycerides increased markedly in the rosiglitazone group but remained unchanged in the placebo group (**Fig. 11**). At baseline, serum triglycerides exceeded 5 mmol/L in 20% of the patients both in the rosiglitazone and the placebo groups. After 6 and 12 weeks of treatment with rosiglitazone these percentages had increased to 40% and 53%, respectively. These data imply, given the risk of pancreatitis and the need of lipid-lowering drugs when triglycerides exceed 10 mmol/l (479) that triglycerides need to be monitored closely in future trials using rosiglitazone in patients with HAL. The cause of the increase in serum triglycerides remains speculative as effects of rosiglitazone on VLDL kinetics are unknown even in HIV negative individuals. Possibly, rosiglitazone mobilized triglycerides from the liver, but was unable to sufficiently enhance their clearance by adipose tissue.

Despite the lack of effect on adipose tissue mass or distribution, rosiglitazone decreased liver fat content and fasting serum insulin concentrations in the current study (**Table 9**). Rosiglitazone improved insulin sensitivity measured using the clamp technique also in the study by Gelato et al. in patients with HAL (385). In the present study, liver function tests continuously improved in the rosiglitazone group, possibly as a consequence of the decrease in the liver fat content (**Fig. 12**). The decrease in the liver fat content by rosiglitazone is similar to that reported in HIV negative subjects in an uncontrolled study (382).

Regarding treatment of HAL, the effects of rosiglitazone in the current study should be compared with those of metformin in HAART-treated patients (375). Although inclusion criteria were somewhat different, both

metformin and rosiglitazone improved insulin sensitivity and reduced PAI-1 concentrations (**Fig. 14**) (336,375). Metformin decreased serum triglycerides, whereas rosiglitazone at least temporarily worsened dyslipidemia. Rosiglitazone, however, decreased liver fat content and transaminase concentrations, which remained unchanged after metformin treatment. Liver fat content was not assessed in the metformin study. Although neither rosiglitazone nor metformin reversed lipodystrophy, metformin might be considered at the moment the drug of choice to treat insulin resistance in these patients in view of the significant increases in blood lipids by rosiglitazone. On the other hand, the two drugs have not yet been compared in the same study in patients with HAL.

In vitro, both PIs (**Table 3**) and NRTIs (310) can inhibit adipocyte differentiation. The suggested mechanisms include both SREBP-1 / PPARγ -dependent and -independent mechanisms (**Table 3**). *In vitro*, the PI-induced block in adipocyte differentiation can be prevented by pre- or co-incubation of preadipocytes with rosiglitazone (**Table 3**). However, it is unclear to what extent PIs vs. NRTIs are responsible for the loss of subcutaneous fat in humans (Chapter 2.3.4.). The present data imply that the reversal of the PI-induced block in adipocyte differentiation observed *in vitro* does not appear to happen *in vivo*. Because glitazones promote preadipocyte differentiation into mature adipocytes through activation of PPARγ (378), the low baseline expression of PPARγ in the lipodystrophic adipose tissue may contribute to the poor effect (**Table 8**) (262). Another possibility is that the loss of adipocytes could perhaps be prevented if patients were treated with glitazones before rather than after the development of lipodystrophy simulating the *in vitro* experiments of pre- or co-incubation with rosiglitazone (**Table 3**).

7.4.2. EFFECTS ON GENE EXPRESSION IN SAT

Effects of thiazolidinediones on gene expression in human adipose tissue *in vivo* have not been previously reported. In human adipocytes *in vitro*, rosiglitazone has been shown to increase the expression of UCP-2 and the p85α-subunit of PI 3 kinase, decrease leptin expression, and have no effect on the expression of insulin receptor, IRS-1, GLUT4, LPL, HSL, ASP, FATP-1, angiotensinogen, PAI-1 and PPARγ (480).

Despite the lack of effect on the amount of subcutaneous and intra-abdominal fat (**Table 9**), rosiglitazone induced changes in gene expression in SAT of patients with HAL. These included significant increases in adiponectin and PGC-1 expression, and a decrease in the expression of IL-6. Rosiglitazone also increased PPARγ expression. However, the increase in PPARγ expression was of limited magnitude and significant only when compared with the decrease in the placebo group. Rosiglitazone also caused a significant increase in the serum concentration of adiponectin, which correlated significantly with the decrease in serum insulin concentration and liver fat content. These data demonstrate that rosiglitazone can have insulin-sensitizing effects without increasing the amount of SAT.

A 23% decrease in FFA concentration in the rosiglitazone group in the present study is in keeping with previous findings of 20-30% decreases in FFA concentrations in patients with type 2 diabetes treated with rosiglitazone (379,478). The decrease in serum FFA concentration can be due to decreased production or increased clearance of FFA. In patients with type 2 diabetes, rosiglitazone seems to lower fasting FFA concentrations by decreasing lipolysis (379). In patients with HAL, rates of lipolysis have been suggested to be increased (320). Since the sizes of adipose tissue depots remained unchanged, it is not possible to explain the decrease in serum FFA concentration by a decrease in lipolysis in adipose tissue. FFA originating from intravascular lipolysis is unlikely to be decreased, since serum triglycerides increased and the expression of LPL remained unchanged. Other possibilities, which cannot be resolved based on the present study, include increased FFA utilization in skeletal muscle as has been found in the rat (481), possibly mediated by an increase in adiponectin production (113). In mice, thiazolidinediones induce expression of fatty acid transport proteins (FATP-1, CD36), intracellular fatty acid binding protein (aP2) and acyl CoA synthase in white adipose tissue (482). Such changes could increase the clearance of FFA. Human data are limited regarding effects of rosiglitazone on the expression of genes involved in FFA utilization. In isolated human adipocytes, rosiglitazone has been reported to have no effect on the expression of FATP-1 (480). The lack of induction of these genes and of other genes involved in lipogenesis (SREBP-1c, ACS, PPARδ, LPL) may have contributed to the lack of increase in adipose tissue mass in the current study. Rosiglitazone did not increase the expression of LPL as has been described in human SAT *in vitro* (483). The lack of increase in LPL expression could have contributed to the increase in serum triglyceride concentration but cannot explain why triglycerides increased in the first place. Possibly, rosiglitazone mobilized triglycerides from the liver, the fat content of which significantly decreased compared to placebo treatment.

There are conflicting *in vitro* data regarding the effects of thiazolidinediones on glucose transport proteins (480,484,485). The mRNA concentrations of GLUT1 and GLUT4 in SAT remained unchanged in the current study and thus cannot explain the improved insulin sensitivity. These data do not exclude the possibility that rosiglitazone increased GLUT4 expression or translocation in muscle (486,487). On the other hand, the major physiological function of fasting insulin is to control hepatic glucose production (14). Changes in liver fat content have been found to be closely correlated with changes in the ability of insulin to suppress hepatic glucose production (19). Consistent with these data and the idea that the decrease in serum fasting insulin was due, at least in part, to enhanced hepatic insulin sensitivity, the decrease in serum fasting insulin and liver fat content were significantly correlated in the present study.

In the current study, treatment with rosiglitazone decreased serum CRP concentration and total white blood cell count, but did not change serum IL-6 concentration (**Table 9**). Similarly, in patients with type 2 diabetes, rosiglitazone has been found to decrease serum CRP and matrix metalloproteinase-9 concentrations and total white blood cell count, but did not change serum IL-6 concentrations (488). Thiazolidinediones have anti-inflammatory effects both in animals and in humans. In mice, troglitazone decreases the expression of TNFα

and IL-6 in white adipose tissue and in the liver (489). IL-6 is a key regulator of CRP production in hepatocytes (490). The unchanged serum IL-6 concentration in the present study cannot explain the decrease in serum CRP concentration. In mice, thiazolidinediones dowregulate pro-inflammatory cytokines in Kupffer cells in the liver (491). Whether thiazolidinediones have similar local anti-inflammatory properties in the liver of humans is not known. In the present study, despite having no effect on the total circulating IL-6 concentration (**Table 9**), rosiglitazone markedly decreased the expression of IL-6 in SAT (**Table 10**). Very recently, expression of CRP has been demonstrated also in human adipose tissue (446). If IL-6 regulates the expression of CRP in adipose tissue, it is possible that the decreased IL-6 expression in SAT may have decreased the expression of CRP in SAT. However, the contribution of adipose tissue-derived CRP to serum CRP concentration is unknown.

Rosiglitazone significantly increased adiponectin expression in SAT (**Table 10**) and almost doubled its circulating concentration (**Table 9**). Thiazolidinediones appear to have a direct effect on adiponectin expression via a recently identified functional PPAR-responsive element in the promoter region of the human adiponectin gene (112). The change in serum adiponectin concentration correlated inversely with the change in serum insulin concentration and liver fat content (**Fig. 13**). In rats, pioglitazone treatment increases plasma adiponectin, which is inversely correlated with hepatic glucose output (481). *In vivo* expression of adiponectin during thiazolidinedione treatment has previously not been reported in humans. *In vitro* incubation of isolated human adipocytes from omental but not from subcutaneous depots with rosiglitazone increases the secretion of adiponectin (155). In keeping with the results of the current study, an increase in the serum adiponectin concentration by rosiglitazone treatment has also been reported in patients with type 2 diabetes (110), glucose intolerant (111) and normal (492) subjects.

Based on animal data, one can hypothesize that adiponectin may have mediated most of the favorable effects of rosiglitazone treatment, such as the decrease in liver fat content (22), in serum insulin and FFA concentrations (113), and in inflammatory markers (445). However, other effects of rosiglitazone, such as a decrease in the expression of 11β-hydroxysteroid dehydrogenase type 1 could also have contributed (493).

7.4.3. EFFECTS ON PAI-1

In the current study, the mRNA concentrations of PAI-1 in SAT did not change in the rosiglitazone group, but plasma PAI-1 concentrations decreased significantly (**Fig. 14**). The decrease in plasma PAI-1 concentrations is similar to that reported with troglitazone in studies with type 2 diabetic patients (494-496). We did observe a small decrease in the PAI-1 expression in SAT in the placebo group, the cause of which is unclear. However, the changes in the mRNA concentrations of PAI-1 in SAT did not differ between the groups, and could therefore not explain the decrease of plasma PAI-1 concentration in the rosiglitazone group (**Fig. 14**). Of all clinical and biochemical parameters, the only significant correlates of the decrease in

plasma PAI-1 concentration were the decreases in serum insulin concentration and liver fat content (Study VI). The data thus suggest that the fatty liver may significantly contribute to plasma PAI-1 concentrations via affecting either the synthesis or the clearance of PAI-1. This hypothesis is supported by a recent study, which showed a correlation between the degree of steatosis in liver biopsies and plasma PAI-1 concentrations in obese humans (497). In the same report, a significant correlation was found between PAI-1 expression in the liver and its plasma concentration, thus further supporting a role of the liver in the regulation of plasma PAI-1 concentration (497).

7.5. FUTURE PROSPECTS

Life-long treatment with HAART will most likely increase the risk of severe adverse events, such as enhanced cardiovascular morbidity and stigmatizing lipodystrophy. Large prospective studies are needed to determine the incidence and risk factors of HAL, and clinical significance of long-term toxicity of HAART. It is important to increasingly combine the expertise in infectious diseases and metabolism in the routine care of HIV-infected individuals in order to assure the optimal virologic response to HAART and to minimize the adverse consequences of long-term HAART. In order to prevent future complications, blood lipid and glucose levels must be regularly monitored in patients receiving HAART. Emphasis should also be placed on the reduction of classical risk factors of cardiovascular diseases, such as smoking. Fully developed lipodystrophic, especially lipoatrophic changes appear to be resistant to reversal. Therefore it is increasingly important to try to prevent the loss of subcutaneous fat in patients receiving HAART.

Understanding of the pathogenesis of HAL is ultimately needed for its successful prevention and treatment. Since HIV-infected patients are treated with a combination of antiretroviral agents, it is difficult to determine the contribution of each individual antiretroviral agent to the metabolic adverse events. Single antiretroviral agents could be tested as monotherapy in HIV negative subjects, since in the absence of the virus there is no risk of the development of viral drug resistance. Quantifying gene expression in SAT instead of waiting for the appearance of visible changes in body composition may considerably shorten the exposure time needed for these studies.

The finding of an increased liver fat content in patients with HAL warrants further studies on its pathogenesis and clinical impact. The potential role of NRTI-induced mitochondrial toxicity in the pathogenesis of hepatosteatosis warrants to be evaluated. Hepatosteatosis in patients with HAL may not only contribute to insulin resistance, but also increase the risk of steatohepatitis and cirrhosis. Monitoring of the potential consequences of the fatty liver in patients with HAL should be included in future studies.

Although rosiglitazone did not alleviate lipoatrophy in the current study, it decreased liver fat content and serum insulin levels. It remains to be studied, whether treatment with rosiglitazone could increase SAT in patients whose HAART regimen would be simultaneously modified by replacing the more toxic drug(s) with

metabolically less toxic antiretroviral agent(s). Under these circumstances, the adipogenic effects of rosiglitazone could possibly exceed the diminished anti-adipogenic effects of the modified HAART, and eventually increase the amount of SAT. It would also be of interest to study whether rosiglitazone could prevent HAL if started before lipoatrophy has fully developed. Pioglitazone, which may act as a partial PPARα agonist (498), would also be an interesting agent, since pioglitazone appears to have more favorable effects on blood lipids than rosiglitazone at least in patients with type 2 diabetes (499). In the future, agonists which are active for both PPARγ and α may offer a dual effect by improving insulin sensitivity and correcting dyslipidemia (500). However, the effects of these drugs on lipoatrophy are probably not different from those of thiazolidinediones, since their action in adipose tissue is dependent on the activation of PPARγ as is that of rosiglitazone.

Currently there are no human data, and very limited *in vitro* or animal data regarding the mechanisms underlying the intra-abdominal fat accumulation in HAL. Since VAT is anatomically difficult to access, studies on the hypertrophic fat in buffalo humps might provide information regarding the pathogenic differences between the hypertrophic and atrophic adipose tissue in HAL.

8. SUMMARY

The results of the Studies I-VI can be summarized as follows:

I. Liver fat content was significantly increased in HIV-infected patients with HAL when compared to HIV-infected, HAART-treated patients without lipodystrophy and healthy controls. Fasting serum insulin concentrations correlated more closely with liver fat content than with other measures of body composition.

II. The expression of adiponectin in SAT and its circulating concentrations were decreased in HIV-infected patients with HAL when compared to HIV-infected, HAART-treated patients without lipodystrophy. Both adiponectin concentration in serum and its expression in SAT correlated with features of insulin resistance including liver fat content.

III. The expression of several transcription factors (PPARγ, SREBP-1c, PPARδ, PGC-1) important for the normal maturation of adipocytes were decreased in SAT of patients with HAL when compared to HIV-infected, HAART-treated patients without lipodystrophy. Also the expression of other genes involved in adipogenesis (LPL, ACS) and in glucose transport (GLUT4, GLUT1) were decreased in patients with HAL. The markers of inflammation, i.e. the expression of IL-6 and CD45 were increased in SAT of patients with HAL compared to HIV-infected, HAART-treated patients without lipodystrophy.

IV. Rosiglitazone did not increase the amount of subcutaneous fat in patients with HAL after 24 weeks of treatment. Rosiglitazone appeared to ameliorate insulin resistance as judged by the decrease in fasting serum insulin concentration and in liver fat content. Rosiglitazone markedly increased serum triglyceride and cholesterol concentrations in most patients.

V. Rosiglitazone upregulated the expression of adiponectin, PPARγ and PGC-1, and downregulated the expression of IL-6 in SAT of patients with HAL. Rosiglitazone also increased serum adiponectin concentration. The change in serum adiponectin concentration correlated with the change in fasting serum insulin concentration and the change in liver fat content.

VI. PAI-1 concentration in plasma and its expression in SAT were increased in HIV-infected patients with HAL when compared to HIV-infected, HAART-treated patients without lipodystrophy. Plasma PAI-1 concentration correlated with the amount of hepatic fat. Rosiglitazone did not change the expression of PAI-1 in SAT, but decreased PAI-1 concentration in plasma. The decrease in plasma PAI-1 concentration correlated with the decrease in liver fat content.

9. CONCLUSIONS

The results of the current studies imply that the pathogenesis of HAL involves multiple mechanisms. Downregulation of several transcription factors and other genes involved in adipogenesis in SAT may result in reduced adipocyte maturation and lipid accumulation in fat cells. Increased inflammation in SAT may inhibit adipocyte differentiation and increase lipolysis. Increased inflammation and mitochondrial alterations may also increase apoptosis of adipocytes.

Increased liver fat content in patients with HAL appears to contribute to hepatic insulin resistance. Liver fat also seems to regulate plasma PAI-1 concentrations in these patients. Increased hepatic fat accumulation may be a consequence of a direct effect of antiretroviral agents on the liver, or alternatively the inability to store fat in SAT may cause shifting of lipids into the liver and skeletal muscle. Decreased expression of adiponectin and increased inflammation in SAT may also contribute to the increased liver fat content and insulin resistance.

These data do not support the use of rosiglitazone for the treatment of subcutaneous lipoatrophy in HAART-treated patients, although rosiglitazone appeared to ameliorate insulin resistance and hepatosteatosis. Because of the worsened dyslipidemia by rosiglitazone, blood lipid concentrations should be monitored carefully in future trials using thiazolidinediones in patients with HAL. Increased expression of adiponectin may contribute to the insulin-sensitizing effects of rosiglitazone.

Finally, regardless the potential long-term toxicity of HAART, it is important to emphasize the dramatically decreased total HIV-associated mortality and morbidity after the introduction of HAART. Therefore, HAL and other metabolic adverse events must not prevent the use of HAART in HIV-infected patients when treatment is clinically indicated.

10. ACKNOWLEDGEMENTS

This study was carried out at the Department of Medicine, Divisions of Diabetes and Infectious Diseases at the Helsinki University Central Hospital during the years 2000-2003. I want to express my gratitude to Professor Hannele Yki-Järvinen and Professor Ville Valtonen for providing me with excellent research facilities.

I am most grateful to my supervisor Professor Hannele Yki-Järvinen for her ever-lasting energy, devotion to science, her attitude not only to look for challenges but also to accomplish them.

I want to express my gratitude to Docent Petri Kovanen and Docent Esa Rintala for their valuable advice and constructive criticism during the review of the thesis.

This work would not have been possible without our collaborators in Finland, Sweden, France and Japan. I am especially grateful to MD, PhD Matti Ristola for his unfailing support and guidance in HIV medicine, Docent Anna-Maija Häkkinen for her expert spectroscopy analyses and Professor Anders Hamsten for the fruitful Finnish-Swedish collaboration.

The help and support from my coworkers in Yki-team have been fundamental for the completion of this work. I want to thank Docent Antti Virkamäki for being the first "metabolic person" interested in HIV-lipodystrophy. I am deeply indebted to Elena Korsheninnikova and Katja Kannisto for their invaluable work in the lab. Jukka Westerbacka and Mirja Tiikkainen have not only been great coworkers, but also good friends already prior to this research project. I feel very fortunate to have shared so much work and so much fun with Robert Bergholm, Marjo Tamminen, Satu Vehkavaara, Anja Corner and Kirsi Pietiläinen. A special thank you goes to Katja Tuominen for her energetic spirit, superb organizing skills and good laughs. Maarit Toivonen and Pentti Pölönen are gratefully acknowledged for skilled technical assistance. I also want to express my greatest appreciation for the welcoming and helpful attitude that I have always experienced from Professor Marja-Riitta Taskinen and her team, and from all the staff, especially Tuulikki Nyman and Mia Urjansson, at Minerva Foundation.

I am deeply grateful to my original home base, Infectious Disease Clinic. The help and support from Docent Asko Järvinen, other colleagues and staff, particularly the skilled nurses at the HIV Clinic, are highly acknowledged. Their encouraging attitude to my shuttling between the worlds of metabolism and infectious diseases has made it a pleasant adventure.

Without volunteers there would not be any clinical research. The time and effort of all the volunteers participating in these studies are greatly appreciated.

My gratitude for persistently keeping me aware of the non-scientific world during the last three years goes to my true friends: Helena, Hörps, Juha & Sönke, Korppu, La Profa & Los Estudiantes, Mappe & Hepa, Mersu, Miia, Pekka & Tita, Petteri, Risto & Eija, Satu, Terhi, Timo & Maarit, Tuija and others. I am very privileged to have parents with genuine wisdom reaching far beyond the rational thinking required in science. Thank you, Kaisa and Matti, for teaching me some of your tolerant and humorous attitude in life. I also want thank my sister Maikki, brother Asko and their families for their continuous support. My ever-growing appreciation goes to my little brother Köpi with Sanni and Kaisla for always remaining calm and having time to help. The final thank you goes to Aatu for sharing all the ups and downs with never-failing humor and patience. Kiitos. :-)

This work has been supported by grants from the Finnish Medical Foundation and Research Foundation of Orion Corporation. I also want to express my sincere appreciation to Thanks to Scandinavia for generously financing my stay at Beth Israel Medical Center, New York 1997-1998 where Dr Usha Mathur-Wagh and Dr Donna Mildvan originally introduced me to the metabolic complications of HAART.

Helsinki, December 2003



11. REFERENCES

1. Palella FJJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. *N Engl J Med* 1998;338:853-860.

2. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J, Siliciano RF. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. *Nat Med* 1999;5:512-517.

3. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. *Lancet* 2000;356:1423-1430.

4. Ammassari A, Antinori A, Cozzi-Lepri A, Trotta MP, Nasti G, Ridolfo AL, Mazzotta F, Wu AW, d'Arminio MA, Galli M. Relationship between HAART adherence and adipose tissue alterations. *J Acquir Immune Defic Syndr* 2002;31 Suppl 3:S140-S144.

5. Duran S, Saves M, Spire B, Cailleton V, Sobel A, Carrieri P, Salmon D, Moatti JP, Leport C. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. *AIDS* 2001;15:2441-2444.

6. Friis-Moller N, Weber R, D'Arminio Monforte A, El-Sadr W, Reiss P, Dabis F, Morfeldt L, De Wit S, Pradier C, Calvo G, Law M, Kirk O, Sabin C, Lundgren JD. Exposure to HAART Is Associated with an Increased Risk of Myocardial Infarction: The D:A:D Study. *10th Conference on Retroviruses and Opportunistic Infections, February 10-14, 2003, Boston, USA* 2003;Abstract 130.

7. Garg A. Lipodystrophies. *Am J Med* 2000;108:143-152.

8. Burant CF, Sreenan S, Hirano K, Tai TA, Lohmiller J, Lukens J, Davidson NO, Ross S, Graves RA. Troglitazone action is independent of adipose tissue. *J Clin Invest* 1997;100:2900-2908.

9. Fruhbeck G, Gomez-Ambrosi J, Muruzabal FJ, Burrell MA. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. *Am J Physiol Endocrinol Metab* 2001;280:E827-E847.

10. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. *JAMA* 2000;283:1695-1702.

11. Kruszynska YT. Normal metabolism: the physiology of fuel homeostasis. In: Pickup JC, Williams G, editors. *Textbook of Diabetes* 3rd ed. Massachusetts, Blackwell Science Ltd, 2003, Chapter 9.

12. Petersen KF, Price T, Cline GW, Rothman DL, Shulman GI. Contribution of net hepatic glycogenolysis to glucose production during the early postprandial period. *Am J Physiol* 1996;270:E186-E191.

13. Corssmit EP, Romijn JA, Sauerwein HP. Review article: Regulation of glucose production with special attention to nonclassical regulatory mechanisms: a review. *Metabolism* 2001;50:742-755.

14. Yki-Järvinen H. Action of insulin on glucose metabolism in vivo. *Baillieres Clin Endocrinol Metab* 1993;7:903-927.

15. Foufelle F, Ferre P. New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c. *Biochem J* 2002;366:377-391.

16. Tirone TA, Brunicardi FC. Overview of glucose regulation. *World J Surg* 2001;25:461-467.

17. Boyle PJ, Shah SD, Cryer PE. Insulin, glucagon, and catecholamines in prevention of hypoglycemia during fasting. *Am J Physiol* 1989;256:E651-E661.

18. Ho KK, O'Sullivan AJ, Hoffman DM. Metabolic actions of growth hormone in man. *Endocr J* 1996;43 Suppl:S57-S63.

19. Seppälä-Lindroos A, Vehkavaara S, Häkkinen AM, Goto T, Westerbacka J, Sovijärvi A, Halavaara J, Yki-Järvinen H. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. *J Clin Endocrinol Metab* 2002;87:3023-3028.

20. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. *Nat Med* 2001;7:947-953.

21. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. *Nat Med* 2002;11:1288-1295.

22. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. *Nat Med* 2001;7:941-946.

23. Kelley D, Mitrakou A, Marsh H, Schwenck F, Benn J, Sonnenberg G, Arcangeli M, Aoki T, Sörensen J, Berger M, Sönksen P, Gerich JE. Skeletal muscle glycolysis, oxidation, and storage of an oral glucose load. *J Clin Invest* 1988;81:1563-1571.

24. Le Roith D, Zick Y. Recent advances in our understanding of insulin action and insulin resistance. *Diabetes Care* 2001;24:588-597.

25. Kido Y, Nakae J, Accili D. Clinical review 125: The insulin receptor and its cellular targets. *J Clin Endocrinol Metab* 2001;86:972-979.

26. Furtado LM, Somwar R, Sweeney G, Niu W, Klip A. Activation of the glucose transporter GLUT4 by insulin. *Biochem Cell Biol* 2002;80:569-578.

27. Sonksen P, Sonksen J. Insulin: understanding its action in health and disease. *Br J Anaesth* 2000;85:69-79.

28. Poirier P , Despres J-P. Lipid disorders in diabetes. In: Pickup JC, Williams G, editors. *Textbook of Diabetes* 3rd ed. Massachusetts, Blackwell Science Ltd, 2003, Chapter 54.

29. Yki-Järvinen H. Insulin resistance in type 2 diabetes. In: Pickup JC, Williams G, editors. *Textbook of Diabetes* 3rd ed. Massachusetts, Blackwell Science Ltd, 2003, Chapter 22.

30. Taskinen MR, Nikkilä EA, Nousiainen R, Gordin A. Lipoprotein lipase activity in adipose tissue and skeletal muscle of human diabetics during insulin deprivation and restoration. *Scand J Clin Lab Invest* 1981;41:263-268.

31. Farese RVJ, Yost TJ, Eckel RH. Tissue-specific regulation of lipoprotein lipase activity by insulin/glucose in normal-weight humans. *Metabolism* 1991;40:214-216.

32. Holm C, Osterlund T, Laurell H, Contreras JA. Molecular mechanisms regulating hormone-sensitive lipase and lipolysis. *Annu Rev Nutr* 2000;20:365-393.

33. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. *Nature* 2001;414:799-806.

34. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. *N Engl J Med* 2000;342:1792-1801.

35. Banfi C, Eriksson P, Giandomenico G, Mussoni L, Sironi L, Hamsten A, Tremoli E. Transcriptional regulation of plasminogen activator inhibitor type 1 gene by insulin: insights into the signaling pathway. *Diabetes* 2001;50:1522-1530.

36. Harte AL, McTernan PG, McTernan CL, Smith SA, Barnett AH, Kumar S. Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human abdominal subcutaneous adipocytes. *Diabetes Obes Metab* 2003;5:302-310.

37. Westerbacka J, Wilkinson I, Cockcroft J, Utriainen T, Vehkavaara S, Yki-Järvinen H. Diminished wave reflection in the aorta: A novel physiological action of insulin on large blood vessels. *Hypertension* 1999;33:1118-1122.

38. Ravussin E, Smith SR. Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and type 2 diabetes mellitus. *Ann N Y Acad Sci* 2002;967:363-378.

39. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med* 2001;344:1343-1350.

40. Stewart KJ. Exercise training and the cardiovascular consequences of type 2 diabetes and hypertension: plausible mechanisms for improving cardiovascular health. *JAMA* 2002;288:1622-1631.

41. Starkie R, Ostrowski SR, Jauffred S, Febbraio M, Pedersen BK. Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans. *FASEB J* 2003;17:884-886.

42. Koistinen HA, Zierath JR. Regulation of glucose transport in human skeletal muscle. *Ann Med* 2002;34:410-418.

43. Winder WW. Energy-sensing and signaling by AMP-activated protein kinase in skeletal muscle. *J Appl Physiol* 2001;91:1017-1028.

44. Hayashi T, Hirshman MF, Fujii N, Habinowski SA, Witters LA, Goodyear LJ. Metabolic stress and altered glucose transport: activation of AMP- activated protein kinase as a unifying coupling mechanism. *Diabetes* 2000;49:527-531.

45. Winder WW , Hardie DG. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. *American Journal of Physiology* 1999;277:E1-E19.

46. Musi N, Goodyear LJ. Targeting the AMP-activated protein kinase for the treatment of type 2 diabetes. *Curr Drug Targets Immune Endocr Metabol Disord* 2002;2:119-127.

47. Yki-Järvinen H. Sex and insulin sensitivity. *Metabolism* 1984;33:1011-1015.

48. Vehkavaara S, Westerbacka J, Hakala AP, Virkamäki A, Hovatta O, Yki-Järvinen H. Effect of estrogen replacement therapy on insulin sensitivity of glucose metabolism and preresistance and resistance vessel function in healthy postmenopausal women. *J Clin Endocrinol Metab* 2000;85:4663-4670.

49. Chang AM, Halter JB. Aging and insulin secretion. *Am J Physiol Endocrinol Metab* 2003;284:E7-12.

50. Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, DiPietro L, Cline GW, Shulman GI. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. *Science* 2003;300:1140-1142.

51. Shulman GI. Cellular mechanisms of insulin resistance. *J Clin Invest* 2000;106:171-176.

52. Koutnikova H, Auwerx J. Regulation of adipocyte differentiation. *Ann Med* 2001;33:556-561.

53. Rosen ED, Spiegelman BM. Molecular regulation of adipogenesis. *Annu Rev Cell Dev Biol* 2000;16:145-171.

54. Gregoire FM. Adipocyte differentiation: from fibroblast to endocrine cell. *Exp Biol Med* 2001;226:997-1002.

55. Charriere G, Cousin B, Arnaud E, Andre M, Bacou F, Penicaud L, Casteilla L. Preadipocyte conversion to macrophage. Evidence of plasticity. *J Biol Chem* 2003;278:9850-9855.

56. MacDougald OA, Mandrup S. Adipogenesis: forces that tip the scales. *Trends Endocrinol Metab* 2002;13:5-11.

57. Reusch JE, Colton LA, Klemm DJ. CREB activation induces adipogenesis in 3T3-L1 cells. *Mol Cell Biol* 2000;20:1008-1020.

58. Tominaga S, Morikawa M, Osumi T. Growth Hormone Has Dual Stage-Specific Effects on the Differentiation of 3T3-L1 Preadipocytes. *J Biochem* 2002;132:881-889.

59. Sniderman AD, Cianflone K, Arner P, Summers LK, Frayn KN. The adipocyte, fatty acid trapping, and atherogenesis. *Arterioscler Thromb Vasc Biol* 1998;18:147-151.

60. Abumrad N, Coburn C, Ibrahimi A. Membrane proteins implicated in long-chain fatty acid uptake by mammalian cells: CD36, FATP and FABPm. *Biochim Biophys Acta* 1999;1441:4-13.

61. Sniderman AD, Maslowska M, Cianflone K. Of mice and men (and women) and the acylation-stimulating protein pathway. *Curr Opin Lipidol* 2000;11:291-296.

62. Fisher RM, Eriksson P, Hoffstedt J, Hotamisligil GS, Thorne A, Ryden M, Hamsten A, Arner P. Fatty acid binding protein expression in different adipose tissue depots from lean and obese individuals. *Diabetologia* 2001;44:1268-1273.

63. Schaffer JE, Lodish HF. Expression cloning and characterization of a novel adipocyte long chain fatty acid transport protein. *Cell* 1994;79:427-436.

64. Van Harmelen V, Reynisdottir S, Cianflone K, Degerman E, Hoffstedt J, Nilsell K, Sniderman A, Arner P. Mechanisms involved in the regulation of free fatty acid release from isolated human fat cells by acylation-stimulating protein and insulin. *J Biol Chem* 1999;274:18243-18251.

65. Hauner H, Petruschke T, Russ M, Rohrig K, Eckel J. Effects of tumour necrosis factor alpha (TNF alpha) on glucose transport and lipid metabolism of newly-differentiated human fat cells in cell culture. *Diabetologia* 1995;38:764-771.

66. Lafontan M, Berlan M. Do regional differences in adipocyte biology provide new pathophysiological insights? *Trends Pharmacol Sci* 2003;24:276-283.

67. Cinti S. Adipocyte differentiation and transdifferentiation: plasticity of the adipose organ. *J Endocrinol Invest* 2002;25:823-835.

68. Himms-Hagen J. Does brown adipose tissue (BAT) have a role in the physiology or treatment of human obesity? *Rev Endocr Metab Disord* 2001;2:395-401.

69. Oberkofler H, Dallinger G, Liu YM, Hell E, Krempler F, Patsch W. Uncoupling protein gene: quantification of expression levels in adipose tissues of obese and non-obese humans. *J Lipid Res* 1997;38:2125-2133.

70. Tiraby C, Tavernier G, Lefort C, Larrouy D, Bouillaud F, Ricquier D, Langin D. Acquirement of brown fat cell features by human white adipocytes. *J Biol Chem* 2003;278:33370-33376.

71. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. *Cell* 1998;92:829-839.

72. Knutti D, Kralli A. PGC-1, a versatile coactivator. *Trends Endocrinol Metab* 2001;12:360-365.

73. Michael LF, Wu Z, Cheatham RB, Puigserver P, Adelmant G, Lehman JJ, Kelly DP, Spiegelman BM. Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1. *Proc Natl Acad Sci U S A* 2001;98:3820-3825.

74. Lin J, Wu H, Tarr PT, Zhang CY, Wu Z, Boss O, Michael LF, Puigserver P, Isotani E, Olson EN, Lowell BB, Bassel-Duby R, Spiegelman BM. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. *Nature* 2002;418:797-801.

75. Rondinone CM, Wang LM, Lonnroth P, Wesslau C, Pierce JH, Smith U. Insulin receptor substrate (IRS) 1 is reduced and IRS-2 is the main docking protein for phosphatidylinositol 3-kinase in adipocytes from subjects with non-insulin-dependent diabetes mellitus. *Proc Natl Acad Sci U S A* 1997;94:4171-4175.

76. Carvalho E, Jansson PA, Axelsen M, Eriksson JW, Huang X, Groop L, Rondinone C, Sjöström L, Smith U. Low cellular IRS 1 gene and protein expression predict insulin resistance and NIDDM. *FASEB J* 1999;13:2173-2178.

77. Carvalho E, Jansson PA, Nagaev I, Wenthzel AM, Smith U. Insulin resistance with low cellular IRS-1 expression is also associated with low GLUT4 expression and impaired insulin-stimulated glucose transport. *FASEB J* 2001;15:1101-1103.

78. Jansson PA, Pellme F, Hammarstedt A, Sandqvist M, Brekke H, Caidahl K, Forsberg M, Volkmann R, Carvalho E, Funahashi T, Matsuzawa Y, Wiklund O, Yang X, Taskinen MR, Smith U. A novel cellular marker of insulin resistance and early atherosclerosis in humans is related to impaired fat cell differentiation and low adiponectin. *FASEB J* 2003;17:1434-1440.

79. Garvey WT, Maianu L, Zhu JH, Hancock JA, Golichowski AM. Multiple defects in the adipocyte glucose transport system cause cellular insulin resistance in gestational diabetes. Heterogeneity in the number and a novel abnormality in subcellular localization of GLUT4 glucose transporters. *Diabetes* 1993;42:1773-1785.

80. Garvey WT, Maianu L, Hueckstead TP, Birnbaum MJ, Molina JM, Ciaraldi TP. Pretranslational suppression of a glucose transporter protein causes insulin resistance in adipocytes from patients with non-insulin-dependent diabetes mellitus and obesity. *J Clin Invest* 1991;87:1072-1081.

81. Boden G. Interaction between free fatty acids and glucose metabolism. *Curr Opin Clin Nutr Metab Care* 2002;5:545-549.

82. Ferrannini E, Barrett EJ, Bevilacqua S, DeFronzo RA. Effect of fatty acids on glucose production and utilization in man. *J Clin Invest* 1983;72:1737-1747.

83. Yki-Järvinen H, Puhakainen I, Koivisto VA. Effect of free fatty acids on glucose uptake and nonoxidative glycolysis across human forearm tissues in the basal state and during insulin stimulation. *J Clin Endocrinol Metab* 1991;72:1268-1277.

84. Dresner A, Laurent D, Marcucci M, Griffin ME, Dufour S, Cline GW, Slezak LA, Andersen DK, Hundal RS, Rothman DL, Petersen KF, Shulman GI. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. *J Clin Invest* 1999;103:253-259.

85. Bevilacqua S, Bonadonna R, Buzzigoli G, Boni C, Ciociaro D, Maccari F, Giorico MA, Ferrannini E. Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects. *Metabolism* 1987; 36:502-506.

86. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. *Endocr Rev* 2002;23:201-229.

87. Frayn KN, Karpe F, Fielding BA, MacDonald IA, Coppack SW. Integrative physiology of human adipose tissue. *Int J Obes Relat Metab Disord* 2003;27:875-888.

88. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. *J Biol Chem* 1995;270:26746-26749.

89. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. *Trends Endocrinol Metab* 2002;13:84-89.

90. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. *Biochem Biophys Res Commun* 1999;257:79-83.

91. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. *Arterioscler Thromb Vasc Biol* 2000;20:1595-1599.

92. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, Arita Y, Okamoto Y, Shimomura I, Hiraoka H, Nakamura T, Funahashi T, Matsuzawa Y. Association of hypoadiponectinemia with coronary artery disease in men. *Arterioscler Thromb Vasc Biol* 2003;23:85-89.

93. Statnick MA, Beavers LS, Conner LJ, Corominola H, Johnson D, Hammond CD, Rafaeloff-Phail R, Seng T, Suter TM, Sluka JP, Ravussin E, Gadski RA, Caro JF. Decreased expression of apM1 in omental and subcutaneous adipose tissue of humans with type 2 diabetes. *Int J Exp Diabetes Res* 2000;1:81-88.

94. Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC, Matsuzawa Y. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. *Diabetes* 2001;50:1126-1133.

95. Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF. Adiponectin and protection against type 2 diabetes mellitus. *Lancet* 2003;361:226-228.

96. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, Knowler WC, Krakoff J. Adiponectin and development of type 2 diabetes in the Pima Indian population. *Lancet* 2002;360:57-58.

97. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. *Circulation* 1999;100:2473-2476.

98. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, Ishigami M, Kuriyama H, Kishida K, Nishizawa H, Hotta K, Muraguchi M, Ohmoto Y, Yamashita S, Funahashi T, Matsuzawa Y. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. *Circulation* 2001;103:1057-1063.

99. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. *Biochem Biophys Res Commun* 2002;290:1084-1089.

100. Fasshauer M, Kralisch S, Klier M, Lossner U, Bluher M, Klein J, Paschke R. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. *Biochem Biophys Res Commun* 2003;301:1045-1050.

101. Ott V, Fasshauer M, Dalski A, Meier B, Perwitz N, Klein HH, Tschop M, Klein J. Direct peripheral effects of ghrelin include suppression of adiponectin expression. *Horm Metab Res* 2002;34:640-645.

102. Kappes A, Loffler G. Influences of ionomycin, dibutyryl-cycloAMP and tumour necrosis factor-alpha on intracellular amount and secretion of apM1 in differentiating primary human preadipocytes. *Horm Metab Res* 2000;32:548-554.

103. Bruun JM, Lihn AS, Verdich C, Pedersen SB, Toubro S, Astrup A, Richelsen B. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. *Am J Physiol Endocrinol Metab* 2003;285:E527-E533.

104. Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. *Diabetes* 2003;52:1779-1785.

105. Bogan JS, Lodish HF. Two compartments for insulin-stimulated exocytosis in 3T3-L1 adipocytes defined by endogenous ACRP30 and GLUT4. *J Cell Biol* 1999;146:609-620.

106. Mohlig M, Wegewitz U, Osterhoff M, Isken F, Ristow M, Pfeiffer AF, Spranger J. Insulin decreases human adiponectin plasma levels. *Horm Metab Res* 2002; 34:655-658.

107. Delporte ML, Funahashi T, Takahashi M, Matsuzawa Y, Brichard SM. Pre- and post-translational negative effect of beta-adrenoceptor agonists on adiponectin secretion: in vitro and in vivo studies. *Biochem* 2002;367:677-685.

108. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Adiponectin gene expression is inhibited by beta-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes. *FEBS Lett* 2001;507:142-146.

109. Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, Matsuda M, Kondo H, Furuyama N, Kihara S, Nakamura T, Tochino Y, Funahashi T, Matsuzawa Y. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. *Diabetes* 2002;51:2734-2741.

110. Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y, Wang JP, Chen CL, Tai TY, Chuang LM. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. *Diabetes Care* 2002;25:376-380.

111. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. *Diabetes* 2001;50:2094-2099.

112. Iwaki M, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, Makishima M, Shimomura I. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. *Diabetes* 2003;52:1655-1663.

113. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D , Erickson MR, Yen FT, Bihain BE, Lodish HF. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. *Proc Natl Acad Sci U S A* 2001;98:2005-2010.

114. Musi N, Yu H , Goodyear LJ. AMP-activated protein kinase regulation and action in skeletal muscle during exercise. *Biochem Soc Trans* 2003;31:191-195.

115. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S , Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. *Nature* 2003;423:762-769.

116. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. *Nature* 1994;372:425-432.

117. Lee DW, Leinung MC, Rozhavskaya-Arena M, Grasso P. Leptin and the treatment of obesity: its current status. *Eur J Pharmacol* 2002;440:129-139.

118. Andersson LB. Genes and obesity. *Ann Med* 1996;28:5-7.

119. Lönnqvist F, Arner P, Nordfors L, Schalling M. Overexpression of the obese (ob) gene in adipose tissue of human obese subjects. *Nat Med* 1995;1:950-953.

120. Considine RV, Sinha MK, Heiman ML, Kriauciunas A , Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. *N Engl J Med* 1996;334:292-295.

121. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, Collins F. Effects of the obese gene product on body weight regulation in ob/ob mice. *Science* 1995;269:540-543.

122. Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM , Kushner R, Hunt T, Lubina JA, Patane J, Self B, Hunt P, McCamish M. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. *JAMA* 1999;282:1568-1575.

123. Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner AJ, DePaoli AM, Reitman ML, Taylor SI, Gorden P, Garg A. Leptin-replacement therapy for lipodystrophy. *N Engl J Med* 2002;346:570-578.

124. Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, Cline GW, DePaoli AM, Taylor SI, Gorden P, Shulman GI. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. *J Clin Invest* 2002;109:1345-1350.

125. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. *J Clin Invest* 1995;95:2111-2119.

126. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. *J Clin Invest* 1995;95:2409-2415.

127. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. *J Clin Endocrinol Metab* 1997;82:4196-4200.

128. Koistinen HA, Bastard JP, Dusserre E, Ebeling P, Zegari N, Andreelli F, Jardel C, Donner M, Meyer L, Moulin P, Hainque B, Riou JP, Laville M, Koivisto VA, Vidal H. Subcutaneous adipose tissue expression of tumour necrosis factor-alpha is not associated with whole body insulin resistance in obese nondiabetic or in type-2 diabetic subjects. *Eur J Clin Invest* 2000;30:302-310.

129. Liu LS, Spelleken M, Rohrig K, Hauner H, Eckel J. Tumor necrosis factor-alpha acutely inhibits insulin signaling in human adipocytes: implication of the p80 tumor necrosis factor receptor. *Diabetes* 1998;47:515-522.

130. Moller DE. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. *Trends Endocrinol Metab* 2000;11:212-217.

131. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. *Diabetes* 1996;45:881-885.

132. Straub RH, Hense HW, Andus T, Scholmerich J, Riegger GA, Schunkert H. Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: a population-based study. *J Clin Endocrinol Metab* 2000;85:1340-1344.

133. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. *Diabetologia* 1997;40:1286-1292.

134. Hak AE, Pols HA, Stehouwer CD, Meijer J, Kiliaan AJ, Hofman A, Breteler MM, Witteman JC. Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly: the Rotterdam study. *J Clin Endocrinol Metab* 2001;86:4398-4405.

135. Fernandez-Real JM, Vayreda M, Richart C, Gutierrez C, Broch M, Vendrell J, Ricart W. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. *J Clin Endocrinol Metab* 2001;86:1154-1159.

136. Bastard JP, Maachi M, Van Nhieu JT, Jardel C, Bruckert E, Grimaldi A, Robert JJ, Capeau J, Hainque B. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. *J Clin Endocrinol Metab* 2002;87:2084-2089.

137. Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, Vidal H, Hainque B. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. *J Clin Endocrinol Metab* 2000;85:3338-3342.

138. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, Giugliano D. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. *JAMA* 2003;289:1799-1804.

139. Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. *Diabetes* 2002;51:3391-3399.

140. Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and TNFalpha, overexpressed in human fat cells from insulin-resistant subjects. *J Biol Chem* 2003;278:45777-45784.

141. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. *Nature* 2001;409:307-312.

142. Ukkola O. Resistin - a mediator of obesity-associated insulin resistance or an innocent bystander? *Eur J Endocrinol* 2002; 147:571-574.

143. McTernan CL, McTernan PG, Harte AL, Levick PL, Barnett AH, Kumar S. Resistin, central obesity, and type 2 diabetes. *Lancet* 2002;359:46-47.

144. McTernan PG, McTernan CL, Chetty R, Jenner K, Fisher FM, Lauer MN, Crocker J, Barnett AH, Kumar S. Increased resistin gene and protein expression in human abdominal adipose tissue. *J Clin Endocrinol Metab* 2002;87:2407.

145. Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. *Am J Clin Nutr* 1956;4:20-34.

146. Ashwell M, Cole TJ, Dixon AK. Obesity: new insight into the anthropometric classification of fat distribution shown by computed tomography. *Br Med J* 1985;290:1692-1694.

147. Frayn KN. Visceral fat and insulin resistance--causative or correlative? *Br J Nutr* 2000;83 Suppl 1:S71-S77.

148. Arner P. Regional differences in protein production by human adipose tissue. *Biochem Soc Trans* 2001;29:72-75.

149. Thörne A, Lönnqvist F, Apelman J, Hellers G, Arner P. A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding. *Int J Obes Relat Metab Disord* 2002;26:193-199.

150. Arner P. Not all fat is alike. *Lancet* 1998;351 :1301-1302.

151. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. *J Clin Endocrinol Metab* 1998;83:847-850.

152. Montague CT, Prins JB, Sanders L, Digby JE, O'Rahilly S. Depot- and sex-specific differences in human leptin mRNA expression: implications for the control of regional fat distribution. *Diabetes* 1997;46:342-347.

153. Van Harmelen V, Reynisdottir S, Eriksson P, Thörne A, Hoffstedt J, Lönnqvist F, Arner P. Leptin secretion from subcutaneous and visceral adipose tissue in women. *Diabetes* 1998;47:913-917.

154. Fisher FM, McTernan PG, Valsamakis G, Chetty R, Harte AL, Anwar AJ, Starcynski J, Crocker J, Barnett AH, McTernan CL, Kumar S. Differences in adiponectin protein expression: effect of fat depots and type 2 diabetic status. *Horm Metab Res* 2002;34:650-654.

155. Motoshima H, Wu X, Sinha MK, Hardy VE, Rosato EL, Barbot DJ, Rosato FE, Goldstein BJ. Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. *J Clin Endocrinol Metab* 2002;87:5662-5667.

156. Montague CT, Prins JB, Sanders L, Zhang J, Sewter CP, Digby J, Byrne CD, O'Rahilly S. Depot-related gene expression in human subcutaneous and omental adipocytes. *Diabetes* 1998;47:1384-1391.

157. Van Harmelen V, Elizalde M, Ariapart P, Bergstedt-Lindqvist S, Reynisdottir S, Hoffstedt J, Lundkvist I, Bringman S, Arner P. The association of human adipose angiotensinogen gene expression with abdominal fat distribution in obesity. *Int J Obes Relat Metab Disord* 2000;24:673-678.

158. Dusserre E, Moulin P, Vidal H. Differences in mRNA expression of the proteins secreted by the adipocytes in human subcutaneous and visceral adipose tissues. *Biochim Biophys Acta* 2000;1500:88-96.

159. Niesler CU, Prins JB, O'Rahilly S, Siddle K, Montague CT. Adipose depot-specific expression of cIAP2 in human preadipocytes and modulation of expression by serum factors and TNFalpha. *Int J Obes Relat Metab Disord* 2001;25:1027-1033.

160. Gabrielsson BG, Johansson JM, Lönn M, Jernås M, Olbers T, Peltonen M, Larsson I, Lönn L, Sjöström L, Carlsson B, Carlsson LM. High expression of complement components in omental adipose tissue in obese men. *Obes Res* 2003;11:699-708.

161. Rebuffe-Scrive M, Brönnegård M, Nilsson A, Eldh J, Gustafsson JA, Björntorp P. Steroid hormone receptors in human adipose tissues. *J Clin Endocrinol Metab* 1990;71:1215-1219.

162. Lefebvre AM, Laville M, Vega N, Riou JP, Van Gaal L, Auwerx J, Vidal H. Depot-specific differences in adipose tissue gene expression in lean and obese subjects. *Diabetes* 1998;47:98-103.

163. Marette A, Mauriege P, Marcotte B, Atgie C, Bouchard C, Theriault G, Bukowiecki LJ, Marceau P, Biron S, Nadeau A, Despres JP. Regional variation in adipose tissue insulin action and GLUT4 glucose transporter expression in severely obese premenopausal women. *Diabetologia* 1997;40:590-598.

164. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect "Cushing's disease of the omentum"? *Lancet* 1997;349:1210-1213.

165. Reynisdottir S, Dauzats M, Thörne A, Langin D. Comparison of hormone-sensitive lipase activity in visceral and subcutaneous human adipose tissue. *J Clin Endocrinol Metab* 1997;82:4162-4166.

166. Zierath JR, Livingston JN, Thörne A, Bolinder J, Reynisdottir S, Lönnqvist F, Arner P. Regional difference in insulin inhibition of non-esterified fatty acid release from human adipocytes: relation to insulin receptor phosphorylation and intracellular signalling through the insulin receptor substrate-1 pathway. *Diabetologia* 1998;41:1343-1354.

167. Fried SK, Russell CD, Grauso NL, Brolin RE. Lipoprotein lipase regulation by insulin and glucocorticoid in subcutaneous and omental adipose tissues of obese women and men. *J Clin Invest* 1993;92:2191-2198.

168. Eriksson P, Van Harmelen V, Hoffstedt J, Lundquist P, Vidal H, Stemme V, Hamsten A, Arner P, Reynisdottir S. Regional variation in plasminogen activator inhibitor-1 expression in adipose tissue from obese individuals. *Thromb Haemost* 2000;83:545-548.

169. Polac I, Cierniewska-Cieslak A, Stachowiak G, Pertynski T, Cierniewski CS. Similar PAI-1 expression in visceral and subcutaneous fat of postmenopausal women. *Thromb Res* 2001;102:397-405.

170. Bastelica D, Morange P, Berthet B, Borghi H, Lacroix O, Grino M, Juhan-Vague I, Alessi MC. Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits. *Arterioscler Thromb Vasc Biol* 2002;22:173-178.

171. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. *Diabetes* 1997;46:860-867.

172. Cigolini M, Tonoli M, Borgato L, Frigotto L, Manzato F, Zeminian S, Cardinale C, Camin M, Chiaramonte E, De Sandre G, Lunardi C. Expression of plasminogen activator inhibitor-1 in human adipose tissue: a role for TNF-alpha? *Atherosclerosis* 1999;143:81-90.

173. Gottschling-Zeller H, Birgel M, Rohrig K, Hauner H. Effect of tumor necrosis factor alpha and transforming growth factor beta 1 on plasminogen activator inhibitor-1 secretion from subcutaneous and omental human fat cells in suspension culture. *Metabolism* 2000;49:666-671.

174. Kolehmainen M, Vidal H, Alhava E, Uusitupa MI. Sterol regulatory element binding protein 1c (SREBP-1c) expression in human obesity. *Obes Res* 2001;9:706-712.

175. Hube F, Birgel M, Lee YM, Hauner H. Expression pattern of tumour necrosis factor receptors in subcutaneous and omental human adipose tissue: role of obesity and non-insulin-dependent diabetes mellitus. *Eur J Clin Invest* 1999;29:672-678.

176. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. *Endocr Rev* 2000;21:697-738.

177. Large V, Arner P, Reynisdottir S, Grober J, Van H, V, Holm C, Langin D. Hormone-sensitive lipase expression and activity in relation to lipolysis in human fat cells. *J Lipid Res* 1998;39:1688-1695.

178. Marin P, Andersson B, Ottosson M, Olbe L, Chowdhury B, Kvist H, Holm G, Sjöström L, Björntorp P. The morphology and metabolism of intraabdominal adipose tissue in men. *Metabolism* 1992;41:1242-1248.

179. Maslowska MH, Sniderman AD, MacLean LD, Cianflone K. Regional differences in triacylglycerol synthesis in adipose tissue and in cultured preadipocytes. *J Lipid Res* 1993;34:219-228.

180. Havel RJ, Kane JP, Balasse EO, Segel N, Basso LV. Splanchnic metabolism of free fatty acids and production of triglyserides of very low density lipoproteins in normotriglyceridemic and hypertriglyceridemic humans. *J Clin Invest* 1970;49:2017-2035.

181. Guo Z, Hensrud DD, Johnson CM, Jensen MD. Regional postprandial fatty acid metabolism in different obesity phenotypes. *Diabetes* 1999;48:1586-1592.

182. Seidell JC, Perusse L, Despres JP, Bouchard C. Waist and hip circumferences have independent and opposite effects on cardiovascular disease risk factors: the Quebec Family Study. *Am J Clin Nutr* 2001;74:315-321.

183. Snijder MB, Dekker JM, Visser M, Bouter LM, Stehouwer CD, Kostense PJ, Yudkin JS, Heine RJ, Nijpels G, Seidell JC. Associations of hip and thigh circumferences independent of waist circumference with the incidence of type 2 diabetes: the Hoorn Study. *Am J Clin Nutr* 2003;77:1192-1197.

184. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. *Gastroenterology* 1999;116:1413-1419.

185. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. *Mayo Clin Proc* 1980;55:434-438.

186. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. *Hepatology* 1995;22:1714-1719.

187. Day CP, James OF. Steatohepatitis: a tale of two "hits"? *Gastroenterology* 1998;114:842-845.

188. Angulo P. Nonalcoholic fatty liver disease. *N Engl J Med* 2002;346:1221-1231.

189. Yu AS, Keeffe EB. Nonalcoholic fatty liver disease. *Rev Gastroenterol Disord* 2002;2:11-19.

190. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. *Diabetes* 2001;50:1844-1850.

191. Ryysy L, Häkkinen AM, Goto T, Vehkavaara S, Westerbacka J, Halavaara J, Yki-Järvinen H. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. *Diabetes* 2000;49:749-758.

192. Tiikkainen M, Tamminen M, Häkkinen AM, Bergholm R, Vehkavaara S, Halavaara J, Teramo K, Rissanen A, Yki-Järvinen H. Liver-fat accumulation and insulin resistance in obese women with previous gestational diabetes. *Obes Res* 2002;10:859-867.

193. Boesch C, Slotboom J, Hoppeler H, Kreis R. In vivo determination of intra-myocellular lipids in human muscle by means of localized 1H-MR-spectroscopy. *Magn Reson Med* 1997;37:484-493.

194. Schick F, Eismann B, Jung WI, Bongers H, Bunse M, Lutz O. Comparison of localized proton NMR signals of skeletal muscle and fat tissue in vivo: two lipid compartments in muscle tissue. *Magn Reson Med* 1993;29:158-167.

195. Virkamäki A, Korsheninnikova E, Seppälä-Lindroos A, Vehkavaara S, Goto T, Halavaara J, Häkkinen AM, Yki-Järvinen H. Intramyocellular lipid is associated with resistance to in vivo insulin actions on glucose uptake, antilipolysis, and early insulin signaling pathways in human skeletal muscle. *Diabetes* 2001;50:2337-2343.

196. Perseghin G, Scifo P, Danna M, Battezzati A, Benedini S, Meneghini E, Del Maschio A, Luzi L. Normal insulin sensitivity and IMCL content in overweight humans are associated with higher fasting lipid oxidation. *Am J Physiol Endocrinol Metab* 2002;283:E556-E564.

197. Schrauwen-Hinderling VB, Schrauwen P, Hesselink MK, van Engelshoven JM, Nicolay K, Saris WH, Kessels AG, Kooi ME. The increase in intramyocellular lipid content is a very early response to training. *J Clin Endocrinol Metab* 2003;88:1610-1616.

198. McGarry JD. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. *Diabetes* 2002; 51:7-18.

199. Yu C, Chen Y , Cline GW, Zhang D, Zong H, Wang Y, Bergeron R, Kim JK, Cushman SW, Cooney GJ, Atcheson B, White MF , Kraegen EW, Shulman GI. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. *J Biol Chem* 2002;277:50230-50236.

200. Hegarty BD, Furler SM, Ye J, Cooney GJ, Kraegen EW. The role of intramuscular lipid in insulin resistance. *Acta Physiol Scand* 2003;178:373-383.

201. Shimomura I, Hammer RE, Richardson JA, Ikemoto S , Bashmakov Y, Goldstein JL, Brown MS. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. *Genes Dev* 1998;12:3182-3194.

202. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. *Nature* 1999;401:73-76.

203. Moitra J, Mason MM, Olive M, Krylov D, Gavrilova O, Marcus-Samuels B, Feigenbaum L, Lee E, Aoyama T, Eckhaus M, Reitman ML, Vinson C. Life without white fat: a transgenic mouse. *Genes Dev* 1998;12:3168-3181.

204. Gavrilova O, Marcus-Samuels B, Graham D, Kim JK, Shulman GI, Castle AL, Vinson C, Eckhaus M, Reitman ML. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. *J Clin Invest* 2000;105:271-278.

205. Kim JK, Gavrilova O, Chen Y, Reitman ML, Shulman GI. Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. *J Biol Chem* 2000;275:8456-8460.

206. Reitman ML, Arioglu E, Gavrilova O, Taylor SI. Lipoatrophy revisited. *Trends Endocrinol Metab* 2000;11:410-416.

207. Shackleton S, Lloyd DJ, Jackson SN, Evans R, Niermeijer MF, Singh BM, Schmidt H, Brabant G, Kumar S, Durrington PN, Gregory S, O'Rahilly S, Trembath RC. LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. *Nat Genet* 2000;24:153-156.

208. Stuurman N, Heins S, Aebi U. Nuclear lamins: their structure, assembly, and interactions. *J Struct Biol* 1998;122:42-66.

209. Lloyd DJ, Trembath RC, Shackleton S. A novel interaction between lamin A and SREBP1: implications for partial lipodystrophy and other laminopathies. *Hum Mol Genet* 2002;11:769-777.

210. Seip M, Trygstad O. Generalized lipodystrophy, congenital and acquired (lipoatrophy). *Acta Paediatr Suppl* 1996;413:2-28.

211. Vantyghem MC, Vigouroux C, Magre J, Desbois-Mouthon C, Pattou F, Fontaine P, Lefebvre J, Capeau J. Late-onset lipoatrophic diabetes. Phenotypic and genotypic familial studies and effect of treatment with metformin and lispro insulin analog. *Diabetes Care* 1999;22:1374-1376.

212. Martens FM, Visseren FL, Lemay J, de Koning EJ, Rabelink TJ. Metabolic and additional vascular effects of thiazolidinediones. *Drugs* 2002;62:1463-1480.

213. Arioglu E, Duncan-Morin J, Sebring N, Rother KI, Gottlieb N, Lieberman J, Herion D, Kleiner DE, Reynolds J, Premkumar A, Sumner AE , Hoofnagle J, Reitman ML, Taylor SI. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. *Ann Intern Med* 2000;133:263-274.

214. Centers for Disease Control. Pneumocystis pneumonia - Los Angeles. *MMWR* 1981;30:250-252.

215. Essex MY. Origin of Acquired Immunodeficiency Syndrome. In: DeVita VT, Hellman S, Rosenberg SA, editors. *AIDS Etiology, Diagnosis, Treatment and Prevention* 2003;4th ed. Philadelphia, Lippincott-Raven Publishers, 1997, Chapter 1.1.

216. Marx JL. New disease baffles medical community. *Science* 1982;217:618-621.

217. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT , Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, Rozenbaum W, Montagnier L. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). *Science* 1983;220:868-871.

218. Gallo RC, Salahuddin SZ, Popovic M, Shearer GM, Kaplan M, Haynes BF, Palker TJ, Redfield R, Oleske J, Safai B. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. *Science* 1984;224:500-503.

219. Coffin J, Haase A, Levy JA, Montagnier L, Oroszlan S, Teich N, Temin H, Toyoshima K, Varmus H, Vogt P. What to call the AIDS virus? *Nature* 1986;321:10-10.

220. The World Health Report 2002. http://www.who.int/whr/2002/en/whr2002_annex2.pdf.

221. http://www.unaids.org/worldaidsday/2002/press/update/epiupdate_en.pdf.

222. Saag MS. Clinical Spectrum of Human Immunodeficiency Virus Diseases. In: DeVita VT, Hellman S, Rosenberg SA, editors. *AIDS Etiology, Diagnosis, Treatment and Prevention* 4th ed. Philadelphia, Lippincott-Raven Publishers, 1997, Chapter 13.

223. Metcalf JA, Davey RT, Lane HC. Acquired Immunodeficiency Syndrome: Serologic and Virologic Tests. In: DeVita VT, Hellman S, Rosenberg SA, editors. *AIDS Etiology, Diagnosis, Treatment and Prevention* 4th ed. Philadelphia, Lippincott-Raven Publishers, 1997, Chapter 11.

224. Centers for Disease Control. 1993 Revised classification system for HIV infection and expanded surveillance of definition for AIDS among adolescents and adults. *MMWR* 1992;41 (RR-17):1-http://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm.

225. Folks TM , Hart CE. The Life Cycle of Human Immunodeficiency Virus Type 1. In: DeVita VT, Hellman S, Rosenberg SA, editors. *AIDS Etiology, Diagnosis, Treatment and Prevention* 4th ed. Philadelphia, Lippincott-Raven Publishers, 1997, Chapter 2.

226. Perelson AS, Neumann AU, Markowitz M, Leonard JM , Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. *Science* 1996;271:1582-1586.

227. Young B, Kuritzkes DR. Viral kinetics: implications for treatment. *AIDS* 1999;13 Suppl 1:S11-S17.

228. Vermund ST. Transmission of the HIV. In: DeVita VT, Hellman S, Rosenberg SA, editors. *AIDS Etiology, Diagnosis, Treatment and Prevention* 4th ed. Philadelphia, Lippincott-Raven Publishers, 1997, Chapter 10.

229. Orenstein R. Presenting syndromes of human immunodeficiency virus. *Mayo Clin Proc* 2002;77:1093-1102.

230. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Schooley RT. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. *N Engl J Med* 1987;317:185-191.

231. Brun-Vezinet F, Boucher C, Loveday C, Descamps D , Fauveau V, Izopet J, Jeffries D, Kaye S, Krzyanowski C, Nunn A, Schuurman R, Seigneurin JM, Tamalet C, Tedder R, Weber J, Weverling GJ. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee. *Lancet* 1997;350:983-990.

232. Mellors JW, Rinaldo CRJ, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. *Science* 1996;272:1167-1170.

233. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L , Meibohm A, Emini EA, Chodakewitz JA. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. *N Engl J Med* 1997;337:734-739.

234. Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C, Sun E, Henry D, Rode R, Potthoff A, Leonard J. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. *Lancet* 1998;351:543-549.

235. Powderly WG. Prophylaxis for opportunistic infections in an era of effective antiretroviral therapy. *Clin Infect Dis* 2000; 31:597-601.

236. Pierson T, McArthur J, Siliciano RF. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. *Annu Rev Immunol* 2000;18:665-708.

237. Temesgen Z, Wright AJ. Antiretrovirals. *Mayo Clin Proc* 1999;74:1284-1301.

238. Squires KE. An introduction to nucleoside and nucleotide analogues. *Antivir Ther* 2001;6 Suppl 3:1-14.

239. Fung HB, Stone EA, Piacenti FJ. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection. *Clin Ther* 2002; 24:1515-1548.

240. Buckheit RW. Non-nucleoside reverse transcriptase inhibitors: perspectives on novel therapeutic compounds and strategies for the treatment of HIV infection. *Expert Opin Investig Drugs* 2001;10:1423-1442.

241. Flexner C. HIV-protease inhibitors. *N Engl J Med* 1998;338:1281-1292.

242. Eron JJJ. HIV-1 protease inhibitors. *Clin Infect Dis* 2000;30 Suppl 2:S160-S170.

243. Cooley LA, Lewin SR. HIV-1 cell entry and advances in viral entry inhibitor therapy. *J Clin Virol* 2003;26:121-132.

244. Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, Katlama C, Stellbrink HJ, Delfraissy JF, Lange J, Huson L, DeMasi R, Wat C, Delehanty J, Drobnes C, Salgo M. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. *N Engl J Med* 2003;348:2186-2195.

245. Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJJ, Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J, Salgo M. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. *N Engl J Med* 2003;348:2175-2185.

246. Chen RY, Kilby JM, Saag MS. Enfuvirtide. *Expert Opin Investig Drugs* 2002;11:1837-1843.

247. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. *Ann Intern Med* 2002;137:381-433.

248. Sandström E, Uhnoo I, Ahlqvist-Rastad J, Bratt G, Berglund T, Gisslen M, Lindbäck S, Morfeldt L, Ståhle L, Sönnerborg A. Antiretroviral treatment of human immunodeficiency virus infection: Swedish recommendations. *Scand J Infect Dis* 2003;35:155-167.

249. Mulligan K, Tai VW, Schambelan M. Cross-sectional and longitudinal evaluation of body composition in men with HIV infection. *J Acquir Immune Defic Syndr Hum Retrovirol* 1997;15:43-48.

250. Kilby JM, Tabereaux PB. Severe hyperglycemia in an HIV clinic: preexisting versus drug-associated diabetes mellitus. *J Acquir Immune Defic Syndr Hum Retrovirol* 1998;17:46-50.

251. Assan R, Perronne C, Assan D, Chotard L, Mayaud C, Matheron S, Zucman D. Pentamidine-induced derangements of glucose homeostasis. Determinant roles of renal failure and drug accumulation. A study of 128 patients. *Diabetes Care* 1995;18:47-55.

252. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. *J Clin Endocrinol Metab* 1992;74:1045-1052.

253. Hengel RL, Watts NB, Lennox JL. Benign symmetric lipomatosis associated with protease inhibitors. *Lancet* 1997;350:1596.

254. Herry I, Bernard L, de Truchis P, Perronne C. Hypertrophy of the breasts in a patient treated with indinavir. *Clin Infect Dis* 1997;25:937-938.

255. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. *Lancet* 1998;351:871-875.

256. Ho TT, Chan KC, Wong KH, Lee SS. Abnormal fat distribution and use of protease inhibitors. *Lancet* 1998;351:1736-1737.

257. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. *AIDS* 1998;12:F51-F58.

258. Shevitz A, Wanke CA, Falutz J, Kotler DP. Clinical perspectives on HIV-associated lipodystrophy syndrome: an update. *AIDS* 2001;15:1917-1930.

259. Chen D, Misra A, Garg A. Clinical review 153: Lipodystrophy in human immunodeficiency virus-infected patients. *J Clin Endocrinol Metab* 2002;87:4845-4856.

260. Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. *Lancet* 2003;361:726-735.

261. Nolan D, Hammond E, Martin A, Taylor L, Herrmann S, McKinnon E, Metcalf C, Latham B, Mallal S. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. *AIDS* 2003;17:1329-1338.

262. Bastard JP, Caron M, Vidal H, Jan V, Auclair M, Vigouroux C, Luboinski J, Laville M, Maachi M, Girard PM, Rozenbaum W, Levan P, Capeau J. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. *Lancet* 2002;359:1026-1031.

263. Domingo P, Matias-Guiu X, Pujol RM, Francia E, Lagarda E, Sambeat MA, Vazquez G. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. *AIDS* 1999;13:2261-2267.

264. Walker UA, Bickel M, Lutke VS, Ketelsen UP, Schofer H, Setzer B, Venhoff N, Rickerts V, Staszewski S. Evidence of nucleoside analogue reverse transcriptase inhibitor--associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. *J Acquir Immune Defic Syndr* 2002;29:117-121.

265. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. *Lancet* 1999;354:1112-1115.

266. Shikuma CM, Hu N, Milne C, Yost F, Waslien C, Shimizu S, Shiramizu B. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. *AIDS* 2001;15:1801-1809.

267. Roth VR, Kravcik S, Angel JB. Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors. *Clin Infect Dis* 1998;27:65-67.

268. van der Valk M, Bisschop PH, Romijn JA, Ackermans MT, Lange JM, Endert E, Reiss P, Sauerwein HP. Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways. *AIDS* 2001;15:2093-2100.

269. Woerle HJ, Mariuz PR, Meyer C, Reichman RC, Popa EM, Dostou JM, Welle SL, Gerich JE. Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. *Diabetes* 2003;52:918-925.

270. Gan SK, Samaras K, Thompson CH, Kraegen EW, Carr A, Cooper DA, Chisholm DJ. Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy. *Diabetes* 2002;51:3163-3169.

271. Luzi L, Perseghin G, Tambussi G, Meneghini E, Scifo P, Pagliato E, Del Maschio A, Testolin G, Lazzarin A. Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy. *Am J Physiol Endocrinol Metab* 2003;284:E274-E280.

272. Hadigan C, Rabe J, Meininger G, Aliabadi N, Breu J, Grinspoon S. Inhibition of lipolysis improves insulin sensitivity in protease inhibitor-treated HIV-infected men with fat redistribution. *Am J Clin Nutr* 2003;77:490-494.

273. Schambelan M, Benson CA, Carr A, Currier JS, Dube MP, Gerber JG, Grinspoon SK, Grunfeld C, Kotler DP, Mulligan K, Powderly WG, Saag MS. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. *J Acquir Immune Defic Syndr* 2002;31:257-275.

274. Dowell P, Flexner C, Kwiterovich PO, Lane MD. Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. *J Biol Chem* 2000;275:41325-41332.

275. Caron M, Auclair M, Vigouroux C, Glorian M, Forest C, Capeau J. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. *Diabetes* 2001; 50:1378-1388.

276. Zhang B, MacNaul K, Szalkowski D, Li Z, Berger J, Moller DE. Inhibition of adipocyte differentiation by HIV protease inhibitors. *J Clin Endocrinol Metab* 1999;84 :4274-4277.

277. Wentworth JM, Burris TP, Chatterjee VK. HIV protease inhibitors block human preadipocyte differentiation, but not via the PPARgamma/RXR heterodimer. *J Endocrinol* 2000;164:R7-R10.

278. Lenhard JM, Furfine ES, Jain RG, Ittoop O, Orband-Miller LA, Blanchard SG, Paulik MA, Weiel JE. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. *Antiviral Res* 2000;47:121-129.

279. Miserez AR, Muller PY, Spaniol V. Indinavir inhibits sterol-regulatory element-binding protein-1c-dependent lipoprotein lipase and fatty acid synthase gene activations. *AIDS* 2002;16:1587-1594.

280. Ranganathan S, Kern PA. The HIV protease inhibitor saquinavir impairs lipid metabolism and glucose transport in cultured adipocytes. *J Endocrinol* 2002;172:155-162.

281. Mondal D, Larussa VF, Agrawal KC. Synergistic antiadipogenic effects of HIV type 1 protease inhibitors with tumor necrosis factor alpha: suppression of extracellular insulin action mediated by extracellular matrix-degrading proteases. *AIDS Res Hum Retroviruses* 2001;17:1569-1584.

282. Rudich A, Vanounou S, Riesenberg K, Porat M, Tirosh A, Harman-Boehm I, Greenberg AS, Schlaeffer F, Bashan N. The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes. *Diabetes* 2001;50:1425-1431.

283. Nguyen AT, Gagnon A, Angel JB, Sorisky A. Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis. *AIDS* 2000;14:2467-2473.

284. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. *J Biol Chem* 2000;275:20251-20254.

285. Schutt M, Meier M, Jost MM, Klein HH. The HIV Protease Inhibitor Indinavir Impairs Glycogen Synthesis in HepG2 Hepatoma Cells. *Exp Clin Endocrinol Diabetes* 2003;111:16-20.

286. Schutt M, Meier M, Meyer M, Klein J, Aries SP, Klein HH. The HIV-1 protease inhibitor indinavir impairs insulin signalling in HepG2 hepatoma cells. *Diabetologia* 2000;43:1145-1148.

287. Ben-Romano R, Rudich A, Torok D, Vanounou S, Riesenberg K, Schlaeffer F, Klip A, Bashan N. Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors. *AIDS* 2003;17:23-32.

288. Hruz PW, Murata H, Qiu H, Mueckler M. Indinavir induces acute and reversible peripheral insulin resistance in rats. *Diabetes* 2002;51:937-942.

289. Riddle TM, Kuhel DG, Woollett LA, Fichtenbaum CJ, Hui DY. Hiv protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. *J Biol Chem* 2001;276:37514-37519.

290. Ye JM, Samaras K, Bonner KM, Cooney GJ, Chisholm DJ, Kraegen EW. Ritonavir has paradoxical effects on lipid metabolism and insulin sensitivity in rats compared with humans. *AIDS* 1998;12:2236-2237.

291. Murata H, Hruz PW, Mueckler M. Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. *AIDS* 2002;16:859-863.

292. Rudich A, Konrad D, Torok D, Ben-Romano R, Huang C, Niu W, Garg RR, Wijesekara N, Germinario RJ, Bilan PJ, Klip A. Indinavir uncovers different contributions of GLUT4 and GLUT1 towards glucose uptake in muscle and fat cells and tissues. *Diabetologia* 2003;46:649-658.

293. Nolte LA, Yarasheski KE, Kawanaka K, Fisher J, Le N, Holloszy JO. The HIV protease inhibitor indinavir decreases insulin- and contraction-stimulated glucose transport in skeletal muscle. *Diabetes* 2001;50:1397-1401.

294. Viraben R, Aquilina C. Indinavir-associated lipodystrophy. *AIDS* 1998;12:F37-F39.

295. Saint-Marc T, Partisani M, Poizot-Martin I, Bruno F, Rouviere O, Lang JM, Gastaut JA, Touraine JL. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. *AIDS* 1999;13:1659-1667.

296. Miller J, Carr A, Emery S, Law M, Mallal S, Baker D, Smith D, Kaldor J, Cooper DA. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. *HIV Med* 2003;4:293-301.

297. Galli M, Cozzi-Lepri A, Ridolfo AL, Gervasoni C, Ravasio L, Corsico L, Gianelli E, Vaccarezza M, Vullo V, Cargnel A, Minoli L, Coronado O, Giacometti A, Antinori A, Antonucci G, d'Arminio MA, Moroni M. Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study. *Arch Intern Med* 2002;162:2621-2628.

298. Heath KV, Chan KJ, Singer J, O'Shaughnessy MV, Montaner JS, Hogg RS. Incidence of morphological and lipid abnormalities: gender and treatment differentials after initiation of first antiretroviral therapy. *Int J Epidemiol* 2002;31:1016-1020.

299. Treluyer JM, Morini JP, Dimet J, Gorin I, Rey E, Deleuze J, Ceccaldi PF, Escande JP, Pons G, Dupin N. High concentrations of nelfinavir as an independent risk factor for lipodystrophy in human immunodeficiency virus-infected patients. *Antimicrob Agents Chemother* 2002;46:4009-4012.

300. Schwenk A, Breuer JP, Kremer G, Romer K, Bethe U, Franzen C, Fatkenheuer G, Salzberger B. Risk factors for the HIV-associated lipodystrophy syndrome in a cross-sectional single-centre study. *Eur J Med Res* 2000;5:443-448.

301. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Korner T, Stoll M, Schmidt RE. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. *AIDS* 1999; 13:F63-F70.

302. Saint-Marc T, Partisani M, Poizot-Martin I, Rouviere O, Bruno F, Avellaneda R, Lang JM, Gastaut JA, Touraine JL. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. *AIDS* 2000;14:37-49.

303. Mulligan K, Grunfeld C, Tai VW, Algren H, Pang M, Chernoff DN, Lo JC, Schambelan M. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. *J Acquir Immune Defic Syndr* 2000;23:35-43.

304. Dever LL, Oruwari PA, Figueroa WE, O'Donovan CA, Eng RH. Hyperglycemia associated with protease inhibitors in an urban HIV-infected minority patient population. *Ann Pharmacother* 2000;34:580-584.

305. Justman JE, Benning L, Danoff A, Minkoff H, Levine A, Greenblatt RM, Weber K, Piessens E, Robison E, Anastos K. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. *J Acquir Immune Defic Syndr* 2003;32:298-302.

306. Noor MA, Lo JC, Mulligan K, Schwarz JM, Halvorsen RA, Schambelan M, Grunfeld C. Metabolic effects of indinavir in healthy HIV-seronegative men. *AIDS* 2001;15:F11-F18.

307. Noor MA, Seneviratne T, Aweeka FT, Lo JC, Schwarz JM, Mulligan K, Schambelan M, Grunfeld C. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. *AIDS* 2002;16:F1-F8.

308. Kosmiski LA, Kuritzkes DR, Lichtenstein KA, Glueck DH, Gourley PJ, Stamm ER, Scherzinger AL, Eckel RH. Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome. *AIDS* 2001;15:1993-2000.

309. Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, Davis B, Sax P, Stanley T, Wilson PW, D'Agostino RB, Grinspoon S. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. *Clin Infect Dis* 2001;32:130-139.

310. Roche R, Poizot-Martin I, Yazidi CM, Compe E, Gastaut JA, Torresani J, Planells R. Effects of antiretroviral drug combinations on the differentiation of adipocytes. *AIDS* 2002;16:13-20.

311. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. *Clin Ther* 2000;22:685-708.

312. Gaou I, Malliti M, Guimont MC, Letteron P, Demeilliers C, Peytavin G, Degott C, Pessayre D, Fromenty B. Effect of stavudine on mitochondrial genome and fatty acid oxidation in lean and obese mice. *J Pharmacol Exp Ther* 2001;297:516-523.

313. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. *AIDS* 2000;14:F25-F32.

314. Tsekes G, Chrysos G, Douskas G, Paraskeva D, Mangafas N, Giannakopoulos D, Papanikolaou M, Georgiou E, Lazanas MC. Body composition changes in protease inhibitor-naive HIV-infected patients treated with two nucleoside reverse transcriptase inhibitors. *HIV Med* 2002;3:85-90.

315. Hadigan C, Corcoran C, Stanley T, Piecuch S, Klibanski A, Grinspoon S. Fasting hyperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition, gonadal function, and protease inhibitor use. *J Clin Endocrinol Metab* 2000;85:35-41.

316. van der Valk M, Gisolf EH, Reiss P, Wit FW, Japour A, Weverling GJ, Danner SA. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. *AIDS* 2001;15:847-855.

317. Saves M, Raffi F, Capeau J, Rozenbaum W, Ragnaud JM, Perronne C, Basdevant A, Leport C, Chene G. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. *Clin Infect Dis* 2002;34:1396-1405.

318. Mauss S, Corzillius M, Wolf E, Schwenk A, Adam A, Jaeger H, Knechten H, Goelz J, Goetzenich A. Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment. *HIV Med* 2002;3:49-55.

319. Norbiato G, Trifiro G, Galli M, Gervasoni C, Clerici M. Fat redistribution in HIV-infected patients. A new hormonal-immune disorder? *Ann N Y Acad Sci* 2000;917:951-955.

320. Hadigan C, Borgonha S, Rabe J, Young V, Grinspoon S. Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy. *Metabolism* 2002;51:1143-1147.

321. Brambilla AM, Novati R, Calori G, Meneghini E, Vacchini D, Luzi L, Castagna A, Lazzarin A. Stavudine or indinavir-containing regimens are associated with an increased risk of diabetes mellitus in HIV-infected individuals. *AIDS* 2003;17:1993-1995.

322. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. *AIDS* 2000;14:1309-1316.

323. van der Valk M, Kastelein JJ, Murphy RL, van Leth F, Katlama C, Horban A, Glesby M, Behrens G, Clotet B, Stellato RK, Molhuizen HO, Reiss P. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. *AIDS* 2001;15:2407-2414.

324. Martinez E, Mocroft A, Garcia-Viejo MA, Perez-Cuevas JB, Blanco JL, Mallolas J, Bianchi L, Conget I, Blanch J, Phillips A, Gatell JM. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. *Lancet* 2001;357:592-598.

325. Duong M, Petit JM, Piroth L, Grappin M, Buisson M, Chavanet P, Hillon P, Portier H. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. *J Acquir Immune Defic Syndr* 2001;27:245-250.

326. Thiebaut R, Daucourt V, Mercie P, Ekouevi DK, Malvy D, Morlat P, Dupon M, Neau D, Farbos S, Marimoutou C, Dabis F. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidemiologie Clinique du Syndrome d'Immunodeficience Acquise en Aquitaine. *Clin Infect Dis* 2000;31:1482-1487.

327. Maher B, Alfirevic A, Vilar FJ, Wilkins EG, Park BK, Pirmohamed M. TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. *AIDS* 2002;16:2013-2018.

328. Nolan D, Moore C, Castley A, Sayer D, Mamotte C, John M, James I, Mallal S. Tumour necrosis factor-alpha gene -238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy. *AIDS* 2003; 17:121-123.

329. Miserez AR, Muller PY, Barella L, Schwietert M, Erb P, Vernazza PL, Battegay M. A single-nucleotide polymorphism in the sterol-regulatory element-binding protein 1c gene is predictive of HIV-related hyperlipoproteinaemia. *AIDS* 2001;15:2045-2049.

330. Yang A, King MS, Han L, Isaacson JD, Mueller T, Grimm DR, Brun SC, Katz DA. Lack of correlation between SREBF1 genotype and hyperlipidemia in individuals treated with highly active antiretroviral therapy. *AIDS* 2003;17:2142-2143.

331. Reus S, Arroyo E, Boix V, Portilla J. [Lipodystrophy and hyperglycemia produced by protease inhibitors]. *An Med Interna* 2000;17:123-126.

332. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study . *Lancet* 1999;353:2093-2099.

333. Walli R, Herfort O, Michl GM, Demant T, Jager H, Dieterle C, Bogner JR, Landgraf R, Goebel FD. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. *AIDS* 1998;12:F167-F173.

334. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio MA, Pradier C, Morfeldt L, Mateu S , Law M, El-Sadr W, De Wit S, Sabin CA, Phillips AN, Lundgren JD. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. *AIDS* 2003;17:1179-1193.

335. Matthews GV, Moyle GJ, Mandalia S, Bower M, Nelson M, Gazzard BG. Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1-infected persons on initial therapy. *J Acquir Immune Defic Syndr* 2000;24:310-315.

336. Hadigan C, Meigs JB, Rabe J, D'Agostino RB, Wilson PW, Lipinska I, Tofler GH, Grinspoon SS. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. *J Clin Endocrinol Metab* 2001;86:939-943.

337. Koppel K, Bratt G, Schulman S, Bylund H, Sandström E. Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. *J Acquir Immune Defic Syndr* 2002;29:441-449.

338. Power R, Tate HL, McGill SM, Taylor C. A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individuals. *Sex Transm Infect* 2003;79:137-141.

339. Collins E, Wagner C, Walmsley S. Psychosocial impact of the lipodystrophy syndrome in HIV infection. *AIDS Read* 2000;10:546-550.

340. Oette M, Juretzko P, Kroidl A, Sagir A, Wettstein M, Siegrist J, Haussinger D. Lipodystrophy syndrome and self-assessment of well-being and physical appearance in HIV-positive patients. *AIDS Patient Care STDS* 2002;16:413-417.

341. Chironi G, Escaut L, Gariepy J, Cogny A, Teicher E, Monsuez JJ, Levenson J, Simon A, Vittecoq D. Brief report: carotid intima-media thickness in heavily pretreated HIV-infected patients. *J Acquir Immune Defic Syndr* 2003;32:490-493.

342. Mercie P, Thiebaut R, Lavignolle V, Pellegrin JL , Yvorra-Vives MC, Morlat P, Ragnaud JM, Dupon M, Malvy D, Bellet H, Lawson-Ayayi S, Roudaut R, Dabis F. Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. *Ann Med* 2003;34:55-63.

343. Acevedo M, Sprecher DL, Calabrese L, Pearce GL, Coyner DL, Halliburton SS, White RD, Sykora E, Kondos GT, Hoff JA. Pilot study of coronary atherosclerotic risk and plaque burden in HIV patients: 'a call for cardiovascular prevention'. *Atherosclerosis* 2002;163:349-354.

344. Bozzette SA, Joyce G, McCaffrey DF, Leibowitz AA , Morton SC, Berry SH, Rastegar A, Timberlake D, Shapiro MF, Goldman DP. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. *N Engl J Med* 2001;344:817-823.

345. Holmberg SD, Moorman AC, Williamson JM, Tong TC, Ward DJ, Wood KC, Greenberg AE, Janssen RS. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. *Lancet* 2002;360:1747-1748.

346. Pialoux G, Raffi F, Brun-Vezinet F, Meiffredy V, Flandre P, Gastaut JA, Dellamonica P, Yeni P, Delfraissy JF, Aboulker JP. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team. *N Engl J Med* 1998;339:1269-1276.

347. Miller V. Structured treatment interruptions in antiretroviral management of HIV-1. *Curr Opin Infect Dis* 2001;14:29-37.

348. Hatano H, Miller KD, Yoder CP, Yanovski JA, Sebring NG, Jones EC, Davey RTJ. Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy. *AIDS* 2000;14:1935-1942.

349. Martinez E, Garcia-Viejo MA, Blanco JL, Bianchi L, Buira E, Conget I, Casamitjana R, Mallolas J, Gatell JM. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. *Clin Infect Dis* 2000;31:1266-1273.

350. Martinez E, Conget I, Lozano L, Casamitjana R, Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. *AIDS* 1999;13:805-810.

351. Negredo E, Ribalta J, Paredes R, Ferre R, Sirera G, Ruiz L, Salazar J, Reiss P, Masana L, Clotet B. Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. *AIDS* 2002;16:1383-1389.

352. Negredo E, Cruz L, Paredes R, Ruiz L, Fumaz CR, Bonjoch A, Gel S, Tuldra A, Balague M, Johnston S, Arno A, Jou A, Tural C, Sirera G, Romeu J, Clotet B. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. *Clin Infect Dis* 2002;34:504-510.

353. Ruiz L, Negredo E, Domingo P, Paredes R, Francia E, Balague M, Gel S, Bonjoch A, Fumaz CR, Johnston S, Romeu J, Lange J, Clotet B. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. *J Acquir Immune Defic Syndr* 2001;27:229-236.

354. Estrada V, De Villar NG, Larrad MT, Lopez AG, Fernandez C, Serrano-Rios M. Long-term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus-infected patients with lipoatrophy. *Clin Infect Dis* 2002;35:69-76.

355. Barreiro P, Soriano V, Blanco F, Casimiro C, de la Cruz JJ, Gonzalez-Lahoz J. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy . *AIDS* 2000;14:807-812.

356. Domingo P, Matias-Guiu X, Pujol RM, Domingo JC, Arroyo JA, Sambeat MA, Vazquez G. Switching to nevirapine decreases insulin levels but does not improve subcutaneous adipocyte apoptosis in patients with highly active antiretroviral therapy-associated lipodystrophy. *J Infect Dis* 2001;184:1197-1201.

357. Walli RK, Michl GM, Bogner JR, Goebel FD. Improvement of HAART-associated insulin resistance and dyslipidemia after replacement of protease inhibitors with abacavir. *Eur J Med Res* 2001;6:413-421.

358. Clumeck N, Goebel F, Rozenbaum W, Gerstoft J, Staszewski S, Montaner J, Johnson M, Gazzard B, Stone C, Athisegaran R, Moore S. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. *AIDS* 2001;15:1517-1526.

359. Martinez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, Knobel H, Riera M, Pedrol E, Force L, Llibre JM, Segura F, Richart C, Cortes C, Javaloyas M, Aranda M, Cruceta A, de Lazzari E, Gatell JM. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. *N Engl J Med* 2003;349:1036-1046.

360. Carr A, Workman C, Smith DE, Hoy J, Hudson J, Doong N, Martin A, Amin J, Freund J, Law M, Cooper DA. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. *JAMA* 2002;288:207-215.

361. John M, McKinnon EJ, James IR, Nolan DA, Herrmann SE, Moore CB, White AJ, Mallal SA. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. *J Acquir Immune Defic Syndr* 2003;33:29-33.

362. Moyle GJ, Baldwin C, Langroudi B, Mandalia S, Gazzard BG. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. *J Acquir Immune Defic Syndr* 2003;33:22-28.

363. Opravil M, Hirschel B, Lazzarin A, Furrer H, Chave JP, Yerly S, Bisset LR, Fischer M, Vernazza P, Bernasconi E, Battegay M, Ledergerber B, Gunthard H, Howe C, Weber R, Perrin L. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. *J Infect Dis* 2002;185:1251-1260.

364. Gavrila A, Tsiodras S, Doweiko J, Nagy GS, Brodovicz K, Hsu W, Karchmer AW, Mantzoros CS. Exercise and vitamin E intake are independently associated with metabolic abnormalities in human immunodeficiency virus-positive subjects: a cross-sectional study. *Clin Infect Dis* 2003;36:1593-1601.

365. Yarasheski KE, Tebas P, Stanerson B, Claxton S, Marin D, Bae K, Kennedy M, Tantisiriwat W, Powderly WG. Resistance exercise training reduces hypertriglyceridemia in HIV-infected men treated with antiviral therapy. *J Appl Physiol* 2001;90:133-138.

366. Jones SP, Doran DA, Leatt PB, Maher B, Pirmohamed M. Short-term exercise training improves body composition and hyperlipidaemia in HIV-positive individuals with lipodystrophy. *AIDS* 2001;15:2049-2051.

367. Henry K, Melroe H, Huebesch J, Hermundson J, Simpson J. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. *Lancet* 1998;352:1031-1032.

368. Roubenoff R, Weiss L, McDermott A, Heflin T, Cloutier GJ, Wood M, Gorbach S. A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution. *AIDS* 1999;13:1373-1375.

369. Batterham MJ, Garsia R, Greenop PA. Dietary intake, serum lipids, insulin resistance and body composition in the era of highly active antiretroviral therapy 'Diet FRS Study'. *AIDS* 2000;14:1839-1843.

370. Barrios A, Blanco F, Garcia-Benayas T, Gomez-Viera JM, de la Cruz JJ, Soriano V, Gonzalez-Lahoz J. Effect of dietary intervention on highly active antiretroviral therapy-related dyslipemia. *AIDS* 2002;16:2079-2081.

371. Carr A, Hudson J, Chuah J, Mallal S, Law M, Hoy J, Doong N, French M, Smith D, Cooper DA. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. *AIDS* 2001;15:1811-1822.

372. Dube MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, Henry WK, Currier JS, Sprecher D, Glesby MJ. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. *Clin Infect Dis* 2003;37:613-627.

373. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, Segal Y, Aberg JA, Blaschke T, Alston B, Fang F, Kosel B, Aweeka F. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. *AIDS* 2002;16:569-577.

374. Saint-Marc T, Touraine JL. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy . *AIDS* 1999;13:1000-1002.

375. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. *JAMA* 2000;284:472-477.

376. Gale EA. Lessons from the glitazones: a story of drug development. *Lancet* 2001;357:1870-1875.

377. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). *J Biol Chem* 1995;270:12953-12956.

378. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. *Diabetes* 1998;47:507-514.

379. Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, Mahankali S, Mandarino LJ, DeFronzo RA. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients. *Diabetologia* 2001;44:2210-2219.

380. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB , Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. *J Clin Endocrinol Metab* 2001;86:280-288.

381. Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. *Diabetes Care* 2001;24:1226-1232.

382. Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Enocksson S, Inzucchi SE, Shulman GI, Petersen KF. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. *Diabetes* 2002;51:797-802.

383. Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. *Diabetes Care* 2001;24:308-315.

384. Walli R, Michl GM, Muhlbayer D, Brinkmann L, Goebel FD. Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus. *Res Exp Med* 2000;199:253-262.

385. Gelato MC, Mynarcik DC, Quick JL, Steigbigel RT, Fuhrer J, Brathwaite CE, Brebbia JS, Wax MR, McNurlan MA. Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study. *J Acquir Immune Defic Syndr* 2002;31:163-170.

386. Wanke C, Gerrior J, Kantaros J, Coakley E, Albrecht M. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. *AIDS* 1999;13:2099-2103.

387. Engelson ES, Glesby MJ, Mendez D, Albu JB, Wang J, Heymsfield SB, Kotler DP. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. *J Acquir Immune Defic Syndr* 2002;30:379-391.

388. Lo JC, Mulligan K, Noor MA, Schwarz JM, Halvorsen RA, Grunfeld C, Schambelan M. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. *J Clin Endocrinol Metab* 2001;86:3480-3487.

389. Ritt MJ, Hillebrand-Haverkort ME, ten Veen JH. Local treatment of facial lipodystrophy in patients receiving HIV protease inhibitor therapy. *Acta Chir Plast* 2001;43:54-56.

390. Walther RA. [Facial lipodystrophy in patients with HIV infections troublesome to treat]. *Läkartidningen* 2002;99:3826-3829.

391. Wolfort FG, Cetrulo CLJ, Nevarre DR. Suction-assisted lipectomy for lipodystrophy syndromes attributed to HIV-protease inhibitor use. *Plast Reconstr Surg* 1999;104:1814-1820.

392. Szczepaniak LS, Babcock EE, Schick F, Dobbins RL , Garg A, Burns DK, McGarry JD, Stein DT. Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. *Am J Physiol* 1999;276:E977-E989.

393. http://www.mrui.uab.es/mrui/.

394. Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier OH, Taegtmeyer H. Metabolic gene expression in fetal and failing human heart. *Circulation* 2001;104:2923-2931.

395. Way JM, Harrington WW, Brown KK, Gottschalk WK, Sundseth SS, Mansfield TA, Ramachandran RK, Willson TM, Kliewer SA. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. *Endocrinology* 2001;142:1269-1277.

396. Desbuquois B, Aurbach GD. Use of polyethylene glycol to separate free and antibody-bound peptide hormones in radioimmunoassay. *J Clin Endocrinol Metab* 1971;33:732-738.

397. Miles J, Classcock R, Aikens J, Gerich J, Haymond N. A microfluorometric method for the determination of free fatty acids in plasma. *J Lipid Res* 1983;24:96-99.

398. Lähdevirta J, Maury CP, Teppo AM, Repo H. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. *Am J Med* 1988;85:289-291.

399. Kehrl JH, Rieckmann P, Kozlow E, Fauci AS. Lymphokine production by B cells from normal and HIV-infected individuals. *Ann N Y Acad Sci* 1992;651:220-227.

400. Hazan U, Romero IA, Cancello R, Valente S, Perrin V, Mariot V, Dumonceaux J, Gerhardt CC, Strosberg AD, Couraud PO, Pietri-Rouxel F. Human adipose cells express CD4, CXCR4, and CCR5 [corrected] receptors: a new target cell type for the immunodeficiency virus-1? *FASEB J* 2002;16:1254-1256.

401. Inglis AM, Miller AK, Culkin KT, Finnerty D, Patterson SD, Jorkasky DK, Freed MI. Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers. *J Clin Pharmacol* 2001;41:683-690.

402. Harris RZ, Inglis AM, Miller AK, Thompson KA, Finnerty D, Patterson S, Jorkasky DK, Freed MI. Rosiglitazone has no clinically significant effect on nifedipine pharmacokinetics. *J Clin Pharmacol* 1999;39:1189-1194.

403. Needleman L, Kurtz AB, Rifkin MD, Cooper HS, Pasto ME, Goldberg BB. Sonography of diffuse benign liver disease: accuracy of pattern recognition and grading. *AJR Am J Roentgenol* 1986;146:1011-1015.

404. Longo R, Ricci C, Masutti F, Vidimari R, Croce LS, Bercich L, Tiribelli C, Dalla PL. Fatty infiltration of the liver. Quantification by 1H localized magnetic resonance spectroscopy and comparison with computed tomography. *Invest Radiol* 1993;28:297-302.

405. Thomsen C, Becker U, Winkler K, Christoffersen P, Jensen M, Henriksen O. Quantification of liver fat using magnetic resonance spectroscopy. *Magn Reson Imaging* 1994;12:487-495.

406. Thomsen C. Quantitative magnetic resonance methods for in vivo investigation of the human liver and spleen. Technical aspects and preliminary clinical results. *Acta Radiol Suppl* 1996;401:1-34.

407. Mulhall BP, Ong JP, Younossi ZM. Non-alcoholic fatty liver disease: an overview. *J Gastroenterol Hepatol* 2002;17:1136-1143.

408. van der Kooy K, Seidell JC. Techniques for the measurement of visceral fat: a practical guide. *Int J Obes Relat Metab Disord* 1993;17:187-196.

409. Schwenk A. Methods of assessing body shape and composition in HIV-associated lipodystrophy. *Curr Opin Infect Dis* 2002;15:9-16.

410. Ross R, Shaw KD, Rissanen J, Martel Y, de Guise J, Avruch L. Sex differences in lean and adipose tissue distribution by magnetic resonance imaging: anthropometric relationships. *Am J Clin Nutr* 1994;59:1277-1285.

411. Kotler DP, Burastero S, Wang J, Pierson RNJ. Prediction of body cell mass, fat-free mass, and total body water with bioelectrical impedance analysis: effects of race, sex, and disease. *Am J Clin Nutr* 1996;64:489S-497S.

412. Schwenk A, Breuer P, Kremer G, Ward L. Clinical assessment of HIV-associated lipodystrophy syndrome: bioelectrical impedance analysis, anthropometry and clinical scores. *Clin Nutr* 2001;20:243-249.

413. Elbers JM, Giltay EJ, Teerlink T, Scheffer PG, Asscheman H, Seidell JC, Gooren LJ. Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects. *Clin Endocrinol* 2003;58:562-571.

414. Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. *J Mol Endocrinol* 2000;25:169-193.

415. Ginzinger DG. Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream. *Exp Hematol* 2002;30:503-512.

416. Vidal H. Quantification of lipid-related mRNAs by reverse transcription-competitive polymerase chain reaction in human white adipose tissue biopsies. *Methods Mol Biol* 2001;155:83-88.

417. Hansen JB, Zhang H, Rasmussen TH, Petersen RK, Flindt EN, Kristiansen K. Peroxisome proliferator-activated receptor delta (PPARdelta)-mediated regulation of preadipocyte proliferation and gene expression is dependent on cAMP signaling. *J Biol Chem* 2001;276:3175-3182.

418. Green DR, Reed JC. Mitochondria and apoptosis. *Science* 1998;281:1309-1312.

419. Hammarstedt A, Jansson PA, Wesslau C, Yang X, Smith U. Reduced expression of PGC-1 and insulin-signaling molecules in adipose tissue is associated with insulin resistance. *Biochem Biophys Res Commun* 2003;301:578-582.

420. Yoon JC, Puigserver P, Chen G, Donovan J, Wu Z, Rhee J, Adelmant G, Stafford J, Kahn CR, Granner DK, Newgard CB, Spiegelman BM. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. *Nature* 2001;413:131-138.

421. Motojima K, Passilly P, Peters JM, Gonzalez FJ, Latruffe N. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner. *J Biol Chem* 1998;273:16710-16714.

422. Makowski L, Boord JB, Maeda K, Babaev VR, Uysal KT, Morgan MA, Parker RA, Suttles J, Fazio S, Hotamisligil GS, Linton MF. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. *Nat Med* 2001;7:699-705.

423. Nicholson AC, Han J, Febbraio M, Silversterin RL, Hajjar DP. Role of CD36, the macrophage class B scavenger receptor, in atherosclerosis. *Ann N Y Acad Sci* 2001;947:224-228.

424. Dressman J, Kincer J, Matveev SV, Guo L, Greenberg RN, Guerin T, Meade D, Li XA, Zhu W, Uittenbogaard A, Wilson ME, Smart EJ. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. *J Clin Invest* 2003;111:389-397.

425. Serghides L, Nathoo S, Walmsley S, Kain KC. CD36 deficiency induced by antiretroviral therapy. *AIDS* 2002;16:353-358.

426. Martin G, Schoonjans K, Lefebvre AM, Staels B, Auwerx J. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators. *J Biol Chem* 1997;272:28210-28217.

427. Memon RA, Fuller J, Moser AH, Smith PJ, Feingold KR, Grunfeld C. In vivo regulation of acyl-CoA synthetase mRNA and activity by endotoxin and cytokines. *Am J Physiol* 1998; 275:E64-E72.

428. Kim JB, Spiegelman BM. ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. *Genes Dev* 1996;10:1096-1107.

429. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, Staels B, Auwerx J. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. *EMBO J* 1996;15:5336-5348.

430. Alexander DR. The CD45 tyrosine phosphatase: a positive and negative regulator of immune cell function. *Semin Immunol* 2000; 12:349-359.

431. Greaves DR, Gordon S. Macrophage-specific gene expression: current paradigms and future challenges. *Int J Hematol* 2002;76:6-15.

432. Lihn AS, Richelsen B, Pedersen SB, Haugaard SB, Rathje GS, Madsbad S, Andersen O. Increased expression of TNF-α, IL-6, and IL-8 in HIV-associated lipodystrophy. Implications for the reduced expression and plasma levels of adiponectin. *Am J Physiol Endocrinol Metab* 2003;285:E1072-E1080.

433. Mynarcik DC, Combs T, McNurlan MA, Scherer PE, Komaroff E, Gelato MC. Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution. *J Acquir Immune Defic Syndr* 2002;31:514-520.

434. Tong Q, Sankale JL, Hadigan CM, Tan G, Rosenberg ES, Kanki PJ, Grinspoon SK, Hotamisligil GS. Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices. *J Clin Endocrinol Metab* 2003;88:1559-1564.

435. Addy CL, Gavrila A, Tsiodras S, Brodovicz K, Karchmer AW, Mantzoros CS. Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. *J Clin Endocrinol Metab* 2003;88:627-636.

436. Vigouroux C, Maachi M, Nguyen TH, Coussieu C, Gharakhanian S, Funahashi T, Matsuzawa Y, Shimomura I, Rozenbaum W, Capeau J, Bastard JP. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. *AIDS* 2003;17:1503-1511.

437. Haque WA, Shimomura I, Matsuzawa Y, Garg A. Serum adiponectin and leptin levels in patients with lipodystrophies. *J Clin Endocrinol Metab* 2002;87:2395-2398.

438. Halleux CM, Takahashi M, Delporte ML, Detry R, Funahashi T, Matsuzawa Y, Brichard SM. Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue. *Biochem Biophys Res Commun* 2001;288:1102-1107.

439. Thamer C, Machann J, Tschritter O, Haap M, Wietek B, Dahl D, Bachmann O, Fritsche A, Jacob S, Stumvoll M, Schick F, Haring HU. Relationship between Serum Adiponectin Concentration and Intramyocellular Lipid Stores in Humans. *Horm Metab Res* 2002;34:646-649.

440. Weiss R, Dufour S, Groszmann A, Petersen K, Dziura J, Taksali SE, Shulman G, Caprio S. Low adiponectin levels in adolescent obesity: a marker of increased intramyocellular lipid accumulation. *J Clin Endocrinol Metab* 2003;88:2014-2018.

441. Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS, Youngren JF, Havel PJ, Pratley RE, Bogardus C, Tataranni PA. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. *Diabetes* 2002;51:1884-1888.

442. Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. *J Clin Invest* 2001;108:1875-1881.

443. Xu A, Wang Y , Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. *J Clin Invest* 2003; 112:91-100.

444. Tsao TS, Lodish HF, Fruebis J. ACRP30, a new hormone controlling fat and glucose metabolism. *Eur J Pharmacol* 2002;440:213-221.

445. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, Matsuzawa Y. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. *Nat Med* 2002;8:731-737.

446. Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, Okamoto Y, Ohashi K, Nagaretani H, Kishida K, Nishizawa H, Maeda N, Kobayashi H, Hiraoka H, Matsuzawa Y. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. *Circulation* 2003;107:671-674.

447. Estrada V, Serrano-Rios M, Larrad MT, Villar NG, Lopez AG, Tellez MJ, Fernandez C. Leptin and Adipose Tissue Maldistribution in HIV-Infected Male Patients With Predominant Fat Loss Treated With Antiretroviral Therapy. *J Acquir Immune Defic Syndr* 2002;29:32-40.

448. Christeff N, Melchior JC, de Truchis P, Perronne C, Nunez EA, Gougeon ML. Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations. *AIDS* 1999;13:2251-2260.

449. Kosmiski L, Kuritzkes D, Lichtenstein K, Eckel R . Adipocyte-derived hormone levels in HIV lipodystrophy. *Antivir Ther* 2003;8:9-15.

450. Nagy GS, Tsiodras S, Martin LD, Avihingsanon A, Gavrila A, Hsu WC, Karchmer AW, Mantzoros CS. Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin. *Clin Infect Dis* 2003;36:795-802.

451. Riddle TM, Fichtenbaum CJ, Hui DY. Leptin replacement therapy but not dietary polyunsaturated fatty acid alleviates HIV protease inhibitor-induced dyslipidemia and lipodystrophy in mice. *J Acquir Immune Defic Syndr* 2003;33:564-570.

452. Eriksson P, Reynisdottir S, Lönnqvist F, Stemme V, Hamsten A, Arner P. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals. *Diabetologia* 1998;41:65-71.

453. Mavri A, Alessi MC, Bastelica D, Geel-Georgelin O, Fina F, Sentocnik JT, Stegnar M, Juhan-Vague I. Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss. *Diabetologia* 2001;44:2025-2031.

454. Yudkin JS, Coppack SW, Bulmer K, Rawesh A, Mohamed-Ali V. Lack of evidence for secretion of plasminogen activator inhibitor-1 by human subcutaneous adipose tissue in vivo. *Thromb Res* 1999;96:1-9.

455. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K, Tokunaga K, Matsuzawa Y. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. *Nat Med* 1996;2:800-803.

456. Monforte AA, Bugarini R, Pezzotti P, De Luca A, Antinori A, Mussini C, Vigevani GM, Tirelli U, Bruno R, Gritti F, Piazza M, Chigiotti S, Chirianni A, De Stefano C, Pizzigallo E, Perrella O, Moroni M. Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. *J Acquir Immune Defic Syndr* 2001;28:114-123.

457. Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. *Clin Infect Dis* 2000;31:162-166.

458. John M, Moore CB, James IR, Nolan D, Upton RP, McKinnon EJ, Mallal SA. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. *AIDS* 2001;15:717-723.

459. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. *Gastroenterology* 2001;120:1183-1192.

460. Van Huyen JP, Landau A, Piketty C, Belair MF, Batisse D, Gonzalez-Canali G, Weiss L, Jian R, Kazatchkine MD, Bruneval P. Toxic effects of nucleoside reverse transcriptase inhibitors on the liver. Value of electron microscopy analysis for the diagnosis of mitochondrial cytopathy. *Am J Clin Pathol* 2003;119:546-555.

461. Gerschenson M, Nguyen VT, St Claire MC, Harbaugh SW, Harbaugh JW, Proia LA, Poirier MC. Chronic stavudine exposure induces hepatic mitochondrial toxicity in adult Erythrocebus patas monkeys. *J Hum Virol* 2001;4:335-342.

462. Jacob S, Machann J, Rett K, Brechtel K, Volk A, Renn W, Maerker E, Matthaei S, Schick F, Claussen CD, Haring HU. Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects. *Diabetes* 1999;48:1113-1119.

463. Krssak M, Falk Petersen K, Dresner A, DiPietro L, Vogel SM, Rothman DL, Roden M, Shulman GI. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. *Diabetologia* 1999;42:113-116.

464. Perseghin G, Scifo P, De Cobelli F, Pagliato E, Battezzati A, Arcelloni C, Vanzulli A, Testolin G, Pozza G, Del Maschio A, Luzi L. Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. *Diabetes* 1999;48:1600-1606.

465. Forouhi NG, Jenkinson G, Thomas EL, Mullick S, Mierisova S, Bhonsle U, McKeigue PM, Bell JD. Relation of triglyceride stores in skeletal muscle cells to central obesity and insulin sensitivity in European and South Asian men. *Diabetologia* 1999;42:932-935.

466. Clark JM, Diehl AM. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. *JAMA* 2003;289:3000-3004.

467. Sanyal AJ, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Stravitz RT, Mills AS. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. *Am J Gastroenterol* 2003;98:2064-2071.

468. Chomiki N, Henry M, Alessi MC, Anfosso F, Juhan-Vague I. Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls. *Thromb Haemost* 1994;72:44-53.

469. Healy AM, Gelehrter TD. Induction of plasminogen activator inhibitor-1 in HepG2 human hepatoma cells by mediators of the acute phase response. *J Biol Chem* 1994;269:19095-19100.

470. Seki T, Healy AM, Fletcher DS, Noguchi T, Gelehrter TD. IL-1beta mediates induction of hepatic type 1 plasminogen activator inhibitor in response to local tissue injury. *Am J Physiol* 1999;277:G801-G809.

471. Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. *Thromb Haemost* 1988;60:491-494.

472. Kooistra T, Bosma PJ, Tons HA, van den Berg AP, Meyer P, Princen HM. Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. *Thromb Haemost* 1989;62:723-728.

473. Cigolini M, Targher G, Agostino G, Tonoli M, Muggeo M, De Sandre G. Liver steatosis and its relation to plasma haemostatic factors in apparently healthy men--role of the metabolic syndrome. *Thromb Haemost* 1996;76:69-73.

474. Asplund-Carlson A, Hamsten A, Wiman B, Carlson LA. Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men. *Diabetologia* 1993;36:817-825.

475. Bruckert E, Ankri A, Giral P, Turpin G. Relation between plasminogen activator inhibitor-1 and hepatic enzyme concentrations in hyperlipidemic patients. *Thromb Haemost* 1994;72:434-437.

476. Fan JG, Chen LH, Xu ZJ, Zeng MD. Overexpression of hepatic plasminogen activator inhibitor type 1 mRNA in rabbits with fatty liver. *World J Gastroenterol* 2001;7:710-712.

477. Andreasen PA, Sottrup-Jensen L, Kjoller L, Nykjaer A, Moestrup SK, Petersen CM, Gliemann J. Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes. *FEBS Lett* 1994;338:239-245.

478. Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardhan R, Freed MI. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. *Diabetologia* 2000;43:278-284.

479. American Diabetes Association: clinical practice recommendations 2002. *Diabetes Care* 2002;25 Suppl 1:S74-S77.

480. Rieusset J, Auwerx J, Vidal H. Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes. *Biochem Biophys Res Commun* 1999;265:265-271.

481. Ye JM, Frangioudakis G, Iglesias MA, Furler SM, Ellis B, Dzamko N, Cooney GJ, Kraegen EW. Prior thiazolidinedione treatment preserves insulin sensitivity in normal rats during acute fatty acid elevation: role of the liver. *Endocrinology* 2002;143:4527-4535.

482. Berger J, Moller DE. The mechanisms of action of PPARs. *Annu Rev Med* 2002;53:409-435.

483. McTernan PG, Harte AL, Anderson LA, Green A, Smith SA, Holder JC, Barnett AH, Eggo MC, Kumar S. Insulin and rosiglitazone regulation of lipolysis and lipogenesis in human adipose tissue in vitro. *Diabetes* 2002;51:1493-1498.

484. Wu Z, Xie Y, Morrison RF, Bucher NL, Farmer SR. PPARgamma induces the insulin-dependent glucose transporter GLUT4 in the absence of C/EBPalpha during the conversion of 3T3 fibroblasts into adipocytes. *J Clin Invest* 1998;101:22-32.

485. Nugent C, Prins JB, Whitehead JP, Savage D, Wentworth JM, Chatterjee VK, O'Rahilly S. Potentiation of glucose uptake in 3T3-L1 adipocytes by PPAR gamma agonists is maintained in cells expressing a PPAR gamma dominant-negative mutant: evidence for selectivity in the downstream responses to PPAR gamma activation. *Mol Endocrinol* 2001;15:1729-1738.

486. el-Kebbi IM, Roser S, Pollet RJ. Regulation of glucose transport by pioglitazone in cultured muscle cells. *Metabolism* 1994;43:953-958.

487. Yonemitsu S, Nishimura H, Shintani M, Inoue R, Yamamoto Y, Masuzaki H, Ogawa Y, Hosoda K, Inoue G, Hayashi T, Nakao K. Troglitazone induces GLUT4 translocation in L6 myotubes. *Diabetes* 2001;50:1093-1101.

488. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. *Circulation* 2002;106:679-684.

489. Sigrist S, Bedoucha M, Boelsterli UA. Down-regulation by troglitazone of hepatic tumor necrosis factor-alpha and interleukin-6 mRNA expression in a murine model of non-insulin-dependent diabetes. *Biochem Pharmacol* 2000;60:67-75.

490. Schultz DR, Arnold PI. Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, alpha 1-acid glycoprotein, and fibrinogen . *Semin Arthritis Rheum* 1990;20:129-147.

491. Boelsterli UA, Bedoucha M. Toxicological consequences of altered peroxisome proliferator-activated receptor gamma (PPARgamma) expression in the liver: insights from models of obesity and type 2 diabetes. *Biochem Pharmacol* 2002;63:1-10.

492. Combs TP, Wagner JA, Berger J, Doebber T, Wang WJ, Zhang BB, Tanen M, Berg AH, O'Rahilly S, Savage DB, Chatterjee K, Weiss S, Larson PJ, Gottesdiener KM, Gertz BJ, Charron MJ, Scherer PE, Moller DE. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. *Endocrinology* 2002;143:998-1007.

493. Berger J, Tanen M, Elbrecht A, Hermanowski-Vosatka A, Moller DE, Wright SD, Thieringer R. Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11beta -hydroxysteroid dehydrogenase type 1 expression and activity. *J Biol Chem* 2001;276:12629-12635.

494. Kato K, Yamada D, Midorikawa S, Sato W, Watanabe T. Improvement by the insulin-sensitizing agent, troglitazone, of abnormal fibrinolysis in type 2 diabetes mellitus. *Metabolism* 2000;49:662-665.

495. Kruszynska YT, Yu JG, Olefsky JM, Sobel BE. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. *Diabetes* 2000;49:633-639.

496. Fonseca VA, Reynolds T, Hemphill D, Randolph C, Wall J, Valiquet TR, Graveline J, Fink LM. Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. *J Diabetes Complications* 1998;12:181-186.

497. Alessi MC, Bastelica D, Mavri A, Morange P, Berthet B, Grino M, Juhan-Vague I. Plasma PAI-1 Levels Are More Strongly Related to Liver Steatosis Than to Adipose Tissue Accumulation. *Arterioscler Thromb Vasc Biol* 2003;23:1262-1268.

498. Smith U. Pioglitazone: mechanism of action. *Int J Clin Pract Suppl* 2001;13-18.

499. Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. *Drugs* 2003;63:1373-1405.

500. Skrumsager BK, Nielsen KK, Muller M, Pabst G, Drake PG, Edsberg B. Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPARalpha and gamma agonist in healthy subjects and patients with type 2 diabetes. *J Clin Pharmacol* 2003;43:1244-1256.